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Chikungunya virus (CHIKV) is an alphavirus in the family Togaviridae. Since 2005 
the virus has caused a major epidemic of disease in humans, ranging from Central 
Africa, South-East Asia, Caribbean and more recently the Americas. The virus is 
spread by mosquitoes, most notably Aedes aegypti and Ae. albopictus. CHIKV 
causes an acute disease in humans, which is characterised by a rapid onset of high 
fever, rash, myalgia and arthralgia. The symptoms typically resolve within a week. 
Remarkably, up to a third of patients who recover from acute chikungunya develop 
chronic arthritis/arthralgia, which may last for months or years and has a large 
negative impact on the quality of life. The mechanism by which this occurs is not yet 
fully understood. CHIKV can infect human monocytes, and macrophages positive 
for CHIKV antigen have been observed in joint tissue from patients recovered from 
acute CHIKV infection but with chronic arthritis. Furthermore, it has been 
demonstrated that macrophages can be infected with CHIKV in vitro by a 
mechanism involving apoptotic debris from CHIKV-infected cells.  
 
Hypothesis and aims 
Infection of monocytes and macrophages with CHIKV contributes to clinical disease 
and virus persistence in vivo. The aim of this project was to investigate the 
mechanism by which alphaviruses infect macrophages in vitro, and to generate a 
CHIKV which is unable to replicate in monocytes and macrophages in vitro, and to 
study its pathogenicity in vivo. 
 
Materials and methods 
HeLa cells were infected with Semliki Forest virus (SFV), an alphavirus closely 
related to CHIKV, or SFV replicon particles (SFV VRP). Following cell death, 
whole cell supernatant or clarified cell supernatant from SFV- and SFV VRP-
infected cells was passaged onto human monocyte-derived macrophages (MDMs). 
These cells were observed microscopically for expression of the fluorescent marker 





presence of alphavirus replication complexes by electron microscopy. Subsequently, 
a recognition element (RE) for a haematopoietic-specific miRNA (miR-142-3P) was 
incorporated into the genome of SFV (proof-of-concept) and CHIKV to investigate if 
blocking virus replication in cells of the mononuclear phagocyte system altered virus 
kinetics in vitro. The replication of the modified viruses was investigated in 
macrophage/monocyte cell lines Thp-1 and IC-21, and in HEK 293 cells modified to 
express miR-142-3P under the control of an inducible tetracycline promoter. 
Modified viruses were tested in animal models of disease (mouse for SFV and non-
human primate for CHIKV) to investigate the pathogenicity of these viruses in vivo. 
 
Results 
The presence of apoptotic debris from SFV-infected cells was required to infect 
MDMs with SFV. The presence or absence of infectious virus particles in the 
apoptotic debris did not affect the infection rate. Intact alphavirus replication 
complexes were found within the apoptotic debris. MiR-142-3P RE was successfully 
incorporated into the genome of both SFV and CHIKV. RE-virus replication in all 
cells expressing miR-142-3P was reduced by 90-99% when compared to control 
viruses. RE-virus replication was not affected in cells which did not express miR-
142-3P. In interferon-α/β receptor knockout mice, RE-SFV generated viraemia 
comparable to the control virus, but could not infect efficiently the population of 
macrophages resident in the marginal zone of the spleen. RE-CHIKV was found to 
be genetically stable in vitro following multiple passages on BHK-21 cells in the 
absence of a selective pressure from miR-142-3P. RE-CHIKV was inoculated into 
two cynomolgus macaques. The data from this experiment are not yet available.  
 
Conclusion 
SFV was shown to infect MDM via apoptotic debris containing intact alphavirus 
replication complexes, which were the most likely infectious agent. SFV and CHIKV 
unable to replicate in haematopoietic cells in vitro were successfully engineered. The 









Chikungunya virus (CHIKV) causes a serious disease in people that is characterised 
by high fever, rash, muscle pain and joint pain. It typically lasts for up to a week but 
in some patients the muscle and joint pain may last for months or years. We do not 
fully understand the process responsible for this long-term disease. CHIKV infects 
mostly cells of the connective tissue (fibroblasts) and muscle cells (myoblasts). 
However, white blood cells monocytes and macrophages infected with CHIKV have 
been observed in patients suffering from the CHIKV disease. Human CHIKV 
infection has been successfully simulated in cynomolgus macaques, creating an 
accurate animal model of human CHIKV disease. The aim of this project was to 
investigate how CHIKV infects human macrophages, and to create a modified 
CHIKV that cannot replicate in monocytes and macrophages, and to study its ability 
to cause a CHIKV disease in cynomolgus macaques.  
 
Semliki Forest virus (SFV), a virus closely related to CHIKV, was used in initial 
proof-of-concept experiments. Human epithelial and fibroblast cells were infected 
with SFV. The virus infection killed those cells, creating cell debris. Human 
macrophages were fed with the resulting cell debris and then observed under a 
microscope for evidence of SFV infection. Cell debris was also inspected by electron 
microscopy. SFV and CHIKV were genetically modified to block their ability to 
replicate in monocytes and macrophages without affecting their ability to replicate in 
other cells, including fibroblasts and myoblasts. The replication of modified viruses 
was investigated in macrophages and monocytes. Modified viruses were tested in 
animal models of disease (mouse for SFV and cynomolgus macaque for CHIKV). 
 
The presence of debris from cells infected with SFV was required to infect human 
macrophages with SFV. The presence or absence of infectious virus particles in the 
cell debris did not change the ability of the cell debris to infect macrophages. 
Undamaged sites of SFV replication called virus replication complexes were found 
inside the cell debris by electron microscopy. Replication of modified SFV and 





control viruses. In a mouse model of SFV disease, the modified SFV could not infect 
the population of macrophages present in the spleen. Modified CHIKV was found to 
be genetically stable. The virus was used to infect two cynomolgus macaques. The 
data from this experiment are not yet available.  
 
In conclusion, SFV was shown to infect human macrophages using cell debris 
containing intact virus replication complexes even when no infectious virus particles 
were present. SFV and CHIKV unable to replicate in monocytes and macrophages 
were successfully created. The ability of modified CHIKV to cause a disease was 
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1.1 Chikungunya virus (CHIKV) 
Chikungunya virus (CHIKV) is an alphavirus in the family Togaviridae (Westaway 
et al. 1985). It belongs to the Semliki Forest virus (SFV) antigenic complex together 
with SFV, Mayaro virus (MAYV), Ross River virus (RRV), Getah virus and 
O’nyong-nyong virus (ONNV) (Powers et al. 2001). Other notable alphaviruses 
include Sindbis virus (SINV), and Venezuelan, Eastern and Western equine 
encephalitis viruses (VEEV, EEEV and WEEV). Until recently, the knowledge of 
the molecular virology and cellular pathogenesis of CHIKV was largely based on 
what we knew of related alphaviruses, such as SFV and SINV. However, in recent 
years there has been an increase in fundamental research on CHIKV infection, 
replication and pathogenesis.  
 
1.2 CHIKV structure 
CHIKV is a small, spherical virus of 70 nm in diameter (Higashi et al. 1967, Strauss 
et al. 1994). The alphavirus nucleocapsid (NC) is 40 nm in diameter and is composed 
of 240 copies of capsid protein (C) arranged as hexamers and pentamers in a T=4 
icosahedral symmetry and complexed with viral genome (Simizu et al. 1984, Strauss 
et al. 1994, Cheng et al. 1995, Mancini et al. 2000, Perera et al. 2001, 
Mukhopadhyay et al. 2006). Similarly to SFV, CHIKV NC is surrounded by a cell 
membrane-derived lipid bilayer containing 240 copies of viral glycoproteins E1 and 
E2, which are arranged as trimers of heterodimers to form the 80 glycoprotein spikes 
of the virion (Simizu et al. 1984, Strauss et al. 1994, Mancini et al. 2000, Voss et al. 
2010). The envelope glycoproteins are, like the capsid, arranged in a T=4 icosahedral 
symmetry (Akahata et al. 2010, Voss et al. 2010). The alphavirus genome is a non-
segmented, single-stranded positive sense RNA with 5’-terminal 7-methylguanylate 
cap and 3’ poly(A) tail (Kääriäinen et al. 1978, Strauss et al. 1994). Consequently, 
viral RNA resembles cellular mRNA and is infectious in the absence of viral 
proteins. CHIKV genome is 11,811 nucleotides long (LR2006 OPY1 strain), 
excluding 5’-cap nucleotide and poly(A) tail (GenBank accession no. DQ443544) 
(Parola et al. 2006). CHIKV contains two open reading frames (ORFs). The non-
structural ORF of 7,425 nucleotides and the structural ORF of 4,245 nucleotides are 





al. 1994). The non-structural ORF encodes 4 non-structural proteins (nsP1-4) while 
the structural ORF encodes 5 structural proteins (C, E3, E2, 6K, E1). The two ORFs 
are separated by a non-coding Junction (J) region of 68 nucleotides. The first 76 and 
the last 501 nucleotides of the genome are the 5’ and 3’ untranslatable regions 
(UTRs), respectively. Khan et al. (2002) identified an internal polyadenylation (I-
poly(A)) site located within the 3’ UTR of the S27 strain, which had been highly 
passaged. However, this does not seem to be a typical CHIKV feature. Similar to 
other alphaviruses, in CHIKV three repeated sequence elements (RSE) of 21-35 
nucleotides exist in the 3’ UTR (Pfeffer et al. 1998, Khan et al. 2002, Zhang et al. 
2013). In addition, a 19-nucleotide highly conserved sequence element (CSE) found 
in all alphaviruses is located directly adjacent to the poly(A) tail (Khan et al. 2002, 
Parola et al. 2006). The schematic organisation of CHIKV LR2006 OPY1 genome is 





Figure 1.1 Genomic organisation of CHIKV strain LR2006 OPY1. CHIKV has a 
non-segmented, single-stranded positive sense RNA genome of 11,811 nucleotides 
with a 5’-terminal cap and 3’ poly(A) tail. Two open reading frames (ORFs) encode 
4 non-structural proteins (nsP1-4) and 5 structural proteins (C, E3, E2, 6K, E1). An 
internal subgenomic promoter (SGP) located at the boundary between nsP4 and J 
region drives the transcription of alphavirus subgenomic RNA. Untranslatable 
regions (UTRs) of 76 and 501 nucleotides long are located at the 5’ and 3’ ends of 
virus genome, respectively. 
 
 
1.3 CHIKV life cycle 
The life cycle of CHIKV and other alphaviruses such as SFV and SINV is 







Figure 1.2 Life cycle of an alphavirus. CHIKV enters cells by receptor-mediated 
endocytosis. E1 mediates virus–host cell membrane fusion. Nucleocapsid is 
disassembled in the cytoplasm. The non-structural polyprotein is translated from the 
virus genomic RNA by cellular machinery and processed into its individual 
components by the nsP2. Non-structural proteins interact with virus genomic RNA 
leading to formation and maturation of virus replication complexes. Replication of 
virus RNA yields full length genomic RNAs and subgenomic RNAs. Structural 
polyproteins are translated from subgenomic RNAs. Capsid is cleavage 
autoproteolyticly from p62-6K-E1 polyprotein. It is released into the cytoplasm 
where it interacts with virus genomic RNA to form a nucleocapsid. The p62-6K-E1 
polyprotein is processed in the endoplasmic reticulum (ER) and in the Golgi 
apparatus. Mature glycoproteins are exported to the plasma membrane. Interaction of 





1.3.1 CHIKV cell entry 
CHIKV can infect a wide range of human, mouse, macaque and Aedes spp. cells in 
vitro and in vivo (Tsetsarkin et al. 2006, Ozden et al. 2007, Sourisseau et al. 2007, 
Couderc et al. 2008, 2009, Her et al. 2009, Labadie et al. 2010, Krejbich-Trotot et al. 
2011, Thon-Hon et al. 2012, Lim et al. 2014). Endocytosis of an alphavirus particle 
is initiated by binding of E2, a type I transmembrane glycoprotein, to a cellular 
receptor (Strauss et al. 1994, Roussel et al. 2006, Voss et al. 2010). Consequently, E2 
largely defines the cellular tropism of CHIKV. Uptake of virus particle into both 
mosquito and mammalian cells is driven by receptor-mediated endocytosis and 
access to an early endosome is a requisite for productive infection of mammalian 
cells (Sourisseau et al. 2007, Salvador et al. 2009, Bernard et al. 2010, Tsetsarkin et 
al. 2011, Gay et al. 2012). In general, alphaviruses enter cells in clathrin coated 
vesicles (Sánchez-San Martín et al. 2009, Kielian et al. 2010, Singh et al. 2011). 
Knock-down of dynamin-2, a key player in the formation of clathrin-coated vesicles, 
is associated with a 20-fold reduction in the infectivity of cells with CHIKV 
(Sourisseau et al. 2007). In contrast, Bernard et al. (2010) demonstrated that CHIKV 
enters cells by a clathrin-independent Eps15-dependent mechanism. It is possible that 
CHIKV uses a range of pathways to enter specific cell types. Following endocytosis, 
the increase in endosome acidity leads to a conformational change in the virus spike 
glycoproteins leading to exposure of E1, a class II viral fusion protein (Kielian et al. 
2010, Voss et al. 2010, Leung et al. 2011, Tang 2012).  E1 mediates fusion of the 
virus envelope with the vesicle membrane and release of nucleocapsid into the 
cytoplasm where it is disassembled leading to release of the RNA genome (Kielian et 
al. 2010, Voss et al. 2010, Leung et al. 2011, Tang 2012). Cholesterol present in cell 
membrane lipid rafts plays an important role in the successful fusion of alphavirus 
and cell membranes (Phalen et al. 1991, Lu et al. 1999, Sourisseau et al. 2007, 
Tsetsarkin et al. 2007, Solignat et al. 2009, Bernard et al. 2010, Gay et al. 2012). It 
appears to be required for the interaction between E1 and the target membrane 
(Phalen et al. 1991). Alphavirus dependence on cholesterol can be modulated by 
amino acid in position 226 in E1 (Vashishtha et al. 1998, Lu et al. 1999). Adaptation 
of CHIKV to Ae. albopictus (E1-A226V) coincided with increased dependence of 





Putative receptors for several alphaviruses have been identified. DC-SIGN, L-SIGN, 
high-affinity laminin receptor and NRAMP have been described as attachment 
receptors for SINV (Wang et al. 1992, Klimstra et al. 2003, Rose et al. 2011). 
Prohibitin 1 (PHB1), expressed on the surface of human microglial cell line CHME-
5, is the first cellular receptor identified for CHIKV (Wintachai et al. 2012). Heparan 
sulphate (HS), a ubiquitously expressed negatively charged cell surface 
glycosaminoglycan, has been demonstrated to facilitate cell entry for VEEV, SINV, 
RRV, SFV and CHIKV (Byrnes et al. 1998, Klimstra et al. 1998, Bernard et al. 2000, 
Heil et al. 2001, Smit et al. 2002, Gardner et al. 2014, Silva et al. 2014, Ferguson et 
al. 2015). The affinity of alphaviruses for HS is typically acquired following serial 
passage in cell culture and results from the selection of viruses with positively-
charged amino acids in virus glycoprotein E2 (Klimstra et al. 1998, Ferguson et al. 
2015). However, natural isolates of EEEV have also been shown to bind HS 
(Gardner et al. 2011, 2013). SINV incorporating the uncleaved precursor envelope 
protein p62 into its virion was demonstrated to efficiently bind HS (Klimstra et al. 
1999, Ryman et al. 2004). The interaction is mediated via the presence of an intact 
furin cleavage site, which acts as a HS-binding domain. Virus adaptation to HS by in 
vitro passage can reduce efficient spread of virus in vivo and lead to attenuation at 
least in animal models of alphavirus disease (Bernard et al. 2000, Ryman et al. 2004, 
Gardner et al. 2014). However, adaptation of SFV, SINV and EEEV to HS has been 
demonstrated to contribute to the neurovirulence of these viruses by enhancing their 
ability to cross the blood-brain barrier and to replicate in brain tissue (Ryman et al. 
2007, Gardner et al. 2011, Ferguson et al. 2015). Krejbich-Trotot et al. (2011) 
proposed a new, receptor-independent, mechanism by which CHIKV spread between 
neighbouring cells in culture via apoptotic blebs from virus-infected cells (discussed 
in more detail in 1.11).  
 
1.3.2 CHIKV replication 
Alphavirus replication (Figure 1.3) takes place in the host cell cytoplasm. Following 
the disassembly of a nucleocapsid, virus genomic RNA is translated to produce the 
non-structural polyprotein nsP1234, which is the replicase (Glanville et al. 1976, 





of nsP3 is present in the majority of alphaviruses, (Strauss et al. 1983, 1988, 
Lanciotti et al. 1998, Weaver et al. 1999, Lavergne et al. 2006). In the presence of an 
opal stop codon, the differential expression of nsP123 and nsP1234 is controlled by 
the read-through translation (Strauss et al. 1983, Strauss et al. 1994). Full-length 
nsP1234 is produced approximately 5-20% of the time (de Groot et al. 1990, Shirako 
et al. 1994). Most CHIKV strains have a sense codon in place of the opal stop codon 
(Khan et al. 2002, Parola et al. 2006). However, Schuffenecker et al. (2006) reported 
that some Indian Ocean isolates do contained an opal stop codon between nsP3 and 
nsP4. Similar strain-specific variations were observed in ONNV (Lanciotti et al. 
1998) and SINV (Simpson et al. 1996). In ONNV, the presence of an opal stop 
codon between nsP3 and nsP4 was shown to provide a fitness advantage in 
mosquitoes (Myles et al. 2006) while passaging on Vero cells lead to the replacement 
of the opal stop codon with a sense codon (Lanciotti et al. 1998). Altogether these 
data suggest that in ONNV the presence of an opal stop codon in virus quasispecies 
may be driven by alternative replication in both vertebrate and invertebrate hosts 
(Atkins 2013). Interestingly, EEEV was also demonstrated to replace the opal stop 
codon with a sense codon following a serial passage in vitro (Weaver et al. 1999). 
Contrary to ONNV, this process is driven by the adaptation of EEEV to mosquito 
and not mammalian cells and therefore is likely to be subject to a different selective 
pressure. The role of the opal codon in CHIKV is yet to be investigated in detail.  
 
Similarly to other alphaviruses, CHIKV polyprotein nsP1234 is processed into its 
individual components in a highly regulated sequential process driven by the nsP2, 
which encodes a papain-like cysteine protease domain in its C-terminal (Ding et al. 
1989, Hardy et al. 1989, de Groot et al. 1990, Strauss et al. 1992, Lemm et al. 1994, 
Merits et al. 2001, Vasiljeva et al. 2003, Pastorino et al. 2008, Lulla et al. 2013). 
First, the non-structural polyprotein nsP1234 is cleaved in cis into nsP123 and nsP4, 
the RNA-dependent RNA polymerase containing GDD amino acid polymerase motif 
within its C-terminal region (Keränen et al. 1979, Kamer et al. 1984, Hahn et al. 
1989, Tomar et al. 2006, Rubach et al. 2009). This process is essential for alphavirus 
replication (Shirako et al. 1994). It has been suggested that nsP4 has a limited 





1984, Takkinen et al. 1990, Takkinen et al. 1991). Cleaved wild-type nsP4 invariably 
contains an aromatic amino acid tyrosine in the N-terminus causing its rapid 
degradation by the N-end rule pathway and likely contributing to the temporal 
control of the viral RNA replication (Wellink et al. 1988, de Groott et al. 1991). 
However, in SINV the nsP4 N-terminal tyrosine was successfully substituted with 
phenylalanine, tryptophan (both aromatic amino acids) or histidine without the loss 
of wild-type nsP4 polymerase activity in vitro (Shirako et al. 1998). Any other amino 
acid at that position rendered the virus nonviable emphasising the biological role of 
this amino acid in virus fitness. NsP4 of SINV has terminal adenyl-transferase 
































Figure 1.3. Diagrammatic representation of alphavirus replication. The 
replication cycle is shown as a series of tightly regulated steps (a) Translation and 
processing of the non-structural polyprotein, synthesis of the complementary RNA 
(antigenome), synthesis of progeny genomes and synthesis of subgenomic RNAs.  
(b) Translation and processing of the structural polyprotein. Autoproteolytic cleavage 
of capsid from p62-6K-E1 polyprotein, capsid is released into cytoplasm, the 
translation of p62-6K-E1 is directed to the endoplasmic reticulum (ER), the 
polyprotein is cleaved to p62, 6K and E1 in the ER by signalase and p62 is cleaved 
to E3 and E2 by furin in the Golgi apparatus, finally E3, E2, 6K and E1 are modified 










The release of nsP4 leads to the synthesis of a negative strand RNA (antigenome) 
replication intermediate (Shirako et al. 1994, Vasiljeva et al. 2003). The synthesis of 
this negative strand is initiated by nsP1 interacting with a region in the 3’ UTR of 
viral genome (Sawicki et al. 1981, Hahn et al. 1989, Wang et al. 1991, Shirako et al. 
2000). NsP1 may directly interact with nsP4 to initiate the negative-strand synthesis 
(Shirako et al. 2000). Das et al. (2014) demonstrated that the nsP2 of CHIKV acts as 
a directional RNA helicase and a RNA-strand annealing protein. It is involved in 
unwinding virus genome during its replication process.  
 
NsP123 is further processed to produce nsP23 and nsP1, which allows synthesis of 
both negative- and positive-strand RNAs (Kim et al. 2004). An internal subgenomic 
promoter (SGP), which drives the transcription of alphavirus subgenomic RNA, is 
located at the boundary between nsP4 and the J region (Ou et al. 1982, Grakoui et al. 
1989, Strauss et al. 1994). In SINV, the minimum size of the SGP sufficient to 
transcribe detectable levels of subgenomic RNA is 24 nucleotides (Ou et al. 1982, 
Levis et al. 1990). This sequence is highly conserved across alphaviruses. At this 
stage of replication, the genomic positive-strand RNA is generated in preference to 
the subgenomic RNA. All positive-strand RNAs are capped by nsP1, which encodes 
methyl and guanylyl transferase domains in its N-terminal (Ahola et al. 1997). NsP2 
is also involved in this process through the activity of its trisphosphatase domains 
(Rikkonen et al. 1994, Gomez de Cedrón et al. 1999, Vasiljeva et al. 2000).  
 
The next stage of polyprotein processing is the cleavage of nsP23 to produce nsP2 
and nsP3 (Lulla et al. 2012). The fully cleaved replicase preferentially produces 
subgenomic positive-strand RNA. Subgenomic RNA is transcribed in 5-20-fold 
molar excess over genomic RNA (Shirako et al. 1994, Strauss et al. 1994, Kim et al. 
2004). In mammalian cells this switch to preferential production of the positive-
strand RNA occurs approximately 3 hours post-infection (Shirako et al. 1994).  
 
Replication of alphaviruses is associated with cellular membranes (Salonen et al. 
2005). The formation and maturation of membrane-bound alphavirus replication 









Figure 1.4. Formation of alphavirus replication complexes. Virus replicase 
polyprotein nsP1234 is translated from virus genomic RNA and then cleaved into 
nsP123 and nsP4 by nsP2. This leads to synthesis of a negative strand RNA that 
forms a macromolecular complex with nsP123 and nsP4. The complex is transported 
to the plasma membrane (PM). NsP1 anchors the complex to the PM, which drives 
invagination of the PM and formation of spherules (early replication complexes). 
Spherules are transferred by endocytosis from the PM to small cytoplasmic vesicles 
leading to formation of intermediate replication complexes. Homotypic fusions and 
fusions with lysosomes and/or late endosomes lead to formation of type I cytopathic 
vacuoles (CPV-1) that contain hundreds of individual spherules on their surface (late 
replication complexes). CPV-1 are transported to the perinuclear area where their 







The initial cleavage of nsP4 from the non-structural polyprotein leads to synthesis of 
a negative strand RNA that forms a macromolecular complex with nsP123 and nsP4. 
The complex is transported to the plasma membrane (PM) by an unknown 
mechanism (Grimley et al. 1968, Froshauer et al. 1988, Spuul et al. 2010, Frolova et 
al. 2010). NsP1 anchors viral replicase proteins to the PM via an amphipathic helix 
and palmitoylation residues (Froshauer et al. 1988, Laakkonen et al. 1996, 1998, 
Kujala et al. 2001a, Spuul et al. 2007, 2010). This drives invagination of the PM and 
formation of spherules (Figure 1.5), which are approximately 50 nm in diameter and 
remain open to the cytoplasm via a narrow neck of 5-10 nm in diameter (Froshauer et 
al. 1988, Peränen et al. 1991). These early replication complexes can be detected 
microscopically at the PM as early as 45 minutes post infection reaching a maximum 
local density of up to 100/µm
2






Figure 1.5. Alphavirus spherule. Spherule membrane is continuous with the 
plasma/vesicle membrane its inside remains open to the cytoplasm via a narrow neck 
of 5-10 nm in diameter. Virus RNA is replicated inside the spherules and the newly 
synthesised RNA is released into the cytoplasm. Virus replicase proteins (nsP1-4) are 
located within the neck controlling the transport of cellular and virus components 
between the inside of a spherule and the cytoplasm. Spherules can be detected at the 










Virus RNA is replicated inside the spherules and the newly synthesised RNA is 
released into the cytoplasm. Virus non-structural proteins are located primarily 
within the neck of a spherule controlling transport of cellular and virus material 
between the inside of a spherule and the cytoplasm (Spuul et al. 2010, Frolova et al. 
2010). RNA template and viral replicase proteins are required for the formation of 
spherules and the size of the RNA template directly governs the size of spherules 
(Kujala et al. 2001, Kallio et al. 2013). Kallio et al. (2013) demonstrated that SFV 
spherules located on the PM were present only in cells actively replicating viral 
genome and that all spherules were active in viral RNA replication.  
 
The maturation of alphavirus replication complexes is associated with sequential 
processing of nsP123 to its individual components. As discussed previously, this 
highly controlled process driven by nsP2 changes the preference of the replicase 
from synthesis of negative strand RNAs to synthesis of positive strand genomic and 
subgenomic RNAs (Figure 1.3). 
 
 Between 2 and 4 hours post-infection spherules are transferred from the PM to small 
cytoplasmic vesicels by endocytosis in phosphatidylinositol 3-kinase (PI3K)- and 
actin-myosine-dependent manner (Spuul et al. 2010). NsP3 may play a role in the 
initiation of this process, however, the mechanism is not well understood (Salonen et 
al. 2003, Spuul et al. 2010). The inside of spherules remains continuously open to the 
cytoplasm. Each individual cytoplasmic vesicle carries several spherules and is often 
termed an intermediate replication complex (Spuul et al. 2010). These vesicles are 
localised primarily at the periphery of the cytoplasm and demonstrate short distance 
and multidirectional movement (Spuul et al. 2010).  
 
Homotypic fusions of intermediate replication complexes and fusions with pre-
existing acidic organelles, such as late endosomes, lead to formation of late 
replication complexes (Figure 1.6), also named type I cytopathic vacuoles (CPV-1) 
(Grimley et al. 1968, Froshauer et al. 1988, Spuul et al. 2010).  Late replication 
complexes are quickly transported in a microtubule-dependant manner to the 







formation of CPV-1 can be observed from 2.5 hours post-infection (Spuul et al. 
2010). They become the predominant type of a replication complex present by 4 
hours post-infection. Mature replication complexes are larger than unmodified 
endosomes (0.5-2 µm) and contain hundreds of individual spherules on their surface 
(Spuul et al. 2010). They are very stable, protecting the negative strand RNA 
template from degradation and ensuring a steady rate of positive sense RNA 





Figure 1.6. Alphavirus late replication complex (CPV-1) structure. a) Schematic 
structure of a mature CPV-1. Each vacuole may contain hundreds of individual 
spherules on its surface. The membrane of each spherule is continuous with the 
vesicle membrane and the inside of each spherule remains continuously open to the 
cytoplasm. b) Transmission electron microscopy showing a mature CPV-1 
(approximately 0.6 µm in diameter) in SFV4-steGFP-infected HeLa cells. Image 
taken using Phillips CM120 transmission electron microscope and a Gatan Orius 
CCD camera at the Electron Microscope facility of the School of Biological 
Sciences, the University of Edinburgh. Spherules connected with the cytoplasm via a 











The subgenomic RNA is translated into a structural polyprotein C-p62-6K-E1, which 
is processed co-translationally and post-translationally into structural proteins. The 
capsid protein (C) has an autoproteolytic function, which drives its rapid cleavage 
and release into the cytoplasm (Aliperti et al. 1978). This process exposes a signal 
sequence in the N-terminal of p62 (precursor to E3 and E2), which directs the 
translation of p62-6K-E1 to the endoplasmic reticulum (ER) (Bonatti et al. 1984, 
Melancon et al. 1986, Garoff et al. 1990). The polyprotein is cleaved to p62, 6K and 
E1 in the ER by signalase and p62 is cleaved to E3 and E2 by furin in the Golgi 
apparatus (Zhang et al. 2003). E3, E2, 6K and E1 are modified post-translationally in 
the Golgi apparatus. Finally, the glycoproteins migrate to the cell membrane.  
 
The RNA poly(A) tail plays an important role in alphavirus replication. As 
mentioned previously, in SINV it is involved in the initiation of negative-strand 
synthesis. However, it is not well understood if the length of the poly(A) tail is a 
determinant of RNA replication efficiency.  
 
1.3.3 CHIKV maturation 
In the cytoplasm, 240 capsid proteins interact with each other to form 12 pentamers 
and 30 hexamers, which bind to virus positive-strand genomic RNA via a packaging 
signal located in the nsP2 gene, to form the nucleocapsid (Weiss et al. 1989, Frolova 
et al. 1997). In SINV, residues 97 through 106 of the capsid protein were suggested 
to dictate the specificity of viral RNA encapsidation (Owen et al. 1996, Kim et al. 
2011). A mutant in which these residues were deleted was shown to encapsidate both 
genomic and subgenomic viral RNAs.    
 
At the plasma membrane, E1 and E2 form trimers of heterodimers (Voss et al. 2010). 
Then, E2 interacts with the nucleocapsid via its cytoplasmic tail. This process drives 
budding and release of new virus particles (Pathak et al. 1976, Suomalainen et al. 
1992, Lopez et al. 1994). Budding can be observed from as early as 3 hours post-
infection (Johnson et al. 1981). In SFV, the 6K protein, although not a structural 
component of the virus, is essential for the assembly of the virus glycoprotein spikes 







1.4 CHIKV and apoptosis 
Apoptosis is a process of programmed cell death (Kerr et al. 1972, Elmore 2007). It 
is a natural process that is essential in development, differentiation and maintenance 
of cell populations within tissues (Vaux et al. 1999, Elmore 2007). Apoptosis is also 
a first line of defence against viral infections and consequently a crucial component 
of the innate immune host responses (Everett et al. 1999, Allsopp et al. 2000, Elmore 
2007, Barry et al. 2010, Krejbich-Trotot et al. 2011). In this context, apoptosis of 
virus-infected cells can be viewed as an altruistic auto-elimination that limits virus 
release and therefore the infection of surrounding cells (Allsopp et al. 2000, Elmore 
2007). It can be highly effective when it occurs prior to completion of virus 
replication and virion assembly. As a consequence, most large DNA viruses that are 
characterised by a long replication have evolved strategies to block or postpone the 
induction of apoptosis (Teodoro et al. 1997, Everett et al. 1999, Chen et al. 2006, 
White 2006, Kepp et al. 2009). On the other hand, small RNA viruses such as 
alphaviruses can replicate to high titres before infected cells can undergo apoptosis 
without the need to suppress it (Barry et al. 2010). Interestingly, some viruses have 
evolved to exploit the apoptosis in order to maximise their replication and overall 
fitness (Krakauer et al. 1997).  
  
Apoptosis is a highly regulated, complex and energy-dependent process (Elmore 
2007). It requires activation of highly conserved cysteine proteases called caspsases 
(Thornberry et al. 1998, Danial et al. 2004, Kurokawa et al. 2009). Once caspases are 
activated, the cell is irreversibly committed towards its death. Various cell types may 
react in different ways in response to a single stimulus, some inducing apoptosis and 
some not. There are two main molecular pathways involved in apoptosis. Both have 
been implicated in cell death induced by viruses (Urban et al. 2008).  
 
The intrinsic pathway is initiated in response to a cell stress. It is controlled by 
members of the Bcl-2 protein family that are classified into two groups, pro-survival 
and pro-apoptotic (Adams et al. 1998, Narita et al. 1998, Shimizu et al. 1999, Willis 
et al. 2005). Activated pro-apoptotic Bcl-2 protein family members such as Bad, Bax 







the outer membrane of mitochondria. This leads to an increase of mitochondrial 
membrane permeability, loss of mitochondrial transmembrane potential and release 
of cytochrome c and other apoptogenic factors into the cytosol (Narita et al. 1998, 
Shimizu et al. 1999, Kroemer et al. 2007, Elmore 2007). Cytosolic cytochrome c 
interacts with protease-activating factor-1 (Apaf-1) and the initiatory caspase-9 to 
promote self-cleavage of caspase-9 and the formation of an apoptosome complex 
(Cecconi et al. 1998, Srinivasula et al. 1998, Yoshida et al. 1998, Zou et al. 1999). 
Conversely, binding of pro-survival Bcl-2 protein family members such as Bcl-2 and 
Bcl-xL to VDACs on the outer membrane of mitochondria blocks the channels and 
prevents the release of the cytochrome c into the cytosol (Shimizu et al. 1999). The 
extrinsic pathway of apoptosis involves stimulation of death receptors that are 
members of the tumour necrosis factor (TNF) receptor gene superfamily by an 
external ligand such as TNF-α or First apoptosis signal (Fas) ligand (Thorburn 2004, 
Elmore 2007, Wilson et al. 2009). Binding of the ligand to the receptor leads to 
formation of the death-inducing signalling complex (DISC) that consists of Fas-
associated death domain (FADD) and the initiatory caspase-8 or caspase-10 (Sprick 
et al. 2002, Thorburn 2004). Both intrinsic and extrinsic pathways lead to cleavage 
and activation of executioner caspases-3, -6 and-7 (Elmore 2007, Kurokawa et al. 
2009). These caspases activate cytoplasmic endonucleases that degrade chromosomal 
DNA, proteases that degrade nuclear and cytoskeletal proteins, and tissue 
transglutaminases that cross-link cellular proteins.  
 
As a direct consequence of the action of effector endonucleases, proteases and 
transglutaminases, a cell dying of apoptosis undergoes various morphological and 
biochemical changes (Kerr et al. 1972, Elmore 2007, Kurokawa et al. 2009). During 
early stages of apoptosis cells shrink and the DNA chromatin is condensed. As a 
result of a smaller cell size, the organelles are more closely packed within a 
condensed cytoplasm. Extensive formation of cytoplasmic blebs and fragmentation 
of the nucleus is observed next. This is followed by formation of apoptotic bodies 
and consequently by cell fragmentation. Apoptotic bodies are characterised by an 
intact plasma membrane, dense cytoplasm and tightly packed organelles that 







bodies. In addition, the outer layer of an apoptotic body plasma membrane express 
unique cell surface markers that include phosphatidylserine, Annexin I and 
calreticulin (Elmore 2007). Finally, apoptotic bodies and smaller blebs are 
phagocytosed by macrophages and subsequently degraded within phagolysosomes 
(Elmore 2007). The recognition of apoptotic debris by macrophages is facilitated by 
the presence of the unique apoptotic markers on their plasma membrane, in particular 
phosphatidylserine. The phagocytosis of apoptotic debris by macrophages is a rapid 
and non-inflammatory process.  
 
Virus infection can induce apoptosis by inhibiting cellular protein transcription 
and/or translation, affecting cellular stress pathways, perturbing protein-chaperone 
systems or by activating a range of cellular sensors such as protein kinase R, protein 
kinase RNA-like endoplasmic reticulum kinase (PERK), and ceramide-activate 
kinases (Everett et al. 1999, Allsopp et al. 2000, Gorchakov et al. 2005). This can 
take place at any stage of virus infection, from virus-receptor binding to egress from 
an infected cell.  
 
Alphavirus infection of mammalian cells triggers apoptosis both in vitro and in vivo. 
This has been clearly demonstrated for SFV, SINV, VEEV, RRV and CHIKV 
(Levine et al. 1993, Lewis et al. 1996, Lundstrom et al. 1997, Scallan, Allsopp, et al. 
1997, Glasgow et al. 1997, 1998, Griffin et al. 1997, Jackson et al. 1997, Antalis et 
al. 1998, Nava et al. 1998, Jan et al. 1999, Allsopp et al. 2000, Moriishi et al. 2002, 
Sourisseau et al. 2007, Barry et al. 2010, Krejbich-Trotot et al. 2011). The 
mechanism, by which alphaviruses trigger apoptosis, has been investigated in some 
detail using SFV and SINV. UV-inactivated SINV was shown to induce apoptosis in 
Chinese hamster ovary (CHO) cells in both presence and absence of protein 
biosynthesis inhibitor cycloheximide (Jan et al. 1999). SINV induced cell deaths by 
sphingomyelin degradation and release of ceramide. The apoptotic cascade was 
triggered at the time of virus fusion with the cell membrane, and in absence of virus 
replication. In contrast, SFV requires intact RNA to trigger apoptosis as UV-
inactivated SFV does not kill cells (Urban et al. 2008). This discrepancy may, 







2008). The nsP2 of SINV and SFV drives shutdown of host cell transcription and 
translation (Gorchakov et al. 2005, Garmashova et al. 2007a, Tamm et al. 2008). It 
was shown to be cytotoxic in absence of any other virus proteins and mutations in its 
C terminus are often responsible for prolonged survival of infected cells or persistent 
infection (Dryga et al. 1997, Glasgow et al. 1998, Frolov et al. 1999, 2009, Perri et 
al. 2000, Gorchakov et al. 2005, Garmashova et al. 2006, Garmashova et al. 2007a, 
Tamm et al. 2008). In contrast, the New World alphaviruses VEEV and EEEV use 
the capsid protein for induction of transcriptional shutoff (Garmashova et al. 2007a, 
Garmashova et al. 2007b). The transmembrane domain of SINV envelope 
glycoproteins was also shown to induce apoptosis (Joe et al. 1998). SFV envelope 
glycoproteins were shown to accelerate the apoptotic cell death by induction of the 
ER stress response (Barry et al. 2010).  
 
In neurons, the SINV- and SFV-induced apoptosis is dependent on the virus strain 
and the maturation and differentiation status of neurons (Fazakerley et al. 1993, 
Levine et al. 1993, Ubol et al. 1994, Lewis et al. 1996, Oliver et al. 1998, Allsopp et 
al. 2000). Immature neurons readily undergo apoptosis following an infection while 
mature neurons can remain functional and survive for long periods of time (Lewis et 
al. 1996, Allsopp et al. 2000). The ability of SFV and SINV to trigger apoptosis in 
neurons correlates with neurovirulence and fatal encephalitis observed in vivo 
(Levine et al. 1993, Lewis et al. 1996, Allsopp et al. 2000). 
 
SFV and SINV use primarily the intrinsic pathway for induction of apoptosis 
(Moriishi et al. 2002, Urban et al. 2008). The process is dependent primarily on pro-
apoptotic Bad (SINV) and Bak (SFV) (Moriishi et al. 2002, Urban et al. 2008). 
Fibroblast cells deficient in Apaf-1 were shown to be resistant to SINV-induced 
apoptosis (Balachandran et al. 2000). The overexpression of pro-survival Bcl-2 or 
Bcl-xL can delay induction of apoptosis and lead to persistent infection (Levine et al. 
1993, Cheng et al. 1996, Lundstrom et al. 1997, Scallan & Allsopp 1997, Murphy et 
al. 2001, Moriishi et al. 2002, Urban et al. 2008). However, some studies  failed to 
detect a protective effect of Bcl-2 against SFV- and SINV-induced apoptosis 







al. (1998) suggested that SINV-induced apoptosis has some characteristics of an 
extrinsic pathway. These findings suggest that multiple and independent pathways 
may be involved in the induction of apoptosis in SFV- and SINV-infected cells. 
 
In recent years CHIKV-induced apoptosis has been investigated in some detail 
(Sourisseau et al. 2007, Krejbich-Trotot et al. 2011, Dhanwani et al. 2012, Joubert et 
al. 2012, Judith et al. 2013). In vertebrate cells, CHIKV infection leads to extensive 
cell death and a large amount of cell debris within 24 hours post-infection 
(Sourisseau et al. 2007). Similar to SINV and SFV, CHIKV uses primarily the 
intrinsic pathway for induction of apoptosis (Krejbich-Trotot et al. 2011). The 
process is dependent on pro-apoptotic Bax. The translocation of Bax to mitochondria 
and the release of cytochrome c into the cytosol are visible in HeLa cells from 16 
hours post-infection. Interestingly, Krejbich-Trotot et al. (2011) observed activation 
of caspase-8 in HeLa cells infected at MOI=0.01 from 24 hours post-infection 
suggesting a late involvement of an extrinsic apoptosis pathway. Furthermore, 
bystander caspase-8-dependent induction of apoptosis was observed in CHIKV-
negative cells from 24 hours post-infection. Unfortunately, the signal that initiated 
the extrinsic pathway in these cells was not identified. Similar to SFV and contrary to 
SINV, the capacity of CHIKV to trigger apoptosis is dependent on the presence of 
intact virus RNA and its replication (Krejbich-Trotot et al. 2011). Inhibition of 
CHIKV-induced apoptosis by chemical inhibitors limited the spread of CHIKV in 
HeLa cells culture suggesting that CHIKV exploits apoptosis in order to maximise its 
replication (Krejbich-Trotot et al. 2011). Interestingly, CHIKV-induced autophagy 
was shown to inhibit caspase-dependent apoptosis in mouse cells in vitro and in vivo 
(Joubert et al. 2012, Judith et al. 2013). Yet, in human cells CHIKV-triggered 













1.5 Global distribution and epidemics 
CHIKV was first isolated in 1952 in the Newala district of Tanzania (Ross 1956). 
After the initial outbreak the virus spread across sub-Saharan Africa, where it has 
become endemic (Powers et al. 2007). Subsequently, the virus spread east. The first 
outbreak in Asia was observed in 1958 in Bangkok (Sudeep et al. 2008). There was a 
series of significant urban outbreaks in India from 1963 through 1970 (Ligon 2006, 
Staples et al. 2009). No major epidemics occurred for the next 30 years. The virus 
rose to prominence in 2005 when a large explosive epidemic started on the French 
island of La Réunion (Powers et al. 2007, Her et al. 2009). Between February 2005 
and June 2006 there were 266,000 estimated cases and 237 resultant deaths 
(Townson et al. 2008, Schwartz et al. 2010).  Strikingly, a third of La Réunion 
population (~785,000) was affected. Since then, CHIKV has spread across South-
East Asia and caused large epidemics in India (2006-2007), Malaysia (2009) and 
Thailand (2009) with 1.4-6.4 million, 3,000 and 42,000 estimated cases, respectively 
(Schwartz et al. 2010). First CHIKV outbreak in Europe was observed in 2007, when 
292 human cases of local transmission were reported in north-eastern Italy (Rezza et 
al. 2007, Townson et al. 2008). The source of the outbreak was traced to a traveller 
returning from India (Cavrini et al. 2009, Ng et al. 2010). In September 2010, the 
first autochthonous CHIKV transmission was observed in Europe, in southern France 
(Grandadam et al. 2011). Between 2009 and 2014, CHIKV outbreaks were 
confirmed in China, Bhutan, Yemen, Saudi Arabia, New Caledonia, Papua New 
Guinea, Tonga, French Polynesia and the Lao People’s Democratic Republic (Sam et 
al. 2015). In December 2013, an autochthonous outbreak was reported for the first 
time in the Americas, on the island of Saint Martin in the Caribbean region (Hamer 
et al. 2014, Sam et al. 2015). Since then, CHIKV has spread to over 50 countries and 
territories in the area, including the United States and Brazil, causing over 1.5 
million suspected cases (Powers 2015, Sam et al. 2015). So far CHIKV has been 
observed in over 60 countries and there is a real potential for the emergence and 










1.6 CHIKV transmission 
CHIKV is an arthropod-borne virus (arbovirus). It is spread by mosquitoes, most 
notably Aedes aegypti and Ae. Albopictus (Pialoux et al. 2007). Monkeys, birds and 
rodents are the primary non-human reservoir of CHIKV (Her et al. 2009). There are 
two distinct transmission cycles (Figure 1.7): sylvatic and urban (Sudeep et al. 2008, 
Thiboutot et al. 2010). Prior to 2005, Ae. aegypti was the primary vector of CHIKV. 
However, A226V mutation in E1 glycoprotein of CHIKV was observed in 90% of 
CHIKV isolates after September 2005 (Schuffenecker et al. 2006). The mutation 
increased the transmissibility of the virus by Ae. albopictus 100-fold, which had a 
significant impact on the global epidemiology of CHIKV (Tsetsarkin et al. 2007, Ng 
et al. 2010). Ae. albopictus is a competent vector. It survives in both rural and urban 
environments, it is long lived (4-8 weeks), has a long flight radius, is aggressive, 
silent, diurnal and its eggs are resistant to environmental factors (Schwartz et al. 
2010). Furthermore, its global distribution is expanding. Currently it is present in 
Indian Ocean region, South-East Asia, 25% of the United States and at least 12 
European countries. However, according to European CDC (2009) the mosquito will 
be present in >90% of European territory by 2030. Introduction of CHIKV bearing 
the A226V mutation into an area where Ae. albopictus is present may contribute to 





Figure 1.7. Life cycle of chikungunya virus. Sylvatic cycle is observed primarily in 
Africa, CHIKV is maintained between forest-dwelling Aedes mosquitoes and wild 
non-human primates, human outbreaks are usually small and confined. Urban 
transmission cycle is observed primarily in Asia, Indian Ocean and Caribbean region, 







1.7 Chikungunya disease 
Deaths directly or indirectly caused by CHIKV are rare (approximately 1 in 1000) 
(Staples et al. 2009). Risk factors include underlying medical conditions 
(hypertension, diabetes mellitus, respiratory conditions), co-infection (particularly by 
Dengue virus) and age > 85 years (Das et al. 2010). Approximately 95% of 
individuals infected with CHIKV is symptomatic (Thiboutot et al. 2010, Das et al. 





 plaque forming units per ml of blood) that peaks around 
day 1-2 post-infection and lasts for up to a week (Hoarau et al. 2010). The symptoms 
start abruptly with high fever, myalgia, rash and severe polyarthralgia, which is the 
defining characteristic of CHIKV (Staikowsky et al. 2009, Staples et al. 2009, 
Thiboutot et al. 2010, Simon et al. 2011). Additional symptoms may include 
headache, fatigue, nausea, vomiting and conjunctivitis. The pain affects primarily 
limbs and is symmetric (Staples et al. 2009, de Andrade et al. 2010). It occurs mostly 
in ankles, wrists, fingers, knees, shoulders and elbows (Table 1.1). The joint and 
muscle pain is incapacitating and it causes a characteristic stooped posture in 
affected individuals. Thus the name ‘chikungunya’, which means “that which bends 
up” in the Makonde language (Cavrini et al. 2009). The acute symptoms of CHIKV 
infection typically resolve within 2 weeks, except for polyarthralgia. 
 
 
Table 1.1. Joint pain manifestation in patients suffering from CHIKV infection. 
(de Andrade et al. 2010) 
Location of joint pain Percentage of patients (%) 
Shoulder 54 
Elbow 48 
Hand / wrist 77 
Hip 9 
Knee 72 









A study by de Andrade et al. (2010) showed that over 50% of convalescent patients 
suffered from chronic pain for a mean duration of 90 days. Females were more likely 
to suffer from chronic pain than males, which was also observed in Singapore (Win 
et al. 2010). Similarly, Sissoko et al. (2009) reported that at 15 months following the 
disease onset 57% of patients reported rheumatic symptoms, 36% reported 
permanent suffering and 22% reported recurring symptoms. Risk factors included 
age ≥45 years, severe initial joint pain, and presence of osteoarthritis. Bouquillard et 
al. (2009) reported condition similar to rheumatoid arthritis in 10-20% of patients 4 
to 36 months post the onset of acute infection. Joint manifestations are not usually 
observed in neonates and infants (Suhrbier et al. 2009).  
 
Atypical symptoms associated with CHIKV infection have been reviewed by 
Rajapakse et al. (2010). Most notably, they include neurological manifestations. 
Conditions such as, seizures, acute flaccid paralysis meningitis, encephalitis, 
meningoencephalitis, encephalomyeloradiculitis, altered level of consciousness and 
Guillain-Barré syndrome have been reported, most notably in neonates but also in 
young children and adults (Arpino et al. 2009, Staples et al. 2009, Das et al. 2010). 
The onset of neurological symptoms is usually within 24 hours from the onset of 
fever. CHIKV infection has a significant impact on the quality of life, with working, 
mood and sleep affected the most (Soumahoro et al. 2009, de Andrade et al. 2010). 
 
Robust host immune response is observed during the acute phase of infection. It 
includes dendritic cells (DC), Natural Killer cells (NK), and CD4- and CD8-positive 
T lymphocytes (Hoarau et al. 2010). The acute phase is universally characterised by 
an early IFN-α response (Hoarau et al. 2010, Chow et al. 2011, Wauquier et al. 2011, 
Kelvin et al. 2011, Dupuis-Maguiraga et al. 2012). Overall, the expression of Th1 
and Th2 cytokines (including tumour necrosis factor-α) is low. However, high levels 
of interferon (IFN)-γ and interleukin (IL)-12 were reported in some acute patients 
(Hoarau et al. 2010, Wauquier et al. 2011). There is a correlation between the viral 
load and concentrations of IFN-α, IL-1-RA, IL-6, macrophage chemoattractant 
protein (MCP)-1, IL-12, interferon-inducible protein (IP)-10, IL-18 and IL-18BP 







The chronic phase of infection is associated with increased levels of IL-6, IL-12, and 
granulocyte-macrophage colony stimulating factor (GM-CSF) (Hoarau et al. 2010, 
Chow et al. 2011). However, the upregulation of all the above factors has never been 
observed at once. Anti-CHIKV IgM can persist for up to 24 months after the onset of 
the disease (Malvy et al. 2009, Hoarau et al. 2010). The role of the adaptive immune 
response in the CHIKV chronic disease is not currently known. 
 
1.8 Treatment and vaccination 
Presently, there is no effective treatment against CHIKV infection. The therapy is 
usually supportive and aims to alleviate symptoms. However, studies continue to 
investigate effective treatments (Pohjala et al. 2011, Kaur et al. 2013, Parashar et al. 
2014, Lani et al. 2015). Interestingly, human immune plasma was shown to be 
effective in a mouse model when administrated up to 8 hours post-infection (Couderc 
et al. 2009). Similar treatment had been proven effective in humans against West 
Nile virus (Shimoni et al. 2001). There is no commercially available vaccine for 
CHIKV infection. However, multiple candidates are currently being investigated 
(Plante et al. 2011, García-Arriaza et al. 2014, Roy et al. 2014, Weger-Lucarelli et al. 
2014, Chang et al. 2014, Hallengärd et al. 2014). Preliminary data from most studies 
are encouraging. A vaccine based on virus-like particles (VLPs) successfully 
completed a phase 1 clinical trial in humans (Chang et al. 2014). 
 
1.9 Mononuclear phagocyte system and alphavirus arthritis 
Mononuclear phagocyte system has been defined as a haematopoietic cell lineage 
derived from progenitor cells in the bone marrow, which differentiates to form 
monocytes circulating in the blood that can enter tissue to become resident tissue 
macrophages (Hume et al. 2002). Colony-stimulating factor-1 (CSF-1) has been 
identified as the key macrophage growth factor (Hume 2006). The importance of 
macrophages in the development of rheumatoid arthritis has been well established 
(Kinne et al. 2000, Suhrbier et al. 2009). However, the involvement of macrophages 
in the pathogenesis of viral arthritis is generally not well understood (Perl 1999, 








RRV is an alphavirus closely related to CHIKV. Human infection can cause 
arthralgia and arthritis similar to that of CHIKV (Rulli et al. 2005). In a mouse model 
of RRV disease, infiltration of mononuclear cells into skeletal muscles and joints is 
observed (Rulli et al. 2005, Morrison et al. 2006). Infection of macrophages with 
RRV in vitro leads to an increased expression of proinflammatory factors TNF-α, 
macrophage inflammatory protein (MIP)-1α, MCP-1, IL-1β, IL-8 and IFN-γ, which 
contributes to RRV-induced inflammatory disease (Mateo et al. 2000, Lidbury et al. 
2008). Mice depleted of macrophages and infected with RRV showed reduced levels 
of proinflammatory factors detected and did not develop inflammation of joints and 
skeletal muscles (Lidbury et al. 2008).  The adaptive immune response was 
demonstrated not to play a role in RRV-induced arthralgia/arthritis (Morrison et al. 
2006). RRV was found to persist in human macrophages for up to 170 days post-
infection (Rulli et al. 2005). It has been proposed that a spontaneous or stress-
induced increase in RRV replication in persistently infected macrophages may be 
associated with the periodical relapses of symptoms observed in RRV disease (Way 
et al. 2002). RRV infection of monocytes and macrophages can be promoted by 
antibody-dependent enhancement (Linn et al. 1996, Takada et al. 2003).  
 
SINV is another alphavirus that causes arthritis in humans. Its replication in human 
macrophages was demonstrated by Assunção-Miranda et al. (2010). The infection 
promotes macrophage activation and leads to expression of proinflammatory 
cytokines TNF-α, IL-1β and IL-6, which is followed by expression of matrix 
metalloproteinases (MMPs) 1 and 3.  
 
1.10 Chikungunya infection of human monocytes and macrophages 
Infection of human monocytes and macrophages with CHIKV has been studied in 
some detail in vitro and in vivo. However, there is still debate as to the sensitivity of 
these cells to CHIKV (Schwartz et al. 2010). Her et al. (2010) observed CHIKV 
antigens in blood monocytes from acutely infected patients (n=14). He also noted a 
correlation between the number of monocytes positive for CHIKV antigen and the 
viral load. This was not supported by Sourisseau et al. (2007) who reported no 







viral load in blood plasma (n=3). Unfortunately, the number of samples tested in 
both studies was low and patient-specific factors or differences in virus strains may 
have contributed to the observed discrepancy. Sourisseau et al. also reported that 
peripheral blood mononuclear cells (PBMCs) from healthy donors were not 
susceptible to infection with CHIKV in vitro at MOI of 10. By contrast, Her et al. 
(2010) and Teng et al. (2012) demonstrated that monocytes, and to very small extent 
B-cells, from whole blood were susceptible to infection with CHIKV in vitro at MOI 
of 10. Human monocyte-derived-macrophages were shown to be productively 
infected with CHIKV in vitro (Sourisseau et al. 2007, Labadie et al. 2010).  
 
The lack of consistency between the in vitro studies described above has been a 
matter of debate for some time. It has been suggested, that the differences observed 
may have been be due to the quality of the virus inoculum used. One of the theories 
proposed that presence of apoptotic debris in cell-culture-derived CHIKV inoculum 
that was not suitably purified (e.g. by ultracentrifugation via a sucrose gradient) 
could promote infection of macrophages with CHIKV by a novel mechanism. This 
was investigated by Krejbich-Trotot et al. (2011) who demonstrated that CHIKV 
may infect mouse and human macrophages via engulfment of apoptotic blebs from 
virus-infected neighbouring cells. In brief, primary cultures of mouse macrophages 
and macrophages derived from PMA-differentiated cell lines MM6 and Thp-1 were 
infected with supernatant from CHIKV-infected HeLa cells that was either depleted 
for apoptotic debris (filtered through 0.2 µm) or used crude (unfiltered). The viral 
load in both inoculums was comparable. The presence of apoptotic debris 
significantly contributed to CHIKV infection of macrophages even though they were 
refractory to infection with CHIKV alone. The direct interaction between the 
apoptotic blebs positive for CHIKV antigen and macrophages was confirmed 
microscopically. The infection of differentiated Thp-1 cells via apoptotic debris was 
inhibited when Thp-1 cells were pre-treated with engulfment inhibitors Annexin V 
and Cytochlasin B. CHIKV replication in macrophages infected via apoptotic debris 
did not induce a proinflammatory response. This novel mechanism may allow 
CHIKV to escape host cell defences and induce a robust adaptive immune response 







(Rosen et al. 1995, Krejbich-Trotot, et al. 2011). If true for CHIKV, this could 
contribute to the long-term persistence of the virus in joints of some patients, and the 
joint disease itself. Interestingly, in 1995 Rosen et al. reported presence of 
nucleocapsids in apoptotic blebs budding from HeLa cells infected with a different 
alphavirus, SINV. Unfortunately Krejbich-Trotot et al. did not investigate the role of 
apoptotic debris in the infection of human primary macrophages and fibroblasts, the 
nature of the infectious material present within the apoptotic blebs (e.g. intact virus 
or genomic RNA), or the detailed mechanism by which it can infect macrophages 
following the engulfment of the apoptotic blebs.  
 
The antibody-dependent enhancement (ADE) may also play a role in the 
establishment of persistent CHIKV infection in macrophages in vivo. The ADE of 
virus infection is a process in which non-neutralising virus-specific antibodies 
enhance virus infection of Fc receptor-positive cells such as monocytes, 
macrophages and granulocytes (Tirado et al. 2003, Flipse et al. 2013). As a 
consequence, it can result in an overall increase of virus replication, a higher viral 
load and a more severe disease. The ADE is initiated when antibodies bind to virus 
particles. The resulting virus-antibody complexes bind to Fc receptors on the surface 
of cells leading to increased infectivity in these cells. There are several possible 
mechanisms to explain this process. Most likely the ADE involves bringing virus 
particles into close proximity to virus-specific cell surface receptors, or a promotion 
of virus uptake into target cells via Fc receptor-mediated phagocytosis. Invariably, 
the ADE can bypass the normal mode of virus cell entry resulting in an infection of 
cells that the virus does not normally infect. Among viruses that cause arthritis, the 
ADE has been well documented for RRV (as mentioned previously) and dengue 
virus (DENV) (Tirado et al. 2003, Chareonsirisuthigul et al. 2007, Flipse et al. 2013). 
Interestingly, RRV can induce immunosuppressive L-10 and suppress 
proinflammatory TNF-α and inducible nitric oxide synthase production in 
macrophages infected via ADE (Takada et al. 2003, Rulli et al. 2005). Similarly, 
ADE of DENV infection upregulates the production of anti-inflammatory cytokines 
(Chareonsirisuthigul et al. 2007). The role of ADE in CHIKV infection of monocytes 







Finally, RNA and CHIKV antigens were found in perivascular synovial macrophages 
of a chronic patient 18 months post-infection (Hoarau et al. 2010). Levels of MCP-1, 
IL-6 and IL-8 observed in synovial fluid were high in comparison to serum of the 
same patient. Secretion profiles from monocytes infected with CHIKV in vitro 
showed high levels of IFN-α, IL-12, IL-1Ra and IP10, and decreased levels of 
RANTES, IL-8 and MIP-1β (Her et al. 2010, Ng et al. 2010).  
 
1.11 Animal models of CHIKV infection 
CHIKV does not readily infect adult wild-type mice and hence generating a mouse 
model that accurately mimics the disease observed in humans is challenging (Teo et 
al. 2012). Initial models relied on animals that were immunocompromised, either 
IFN-α/ß receptor knockout mice (IFNAR) or neonatal mice. As a result they could 
not accurately reproduce CHIKV pathogenesis observed in humans. In 2010, 
Gardner et al. proposed a model that reproduced some aspects of CHIKV-induced 
arthralgia/arthritis in adult wild-type mice of C57BL/6 background. Mice are 
inoculated with 10
4
 CCID50 of virus in 40 µl of RPMI medium subcutaneously into 
the ventral side of each hind foot, toward the ankle. Infection leads to the 
development of a transient peripheral blood viraemia and foot swelling. Virus is 
detected in muscle tissue. Symptoms of arthritis in the foot are associated with a 
prolific infiltration of monocytes and macrophages into and around of the synovial 
membrane and the underlying connective tissue. The infiltrates are observed in the 
peritendinous tissue for up to 21 days. The infection is associated with increased 
levels of TNF-α, MCP-1, IFN-γ, IL-6 and IFN-α (Gardner et al. 2010, Rulli et al. 
2011). Depletion of macrophages ameliorates but not eliminates the rheumatic 
disease. Primary mouse macrophages are productively infected in vitro. However, 
there is no evidence that they are infected with CHIKV in vivo. Treatment with 
Bindarit (MCP inhibitor) reduces the number of muscle and joint tissue-infiltrating 
mononuclear cells and ameliorates CHIKV disease in mice (Rulli et al. 2011). 
 
Nonhuman primates have the physiology and the immune system very similar to that 
of humans (Walsh et al. 1996). They have been shown to be relevant for studies of 







2007). Labadie et al. (2010) established a nonhuman model of CHIKV infection in 
cynomolgus macaques (Macaca fascicularis). A clear relationship between the 
inoculation dose and the severity of the disease was observed. Typically, animals 
inoculated with a high dose of CHIKV (>10
7
 PFU) demonstrate swelling of joints, 
clinical symptoms of meningoencephalitis and/or mortality. On the other hand, 
animals inoculated with a low dose (10
1
 PFU) do not develop a clinical disease. The 
pathophysiological basis of CHIKV disease were analysed in 3-5 year old males 
intravenously infected with an intermediate dose of 10
3
 PFU. The model mimics 
viral, clinical and pathological features of human acute disease, however, the chronic 
arthritis/arthralgia are not well reproduced.  
 
The acute phase of infection lasts for up to a week. It is characterised by a high 




 genome copies/ml), high fever (up to 39.6 ºC), 
skin rash, lymphopenia, monocytopenia, granulocytosis, mononuclear cell infiltration 
of synovial tissue, sharp rise and then fall of IFN-α/ß and IL-6 concentrations, and 
gradual rise and then decline of MCP-1 and IFN-γ concentrations. The level of   
TNF-α is significantly increased. Cytokine profiles are similar to the mouse model 
described above and are consistent with monocyte recruitment and macrophage 
activation. CHIKV RNA is detected at high levels in spleen, lymph nodes, liver, and 
at moderate levels in joints, skin, muscle, and central nervous system.   
 
The chronic phase of the infection is characterised by the return of leukocyte levels 
to normal, presence of CHIKV RNA in lymphoid organs and liver for up to 2 
months, persistence of activated macrophages, and persistence of CHIKV RNA and 
antigen in lymphoid organs and liver for up to 90 days post-infection. Monocytes and 
macrophages are infected with CHIKV in vivo. CD68
+
 cells positive for viral antigen 
were present in spleens of all animals 90 days post infection with CHIKV. Viral 
RNA was detected in these cells for up 19 days post-infection. Interestingly, two 
days post-infection the majority of CD68
+
 cells in spleen were CHIKV antigen-
positive. CD68 is a type I transmembrane proteins that is expressed in the endosomal 
compartment of all cells of the mononuclear phagocyte lineage, including monocytes 







humans and macaques. CD68 expression is believed to be driven by a macrophage-
specific promoter (Gough et al. 2001). As a consequence, it is often used as a 
selective marker for monocytes and macrophages. However, there is evidence to 
suggest that CD68 is expressed in a range of haematopoietic and non-haematopoietic 
cells and is merely enriched in macrophages (Gottfried et al. 2008). Labadie et al. 
(2010) postulated that persistently infected macrophages acted as a reservoir for 
CHIKV during the late stages of infection in macaques. 
 
In 2013, Messaoudi et al. demonstrated that reduced immune response (both innate 
and adaptive) in aged Rhesus macaques (Macaca mulatta) (>17 years old) promoted 
a long-term virus persistence in spleen relative to adult macaques (6-13 years old).  
 
1.12 Semliki Forest virus as a model alphavirus 
SFV is an alphavirus most closely related to CHIKV (Fazakerley 2002). It was first 
isolated in Uganda in 1942 from Ae. abnormalis mosquitoes (Smithburn et al. 1944).  
SFV is naturally found in sub-Saharan Africa where it is transmitted predominantly 
by Ae. africanus and Ae. aegypti mosquitoes. The natural vertebrate host of SFV is 
unknown but infections of monkeys, humans and horses have been reported (Robin 
et al. 1974, Willems et al. 1979, Mathiot et al. 1990, Fazakerley 2002).  
 
In humans, SFV infections are typically asymptomatic or very mild (Mathiot et al. 
1990). When present, symptoms include fever, headaches, myalgia and arthralgia. 
The acute phase lasts usually 2-4 days. The only recorded casualty attributed to SFV 
infection was a person who had a history of compromised immune system (Willems 
et al. 1979). In addition to the typical symptoms described above, the patient suffered 
from loss of speech, convulsion, coma, and cardiovascular and respiratory failure. 
The post-mortem examination revealed a typical viral meningoencephalomyelitis and 
SFV was isolated from both the cerebrospinal fluid and the brain.  
 
Several wild-type strains of SFV have been demonstrated to infect mice, guinea pigs, 
rabbits and rats (Seamer et al. 1967, Bradish et al. 1971). Mouse models of SFV 







(Fazakerley 2004, Fragkoudis et al. 2007, Barry et al. 2010). SFV strains can be 
divided into two groups based on their virulence in adult mice (Bradish et al. 1971, 
Fazakerley 2002). Virulent strains of SFV include the L10, V13, Osterrieth and 
prototype (Bradish et al. 1971, Glasgow et al. 1991). The A7, A7(74), A8, V42 and 
MRS MP192/7 strains are avirulent (Henderson et al. 1970, Bradish et al. 1971, 
Deuber et al. 2007). In adult mice inoculated intraperitoneally (IP), all strains of SFV 
initially replicate in smooth muscles and in lymph nodes (Grimley et al. 1970, 
Murphy et al. 1970, Pusztai et al. 1971, Amor et al. 1996). A high titre plasma 
viraemia is observed within the first 24 hours post-infection (Pusztai et al. 1971, 
Fazakerley 2002). It peaks between 1 and 2 days post-infection and then falls rapidly. 
SFV is rarely detected in the blood after 4 days post-infection (Pusztai et al. 1971, 
Fazakerley et al. 1993). SFV is neuroinvasive (Fazakerley 2002). It enters the brain 
via cerebrovascular endothelial cells (Pathak et al. 1974). The virus replicates in 
oligodendrocytes and neurons (Pathak et al. 1978, Balluz et al. 1993, Fazakerley et 
al. 1993, Amor et al. 1996). SFV virulent strain L10 rapidly disseminates throughout 
the brain causing a fatal panencephalitis 3-4 days post-infection (Fazakerley et al. 
1993). Post-mortem examination of infected brains shows widespread neuronal cell 
death (Fazakerley et al. 1993). The replication of SFV avirulent strain A7(74) is 
restricted in neurons of adult mice (>14 days of age) resulting in minimal cell death 
and survival of the infected animals (Fazakerley et al. 1993). Interestingly, mice 
infected with the A7(74) strain at the age of 12 days or less die of panencephalitis 
similar to that caused by the L10 strain (Fleming 1977, Fazakerley et al. 1993). The 
age-dependent virulence of the A7(74) strain is believed to be determined by the 
maturation status of the central nervous system (Fleming 1977, Fazakerley et al. 
1993, Oliver et al. 1997, 1998). 
 
SFV prototype strain was isolated from the same mosquito pool as the L10 strain 
(Bradish et al. 1971). It was one of the first viruses to be sequenced (Garoff et al. 
1980, Takkinen 1986). SFV4 is the molecular clone of the prototype strain 
(Liljeström & Garoff 1991, Liljeström et al. 1991). In vitro, both SFV4 and SFV L10 
demonstrate similar replication kinetics. However, in adult mice inoculated IP, SFV4 







throughput sequencing of the SFV L10 stock revealed 12 nucleotide differences 
between the two strains, six of which were nonsynonymous (Ferguson et al. 2015). A 
single amino acid changes in virus glycoprotein E2 was shown to increase the 
affinity of SFV4 to heparan sulphate resulting in a lower plasma virus load. A 
molecular clone of SFV L10 was generated in 2015 (Ferguson et al. 2015).  
 
In the UK, SFV is classified as a hazard group (HG) 2 agent by Advisory Committee 
on Dangerous Pathogens (ACDP). It is not rated under the Specified Animal 
Pathogen Order (SAPO). In addition, many established cell lines are permissive to 
SFV infection in vitro (Deuber et al. 2007). Hence, SFV can often be used as a safer 
alternative to closely related but more pathogenic alphaviruses such as CHIKV 
(ACDP HG3) in proof-of-concept studies.   
 
1.13 Alphavirus as a research tool 
Alphavirus genome can be easily manipulated at the cDNA level. First, the infectious 
cDNA (icDNA) clone is generated by inserting virus cDNA into an expression 
vector, under control of the SP6, T7 or CMV immediate early promoter. Such 
icDNAs have been generated for many alphaviruses, including SFV and CHIKV 
(Rice et al. 1987, Davis et al. 1989, Liljeström & Garoff 1991).  
 
Foreign sequences can be inserted into the genome of an alphavirus within its non-
structural ORF, structural ORF, 3’ UTR and J region (Figure 1.8) (Pugachev et al. 
1995, Higgs et al. 1999, Thomas et al. 2003, Bick et al. 2003, Vanlandingham et al. 
2005, Frolova et al. 2006, Tsetsarkin et al. 2006, Tamberg et al. 2007, Atasheva et al. 
2007, Fragkoudis et al. 2007, Sun et al. 2014). A large array of inserts has been 
tested and used with alphaviruses and multiple inserts can be cloned into one virus 
genome. The maximum size of all inserts is limited to approximately 5,000 
nucleotides per genome and is determined by the packaging capacity of an alphavirus 









The length and the nature of an insert are important determinants of genetic stability 
demonstrated by the virus. Typically, the larger the insert, the less stable the virus is 
(Hahn et al. 1989, Chen et al. 1995, Pugachev et al. 1995, Caley et al. 1999, Higgs et 
al. 1999, Sun et al. 2014). Genetic stability is also affected by the location of an 
insert. Typically, transgenes cloned into either the non-structural or the structural 
ORFs are more stable than transgenes cloned into either the J region or the 3’ UTR 
(Pugachev et al. 1995, Caley et al. 1999, Vanlandingham et al. 2005, Tsetsarkin et al. 
2006, Fragkoudis et al. 2007). In addition, constructs inserted into the J region are 
typically more stable than constructs inserted into the 3’ UTR (Pugachev et al. 1995, 
Brault et al. 2004, Vanlandingham et al. 2005, Tsetsarkin et al. 2006).  
 
The expression of foreign genes cloned into the non-structural ORF is not as strong 
and prolonged as the expression of genes under control of the subgenomic promoter, 
or a duplicated subgenomic promoter (Pugachev et al. 1995, Caley et al. 1999, 










Figure 1.8. Schematic representation of potential SFV4 clones encoding marker 
genes in different genomic locations. nsP-non-structural protein; GP – genomic 
promoter; SGP – subgenomic promoter; 2SGP – duplicated subgenomic promoter;   
C – capsid; E1-E3 – envelope glycoproteins; GLuc – Gaussia luciferase; vertical 
dashed line – protein cleavage sites; Poly(A) – Poly(A) tail; m
7
GpppA – 5’ CAP;   







Virus replicons do not encode the structural ORF in their genome (Figure 1.9). They 
are replication-deficient and cannot establish a productive infection. To generate 
virus replicon particles (VRPs) structural genes have to be provided in trans as a 
separate RNA that lacks the packaging signal, or in a packaging cell line (Figure 







Figure 1.9. Schematic representation of SFV replicon, single-helper construct, 
and split-helper constructs. SFV1 – Semliki Forest virus replicon based on SFV4; 
nsP-non-structural protein; GP – genomic promoter; SGP – subgenomic promoter;   
C – capsid; E1-E3 – envelope glycoproteins; Poly(A) – Poly(A) tail; m
7













To generate VRPs, structural genes may be provided in trans using either a single 
helper system or a split-helper system (Figure 1.9). In a single helper system, all 
structural genes are provided on a single RNA message. However, recombinations 
between replicon and helper plasmids can lead to production of an infectious virus 
(Berglund et al. 1993, Pushko et al. 1997).  This problem is circumvented in the split-
helper system where glycoproteins and capsid are provided as two separate RNA 





Figure 1.10. Schematic representations of VRP production and VRP infection.    
(a) Virus replicon RNA, Helper-C RNA and Helper-E RNA are electroporated/ 
transfected into cells to generate VRPs. Only replicon RNA encodes the packaging 
signal [P] located within the gene of nsP2.  (b) Upon infection of a cell, replicon 
genome is replicated. However, in absence of the structural ORF no virus particles 







Similarly to full-length virus, replicons may be modified to encode marker genes in 
multiple genomic locations (Figure 1.11). Since replicons lack the structural region, 





Figure 1.11. Schematic representation of SFV1 clones encoding marker genes in 
different genomic locations. SFV1 – Semliki Forest virus replicon based on SFV4; 
nsP-non-structural protein; GP – genomic promoter; SGP – subgenomic promoter;   
C – capsid; E1-E3 – envelope glycoproteins; GLuc – Gaussia luciferase; Poly(A) – 
Poly(A) tail; m
7







SFV has been successfully used as a vector for vaccines and transgene expression 
(Frolov et al. 1996, Colmenero et al. 2001, Lundstrom et al. 2001). This has been 
possible because of its unique features: 
1. Safe to use. 
2. Large coding capacity. 
3. High level of transient heterologous protein expression. 
4. Ability to induce humoral and cellular immunity. 
5. Wide host and cell tropism. 
6. Lack of pre-existing immunity. 
 
1.14 Harnessing endogenous cellular miRNAs to control viral tissue tropism 
MicroRNAs (miRNAs) are 18-22 nucleotide long endogenous RNAs that function as 
post-transcriptional regulators of gene expression (He et al. 2004, Bushati et al. 
2007). MiRNAs do so by binding to complementary sequences present primarily in 
the 3’ non-translated (NTR) region of host messenger RNAs (mRNAs) (Bartel 2004, 
Lim et al. 2005, Guo et al. 2010). The extent of complementarity between a miRNA 
and its target mRNA leads to either translational repression of the mRNA or its 
degradation (Lagos-Quintana et al. 2001, Bartel 2004, Doench 2004, Bushati et al. 
2007, Guo et al. 2010, Djuranovic et al. 2012).  
 
MiRNAs are encoded in mammalian genome within introns of protein-coding pre-
mRNAs or as independent transcription entities (Lagos-Quintana et al. 2001, Lau et 
al. 2001, Swaminathan et al. 2013). The primary miRNA transcript (pri-miRNA) is 
generated by RNA polymerase II and it contains a stem-loop-like structure (Lee et al. 
2004). Pri-miRNAs are processed by the nuclear microprocessor complex, which is 
composed of the RNase III protein Drosha and a double-stranded RNA (dsRNA)-
binding protein DGCR8 (the DiGeorge syndrome critical region 8) to produce a 60-
70 nucleotide hairpin termed pre-miRNA (Bartel 2004). The pre-mRNA hairpin 
contains a 3’ overhang of 2 nucleotides that is necessary for transport of the pre-
miRNA into the cytoplasm via Exportin 5 (Yi et al. 2003, Lund et al. 2004). In the 
cytoplasm, pre-miRNAs are recognised and processed by RNase III protein Dicer to 







two strands, known as the guide strand (the miRNA), is recruited into the 
multiprotein RNA-induced silencing complex (RISC). A miRNA-loaded RISC binds 
the target mRNA in a sequence-dependent manner via the seed region of the miRNA 
(bases 2-8 of the miRNA) (Lai 2002, Lewis et al. 2005, tenOever 2013, 
Swaminathan et al. 2013). The base pairing must occur with full complementarity in 
the miRNA seed region but occurs only with partial complementarity outside of. This 
leads to a translational repression of the mRNA but not its degradation. However, 
miRNA-loaded RISC will cleave a fully complementary target, including viral RNA 
(Figure 1.12) (tenOever 2013). In such case, the miRNA acts effectively like a small 
interfering RNA (siRNA) (tenOever 2013). 
 
MiRNAs are involved in cell development and they control many aspects of cellular 
physiology (Chen et al. 2007). As a result, miRNA expression patterns are tissue 
specific and tissues are defined by expression of specific miRNAs (Lagos-Quintana 
et al. 2002, Chen et al. 2004, Barnes et al. 2008). The abundance of an individual 
miRNA may vary greatly between different cell lineages and tissues (Lagos-

























Figure 1.12. Using cellular RNA silencing pathway to target alphavirus genome 
for degradation. The primary miRNA transcript (pri-miRNA) is generated by RNA 
polymerase II. The pri-miRNAs are processed by Drosha to produce a pre-miRNA, 
which is transported into the cytoplasm via Exportin 5. In cytoplasm, pre-miRNAs 
are processed Dicer to produce an RNA duplex of 10-25 nucleotides. MiRNA is 
recruited into the RISC complex. The miRNA-loaded RISC mediates cleavage of the 
target viral RNA encoding a fully complementary miRNA target sequence.  
 
 
In recent years, host miRNAs have been employed to control tissue tropism of 
dengue virus, SFV, influenza A virus, vesicular stomatitis virus, poliovirus, 
lentivirus, Japanese encephalitis virus and measles virus (Brown et al. 2006, 
Gottwein et al. 2006, Barnes et al. 2008, Edge et al. 2008, Papapetrou et al. 2009, 
Colin et al. 2009, Perez et al. 2009, Kelly et al. 2010, Lee et al. 2010, Kamrud et al. 
2010, Heiss et al. 2011, 2012, Leber et al. 2011, Yen et al. 2011, Pham et al. 2012, 







Tsetsarkin et al. 2015, Feng et al. 2015). The tropism of each virus was restricted by 
a miRNA recognition element (RE) inserted into the virus genome, most often in its   
3’ UTR but also in the coding region. Each miRNA RE was designed to incorporate 
one to six copies of a target sequence fully complementary to an endogenous miRNA 
that was cell-, tissue- or species-specific. Replication of the resulting viruses was 
significantly inhibited in the presence of their cognate miRNAs but not otherwise. 
This typically led to an attenuated phenotype and a strong protective immunity 
observed in vivo. Neuronal-specific miR-124, haematopoietic-specific miR-124-3P 
and ubiquitously expressed miRNA let-7 were exploited to inhibit virus replication 
most frequently.  
 
Ratnik et al. (2013) demonstrated that a miRNA RE inserted into the coding region 
of a virus was not as effective at attenuating virus replication as an identical RE 
inserted into the 3’ UTR. Heiss et al. (2012) demonstrated that a single copy of a 
target sequence to miR-124 inserted into the 3’ UTR of a chimeric tick borne 
encephalitis virus/dengue virus was sufficient to prevent virus neurovirulence in the 
mature mouse central nervous system. However, the virus was shown to revert to its 
neurovirulent phenotype by accumulating single point mutations within the target 
sequence. Incorporation of multiple targets (up to 4) increased the stability of the 
virus and the RE with four targets yielded the most attenuated phenotype in vivo. 
Pham et al. (2012) reported that a highly attenuated dengue virus encoding a RE with 
4 copies of target sequence to miR-142-3P was reverting to its virulent phenotype by 
complete excision of the RE from the virus genome in vivo. 
 
As discussed above, miR-142-3P is commonly used to control viral tissue tropism in 
haematopoietic cells. It is highly conserved in all vertebrates and it is expressed to 
high levels in haematopoietic cells (Region, Lagos-Quintana et al. 2002, Baskerville 
et al. 2005, Ramkissoon et al. 2006, Jin et al. 2008, Yuan et al. 2008, Reddy et al. 
2009, Sun et al. 2010, Bissels et al. 2011, Wang et al. 2012, Hamer et al. 2014). In 
fact, it is one of the most highly expressed cellular miRNAs in haematopoietic cells 
(Nimmo et al. 2013, Sun et al. 2015), it is constitutively expressed (Sun et al. 2013) 







regulation of cell maturation and differentiation (Yuan et al. 2008, Liao et al. 2008, 
Sun et al. 2011, 2013, Wang et al. 2012, Nishiyama et al. 2012, Lagrange et al. 2013, 
Nimmo et al. 2013, Lu et al. 2013). Abnormal expression of miR-142-3P has been 
observed in some cancers (Yuan et al. 2008, Wu et al. 2011, Lv et al. 2012, 
Kwanhian et al. 2012).  
 
Remarkably, Trobaugh et al. (2014) reported presence of four functional miR-142-3P 
target sites in the 3’UTR of wild-type North American EEEV. Three of them were 
conserved in 17 out of 23 sequenced isolates of North American EEEV strains. The 
authors postulated that the restriction of EEEV replication in myeloid cells limited 
the induction of innate immune response in these cells and consequently promoted 
the neurological disease. The region encompassing the target sites was required for 
an efficient infection of mosquito vectors with EEEV. This may explain why the 





























1) Human primary macrophages can be infected with CHIKV/SFV by a 
mechanism involving apoptotic debris from virus-infected fibroblasts. 
 
The hypothesis is based on previously discussed findings by Krejbich-Trotot et 
al. (2011) who demonstrated that primary cultures of mouse macrophages and 
macrophage cell lines (MM6 and Thp-1) were infected with CHIKV by 
engulfment of apoptotic debris from virus-infected epithelial HeLa cells even 
though they were refractory to infection with CHIKV alone.  
 
2) Infection of monocytes and macrophages with CHIKV contributes to clinical 
disease and virus persistence. 
 
The hypothesis is based on several previously discussed findings. Human 
monocyte-derived macrophages are productively infected with CHIKV 
(Sourisseau et al. 2007, Labadie et al. 2010). RNA and CHIKV antigens were 
found in perivascular synovial macrophages of a chronic CHIKV patient 18 
months post-infection (Hoarau et al. 2010). In spleens from CHIKV infected 
macaques, CD68
+
 macrophages positive for viral antigen are present 90 days 
post infection (Labadie et al. 2010). Viral RNA is detected in these cells for up 
19 days post-infection. Persistently infected macrophages may act as a 
reservoir for CHIKV during the late stage of infection in macaques (Labadie et 
al. 2010). Persistent infection of mouse macrophages with CHIKV in vitro has 
been reported (Kumar et al. 2012). Her et al. (2010) observed CHIKV antigens 
in blood monocytes from acutely infected patients. These cells may act as 
vehicles for virus dissemination during the early phase of CHIKV infection. 
Her et al. (2010) and Teng et al. (2012) demonstrated that monocytes from 










1) To determine the mechanism of human MDM infection with SFV (Chapter 3). 
 
SFV was used as a surrogate for CHIKV. The capacity of purified virus to 
infect human MDMs in vitro was investigated. The capacity of cell debris from 
SFV-infected human cell lines to increase the rate at which SFV infects human 
MDMs was tested. The nature of the infectious material present within cell 
debris from SFV-infected cells was investigated.  
 
2) To design and generate a miRNA recognition element (RE) that will inhibit 
alphavirus replication in haematopoietic cells (Chapter 4).  
 
A miRNA RE with target sequences fully complementary to haematopoietic-
specific miR-142-3P (miR-142-3P RE) was designed and generated. 
 
3) To investigate the effect of miR-142-3P RE on alphavirus replication in cells 
that express miR-142-3P using SFV in proof-of-concept studies (Chapter 4). 
 
SFV was modified to encode miR-142-3P RE in the 3’ UTR of the genome. 
Replication of the modified virus was investigated in vitro in haematopoietic 
cells, in vitro in non-haematopoietic cells induced to express miR-142-3P, and 
in vivo in IFN-α/ß receptor knockout mice. The stability of the virus (in vitro 
and in vivo) was tested. 
 
4) To generate CHIKV that is unable to replicate in haematopoietic cells   
(Chapter 5). 
 
CHIKV was modified to encode miR-142-3P RE in the J region of the genome. 
Replication of the modified virus was investigated in vitro in haematopoietic 
cells and in non-haematopoietic cells induced to express miR-142-3P. The in 







5) To investigating the role of monocyte and macrophage infection with CHIKV 
in the nonhuman primate model of chikungunya disease. 
 
The pathogenesis of CHIKV encoding miR-142-3P RE was investigated in the 
cynomolgus macaque model of CHIKV disease. At the time of writing this 



















Chapter 2:        
 






















2.1 Details of reagents, consumables, buffers and equipment ........................... 53 
2.2 Cells ............................................................................................................. 53 
2.2.1 Primary cells......................................................................................... 53 
2.2.2 Continuous cell lines ............................................................................ 53 
2.2.3 Maintenance and incubation conditions ............................................... 55 
2.2.4 Counting cells ...................................................................................... 55 
2.2.5 Heat inactivation and storage of serum ................................................ 55 
2.2.6 Harvesting and sub-culturing of cells .................................................. 55 
2.2.6.1 Non-haematopoietic cells ................................................................. 56 
2.2.6.2 IC-21 cells ........................................................................................ 57 
2.2.6.3 Thp-1 cells ........................................................................................ 57 
2.2.7 Differentiation of Thp-1 cells into macrophage-like cells ................... 57 
2.2.8 Monocyte-derived macrophages (MDMs) ........................................... 58 
2.2.9 Freezing cells for storage in liquid nitrogen ........................................ 59 
2.2.10 Resurrecting cells from liquid nitrogen................................................ 60 




 293 expression cell lines ........... 60 
2.2.12 Preparation of cloning cylinders for cell colony picking ..................... 61 
2.3 Viruses ......................................................................................................... 61 
2.3.1 Semliki Forest virus (SFV) .................................................................. 61 
2.3.2 Chikungunya virus (CHIKV) ............................................................... 65 
2.3.3 Virus rescue .......................................................................................... 69 
2.3.3.1 Virus cloned under control of the SP6 polymerase promoter .......... 69 
2.3.3.2 Virus cloned under control of the CMV promoter ........................... 71 







2.3.5 Virus titration ....................................................................................... 71 
2.3.6 Assessing stability of SFV and CHIKV encoding miR-142-3P RE .... 72 
2.3.7 One-step growth curves........................................................................ 73 
2.4 Virus replicon particles (VRPs) ................................................................... 74 
2.4.1 Semliki Forest VRPs ............................................................................ 74 
2.4.2 Chikungunya VRPs .............................................................................. 76 
2.4.3 VRP rescue ........................................................................................... 79 
2.4.4 VRP titration ........................................................................................ 79 
2.4.5 Confirmation of absence of propagating virus in VRP stock .............. 79 
2.4.6 Preparation of chikungunya replicon RNA for transfection ................ 80 
2.5 In vitro infections ......................................................................................... 81 
2.5.1 Infecting cells (other than MDM) with virus or VRPs ........................ 81 
2.5.2 Collecting and analysing samples post in vitro infection..................... 82 
2.5.3 Generating apoptotic debris from virus-infected cells ......................... 82 
2.5.4 Infection of MDMs with apoptotic debris ............................................ 82 
2.5.5 Infection of MDMs with purified virus ................................................ 83 
2.5.6 Infection of MDMs with purified virus mixed with apoptotic         
debris from uninfected HeLa cells ....................................................... 84 
2.6 Immunostaining (SFV nsP3)........................................................................ 84 
2.7 Microscopy .................................................................................................. 85 
2.7.1 Epifluorescent microscopy ................................................................... 85 
2.7.2 Confocal microscopy ........................................................................... 85 
2.7.3 Transmission electron microscopy (TEM) of apoptotic debris............ 85 
2.7.4 Calculating the proportion of virus-infected cells ................................ 86 







2.9 Luciferase assay ........................................................................................... 87 
2.9.1 Renilla luciferase – CHIKV ................................................................. 87 
2.9.2 Renilla luciferase – ChikRepl .............................................................. 87 
2.9.3 Gausia luciferase – SFV ...................................................................... 88 
2.10 Transfection of nucleic acids into mammalian cells .................................... 88 
2.10.1 FuGENE® 6 Transfection Reagent (DNA) ......................................... 88 
2.10.2 Lipofectamine® 2000 Transfection Reagent (DNA and RNA)........... 88 
2.11 Polymerase Chain Reaction (PCR) .............................................................. 89 
2.11.1 GoTaq® PCR ....................................................................................... 89 
2.11.2 Vent® PCR .......................................................................................... 89 
2.11.3 Pfu PCR ................................................................................................ 89 
2.11.4 Primer design ....................................................................................... 90 
2.11.5 Colony PCR ......................................................................................... 91 
2.11.6 Annealing of oligonucleotides ............................................................. 91 
2.12 Reverse Transcription .................................................................................. 91 
2.13 Quantitative PCR (qPCR) ............................................................................ 91 
2.14 Agarose gel electrophoresis ......................................................................... 93 
2.15 Nucleic acid isolation and purification ........................................................ 93 
2.15.1 Measuring the concentration and purity of nucleic acids ..................... 93 
2.15.2 Isolation of cellular genomic DNA ...................................................... 94 
2.15.3 Isolation of cellular total RNA ............................................................. 94 
2.15.4 Isolation of Viral RNA ......................................................................... 94 
2.15.5 Purification of RNA from enzymatic reactions ................................... 94 
2.15.6 Purification of DNA from agarose gels ............................................... 94 







2.15.8 Small-scale DNA plasmid propagation and isolation (Mini-prep) ...... 95 
2.15.9 Large-scale DNA plasmid propagation and isolation (Maxi-prep) ..... 95 
2.16 DNA restriction digest ................................................................................. 96 
2.17 DNA dephosphorylation .............................................................................. 97 
2.18 DNA ligation ................................................................................................ 97 
2.19 Transformation of competent bacteria with expression vectors .................. 97 
2.19.1 Preparation of selective LB agar plates ................................................ 97 





 Competent Cells ........................... 98 
2.20 DNA Sequencing ......................................................................................... 98 
2.21 SFV in vivo .................................................................................................. 99 
2.21.1 Mice...................................................................................................... 99 
2.21.2 Infection ............................................................................................... 99 
2.21.3 Sampling .............................................................................................. 99 
2.21.4 Processing of tissues and cryosectioning ........................................... 100 
2.21.5 Immunohistochemistry ....................................................................... 100 
2.21.6 Peritoneal macrophage flow cytometry ............................................. 101 
2.22 CHIKV in vivo ........................................................................................... 101 
2.22.1 Animals .............................................................................................. 102 
2.22.2 Infection ............................................................................................. 102 
2.22.3 Clinical observation ........................................................................... 102 
2.22.4 Sampling ............................................................................................ 102 
2.22.5 Plasma viral RNA quantification (qPCR) .......................................... 103 







2.1 Details of reagents, consumables, buffers and equipment 
The full details of all reagents, consumables, buffers and equipment used in this 
project are located in Annex 1-11. The details were accurate on 1
st




2.2.1 Primary cells 
Primary cells and cell lines used in this project are listed and described in Table 2.1.  
 
 
Table 2.1. Primary cells used in this project. 
Name Type Species Further details Source 
NHDF Fibroblast Human 
Normal human dermal fibroblast 
(NHDF), from foreskin. Non-
haematopoietic. Adherent. Cells at 
passage 10-20 were used. Cells were 
supplied upon request. All cells used 
originated from a single master stock 
deposited in liquid nitrogen (LN2).  
Dr Finn Grey,  





Peripheral blood mononuclear cells 
(PBMCs). Haematopoietic. 
Suspension. PBMCs freshly isolated 
from whole blood of voluntary donors 
were used to culture monocyte-derived 
macrophages (MDM) as described in 
2.1.7.  Surplus PBMCs was deposited 
in LN2 according to the protocol 
described in 2.1.9. 
Voluntary donors, 
The Roslin Institute 
 
 
2.2.2 Continuous cell lines  
Continuous cell lines used in this project are listed and briefly described in Table 2.2.  
 
Upon receipt of a new cell line a master stock was prepared and deposited in liquid 
nitrogen (LN2) as described in 2.2.9. All experiments using a particular cell line were 







Table 2.2. Continuous cell lines used in this project. 
Name Type Species Further details Source 
BHK-21     
(C-13) 
Epithelial Hamster Baby hamster kidney cells. Non-haematopoietic. Adherent. 
Prof Peter Liljeström, 
Karolinska Institutet 
2fTGH Fibroblast Human Human fibrosarcoma cells, IFN competent. Non-haematopoietic. Adherent. 
Dr Mhairi Ferguson,  
The Pirbright Institute 
U4C Fibroblast Human 
2fTGH mutant, truncated JAK1 messenger RNA causing lack of functional JAK1 
protein and defective IFN response. Non-haematopoietic. Adherent. 
Dr Mhairi Ferguson,  
The Pirbright Institute 
NIH 3T3 Fibroblast Mouse Mouse embryo fibroblast. Non-haematopoietic. Adherent. 
Dr Gerald Barry,  
University College Dublin 
Hek 293T Epithelial Human 
Human epithelial kidney cells constitutively expressing SV40 Large T antigen. Non-
haematopoietic. Adherent. 
Dr Helen Wise,  
The Roslin Institute. 
HeLa Epithelial Human 
Human cervix carcinoma epithelial cells, marginal interferon (IFN) production. Non-
haematopoietic. Adherent. 
Dr Gerald Barry,  
University College Dublin 
Thp-1 Monocyte Human Monocyte cell line from acute monocytic leukaemia. Haematopoietic. Suspension. 
Dr Finn Grey,  
The Roslin Institute 
IC-21 Macrophage Mouse  Peritoneal macrophage cell line; SV40 transformed. Haematopoietic. Adherent. 
Dr Finn Grey,  
The Roslin Institute 
Hek 293  
Flp-In T-Rex 
Epithelial Human 







R750-07. Non-haematopoietic. Adherent. 
Dr Finn Grey,  
The Roslin Institute 







 cells transformed using a modified pcDNA™5/FRT/TO 
vector to express miR-142-3P under control of a tetracycline-inducible promoter. 
Adrian Zagrajek, The Roslin 




Hek 293 Flp-In TRex cells transformed using an unmodified pcDNA™5/FRT/TO 
vector to express nothing under control of a tetracycline-inducible promoter.  
Adrian Zagrajek, The Roslin 







2.2.3 Maintenance and incubation conditions 
Unless stated otherwise, all cells were maintained and/or incubated at 37 ºC and 5% 
CO2 in a humidified incubator (Panasonic, Annex 10). Sterile, tissue culture (TC)-





 (Annex 1) were used. BHK-21, NIH 3T3, Hek 293T, Hek 293 
Flp-In TRex, Hek 293 miR-142, Hek 293 Control, 2fTGH, U4C, NHDF and IC-21 
cells were cultured in T-175 TC flasks. Thp-1 cells were cultured in T-80 TC flasks. 
Monocyte-derived macrophages (MDM) were maintained in 100 mm petri dishes. 
 
2.2.4 Counting cells 
Cells were counted using a Neubauer Improved Haemocytometer (0.1 mm depth). 
First, cells were re-suspended as described in 2.2.6. Next, cell suspension was diluted 




-free Phosphate Buffered Saline (PBS) (Sigma-Aldrich®, 
Annex 4), applied to the haemocytometer and then cells were counted in four 1 mm
2
 
squares. The concentration of cells in suspension was calculated according to the 
following formula: 
 
𝐶𝑒𝑙𝑙𝑠/𝑚𝑙 =  𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑝𝑒𝑟 1 𝑚𝑚2 𝑥 10 𝑥 104 
 
Where: 
10 – PBS dilution factor 
104 – Volume adjustment to 1 ml 
 
2.2.5 Heat inactivation and storage of serum 
Foetal Bovine Serum (FBS) and Newborn Calf Serum (NBCS) were stored at or 
below -20 ºC upon receipt. When needed, serum was thawed at 37 ºC, mixed gently 
to prevent formation of bubbles, and incubated at 42 ºC for 30 minutes in a water 
bath (heat-inactivation). Subsequently, serum was aliquoted and stored at 4 ºC for up 
to one month or at -20 º C for up to six months. 
 
2.2.6 Harvesting and sub-culturing of cells 
All cells with the exception of PBMCs were sub-cultured. Composition of complete 







Table 2.3. Composition of complete cell culture media used. 
Name Cells Composition 
Complete DMEM 
NIH 3T3, NHDF, 
2fTGH, U4C, Hek 
293T, Hek 293 Flp-In 
T-Rex, Hek 293 miR-
142, Hek 293 Control 
 Dulbecco’s modified Eagle’s medium with      
4 mM L-glutamine and 4.5 g / L glucose 
(DMEM) 
 10 % v/v FBS, heat-inactivated 
 50 U/ml penicillin and 50 µg/ml of 
streptomycin (P/S) 
Complete GMEM BHK-21 
 Glasgow’s minimum essential medium with 
2 mM L-glutamine (GMEM) 
 10 % v/v NBCS, heat inactivated 
 10% v/v tryptose phosphate broth (TPB) 
 P/S 
Complete RPMI IC-21, Thp-1, MDM 
 Roswell Park Memorial Institute 1640 
(RPMI 1640) without Phenol red 
 10 % v/v FBS, heat-inactivated 
 25 mM 4-(2-Hydroxyethyl)piperazine-1-





2.2.6.1 Non-haematopoietic cells  
Cells were harvested by trypsinisation. Cell monolayer at 80-90% confluence was 




-free sterile PBS, covered with 5 ml of 
0.05% Trypsin-ethylene diamine tetraacetic acid (Trypsin-EDTA) and incubated at 
room temperature (RT) until cells detached. Next, complete cell culture medium 
(volume equal to Trypsin-EDTA used) was added to inactivate trypsin. Cell 
suspension was pipetted up and down several times to disrupt any cell clumps and 
then centrifuged for 5 minutes at 200 x g and RT. Subsequently, the cell supernatant 
was removed and the cell pellet was re-suspended in 5-10 ml of complete cell culture 
medium. Cells were counted, if required. Desired number of cells was seeded into 
new cell culture flasks with complete cell culture medium (final volume of 30 ml). 
The doubling time for all no-haematopoietic cells used was approximately 24 hours. 
Cells were sub-cultured every 2-3 days. Typically, cells were passaged 20-40 times, 
depending on the cell type (e.g. NHDF could be sub-cultured up to passage 20 only 









2.2.6.2 IC-21 cells 




-free PBS, covered with 




-free sterile PBS and incubated for approximately 1 hour at 
RT. Subsequently, flasks were tapped vigorously on their side with the palm of a 
hand to detach the cells from the flask. Cell suspension was centrifuged for 10 
minutes at 200 x g and RT. Subsequently, the cell supernatant was removed and the 
cell pellet was re-suspended in 10 ml of complete cell culture medium (complete 
RPMI). Cells were counted, if required. Desired number of cells was seeded into new 
cell culture flasks with complete cell culture medium (final volume of 35 ml). The 
doubling time for IC-21 cells was approximately 36 hours. Cells were sub-cultured 
every 3-4 days. Cell culture medium was replaced every 2 days as acidic pH 
negatively affected the cell viability of IC-21 cells. Typically, IC-21 cells were 
passaged 20-30 times. Cell culture media without Phenol red was used as prolonged 
metabolism of Phenol red could increase auto-fluorescence of haematopoietic cells 
(Prof David Hume, The Roslin Institute, personal communication). 
 
2.2.6.3 Thp-1 cells 
A required amount of cells was removed from a flask and centrifuged for 10 minutes 
at 200 x g and RT. Subsequently, the cell supernatant was removed and the cell pellet 
was re-suspended in 10 ml of complete cell culture medium (complete RPMI). Cells 
were counted, if required. Desired number of cells was seeded into new cell culture 
flasks cells with complete RPMI (final volume of 40 ml). The doubling time for   
Thp-1 cells was 36-48 hours. Cells were sub-cultured every 3-4 days. Thp-1 cells 
were passaged 20-40 times. 
 
2.2.7 Differentiation of Thp-1 cells into macrophage-like cells 
Thp-1 cells were differentiated into macrophage-like cells by treatment with Phorbol 
12-myristate 13-acetate (PMA, Sigma-Aldrich®, Annex 4) at 20 ng/ml for 48 hours. 
The chosen concentration of PMA was identified as the lowest required to ensured 
complete change of Thp-1 cell morphology and strong adherence (microscopy, cell 
viability, data not shown). At this concentration stable differentiation of Thp-1 cells 







2.2.8 Monocyte-derived macrophages (MDMs) 
Human blood was obtained from healthy volunteers by a certified phlebotomist in a 
designated room at the Roslin Institute. Consent form was obtained. 50-120 mls of 
blood was withdrawn from an antecubital fossa vein into 60 ml syringes (Terumo 
Medical Products, Annex 2) that were pre-filled with 4 ml of anticoagulant citrate 
dextrose (ACD) (Sigma-Aldrich®, Annex 5). Syringes were transported in a closed 
container into a cell culture lab.  
 
Blood was centrifuged for 15 min at 1200 x g and RT, no brake. Plasma supernatant 
was discarded up to 1 cm above the buffy coat, which was subsequently collected. 
Buffy coat was diluted 1:3 in complete RPMI. Next, PBMCs were isolated by ficoll 
gradient separation. In brief, 15 ml of Histopaque-1077 (Sigma-Aldrich®, Annex 4) 
was added to 50 ml centrifuge tubes (Greiner Bio-One, Annex 2), gently overlaid 
with 25 ml of diluted buffy coat and centrifuged for 45 min at 200 x g and RT, no 
brake. Subsequently, 5 defined layers were visible. From the bottom of the tube these 
were: red blood cells (RBCs) pellet, thin white layer of neutrophils directly on top of 
RBCs, ficoll layer, fluffy white layer of PBMCs and diluted plasma with platelets. 
The top layer was discarded and PBMCs were collected without disturbing RBCs. 





-free sterile PBS by centrifugation for 10 min at 300 x g and 10 ºC. 




-free sterile PBS and counted.  
 
At this stage, positive selection of monocytes was performed using MACS® anti-
human CD14 microbeads (Miltenyi Biotec, Annex 9). Manufacturer’s protocol was 
followed. In brief, cells were pelleted by centrifugation at 300 x g for 10 min. The 
cell supernatant was aspirated completely and cells were re-suspended in 80 µl of 
MACS buffer (Annex 11) per 1 x 10
7
 cells. Next, 20 µl of microbeads was added per 
1 x 10
7
 cells, mixed well and incubated at 4 ºC for 15 min. Cells were washed by 
adding 2 ml of MACS buffer per 1 x 10
7
 cells and centrifugation at 300 x g for 10 
min. Cells were re-suspended in 500 µl of MACS buffer per up to 1 x 10
8
 cells. 
Subsequently, MS column (Miltenyi Biotec, Annex 9) was placed in a magnetic field 







buffer. Next, cell suspension was applied to the column and allowed to pass through 
by gravity flow. Subsequently, three washing steps were performed by applying 
500µl of MACS buffer to the column and allowing it to pass through by gravity flow. 
Finally, the column was removed from the magnetic field, 1 ml of MACS buffer was 
added to the column and the cells were flushed into a clean tube by firmly applying a 
plunger into the column. 
 
Purified CD14+ monocytes were centrifuged for 10 min at 400 x g and 10 ºC and re-
suspended at 1 x 10
6
 monocytes per ml in complete RPMI containing 1 x 10
4
 U/ml of 
recombinant human colony stimulating factor-1 (rhCSF-1) (Annex 4). Cells were 
added into a 100 mm sterile square petri dish and incubated for 5 days. Monocytes 
adhered to the surface of the dish within 2 hours. Monocytes started differentiation 
into MDMs due to presence of hrCSF-1.  
 





-free PBS and covered with complete RPMI supplemented 
with 1 x 10
4
 U/ml rhCSF-1. Cells were incubated for another two days to complete 
differentiation. MDMs were detached from the dish by repeated pipetting or by 
incubation with collagenase type I (Sigma-Aldrich®, Annex 4), 4mg/ml, in RPMI 




-free PBS as 
described before, counted, re-suspended in complete RPMI with 1 x 10
4
 U/ml 
rhCSF-1 and plated. MDMs were cultured for further 48 hours before infection. 
 
2.2.9 Freezing cells for storage in liquid nitrogen 
Cells in the middle of their growth phase were used to prepare aliquots for storage in 
LN2 (vapour phase). The optimal balance between the growth phase and yield was 
achieved when cells were passaged 20-24 hours earlier and the confluence of the 
monolayer was 70-80%. Cells were harvested, counted and pelleted as described in 
2.2.6. The pellet was re-suspended in FBS supplemented with 10% v/v dimethyl 
sulfoxide (DMSO, Annex 4) at a concentration of  5 x 10
6
 cells/ml. Cell aliquots 


















, Annex 2) container filled with propan-2-ol (Sigma-
Aldrich®, Annex 5) that ensured a constant freezing rate of -1 ºC per minute. Cells 
were moved to LN2 (vapour phase) 24 hours later.  
 
2.2.10 Resurrecting cells from liquid nitrogen 
An aliquot of cells was removed from LN2, kept on dry ice and then rapidly warmed 
up in a water bath at 37 ºC. Cells were diluted in 10 ml of complete cell culture 
medium and centrifuged for 5 min at 200 x g and RT to remove the cryoprotectant 
(DMSO). Next, the supernatant was carefully removed and the pellet was re-
suspended in 10 ml of complete cell culture medium, transferred to a T-80 flask and 
subsequently subcultured.  
 
2.2.11 Generating stable Flp-InTM T-RexTM 293 expression cell lines  














cells were sub-cultured for one week. Cells were split every 1-2 days to prevent 
monolayer confluence of more than 75%. Next, cells were seeded into 6-well plates 
at 5 x 10
5
 cells/well in 2 ml complete DMEM with no P/S. After 24 hours, cells were 
co-transfected with 9.0 μg pOG44 and 1.0 μg of a pcDNA5/FRT/TO using 
Lipofectamin 2000® Transfection Reagent (Invitrogen
TM
 Life Technologies, Annex 
6), following the protocol in 2.10.2. Cells transfected with pOG44 alone, 
pcDNA5/FRT/TO alone and transfection reagent alone were used as controls. After 





-free PBS, and fresh 2 ml of complete DMEM with P/S was added to each 
well. After further 24 hours, cells in each well were harvested, split 1:2 and re-seeded 
into two 100 mm cell culture dishes (Corning, Annex 1) in 10 ml of complete 
DMEM supplemented with 100 μg/ml hygromycin B (Calbiochem, Annex 4). After 
24 hours, cell culture supernatant was removed and fresh complete DMEM 
supplemented with 200 μg/ml hygromycin B was added. Cells were incubated for 
further 4 days. Subsequently, cell culture supernatant was removed and cells were 




-free PBS. Next, silicon-greased cloning cylinders 







(approximately 32 cells in size) for each cell line. Cells isolated by each cylinder 
were immediately harvested (50 μl of trypsin per cylinder) and sub-cultured into 96-
well plates in presence of hygromycin B at 200 μg/ml. Over the period of two weeks, 
cells were sub-cultured into plates with progressively larger wells (24-, 12- and 6-
well plates), in presence of hygromycin B at 200 μg/ml. Next, the expression of the 
gene of interest (GOI) in all cells was assayed by qPCR following the protocol 
described in 2.13. Selected cell lines were sub-cultured into progressively larger 
flasks (T-80 and T-175) without hygromycin B and then frozen at LN2. The LN2 
masterstock was assigned Passage number 0. 
 
2.2.12 Preparation of cloning cylinders for cell colony picking 




, Annex 2) was 
coated with a thin layer of silicon grease (Beckman Coulter, Annex 5) inside a class 
II microbiological safety cabinet (MBSC). The closed petri dish was microwaved at 
full power for 1 min (Panasonic, Annex 10). Subsequently, the petri dish was moved 
back to the MBSC and cloning cylinders (Sigma-Aldrich®, Annex 2) were pressed 
gently against the silicon grease to ensure complete coating of their edge.  
 
2.3 Viruses  
 
2.3.1 Semliki Forest virus (SFV) 
SFV clones used in this project were of SFV4 backbone and were available as DNA 
infectious clones (icDNA). To generate virus stock, SFV was rescued from icDNAs 
following the protocol outlined in 2.3.3.  
 
Five clones of SFV were available at the beginning of this project. They are 
summarised in Figure 2.1 and Table 2.4. During this project, 10 further clones were 
generated. They are summarised in Table 2.5. Their full design, cloning and testing is 
described in detail in Chapter 4.  
 
Sequence of the unmodified SFV4 is provided in Annex 13. Sequences of all SFV 










Figure 2.1. Schematic representation of SFV4 clones available at the beginning 
of this project. nsP-non-structural protein; GP – genomic promoter; SGP – 
subgenomic promoter; 2SGP – duplicated subgenomic promoter; C – capsid; E1-E3 
– envelope glycoproteins; GLuc – Gaussia luciferase; vertical dashed line – protein 
cleavage sites; Poly(A) – Poly(A) tail; m
7






Table 2.4. SFV4 clones available at the beginning of this project. 





Dr Mhairi Ferguson, The 
Pirbright Institute (originally 
from Prof Andres Merits, 




eGFP inserted into the structural open reading frame, downstream of 
capsid protein, followed by FMDV 2A autoprotease sequence. eGFP is 
released into the cytoplasm of infected cells. 
Dr Rennos Fragkoudis, The 




zsGreen fused to C-terminus of nsP3 protein. zsGreen is localised to 
replication complexes in the cytoplasm. 
Dr Rennos Fragkoudis, The 
Pirbright Institute (originally 
from Prof Andres Merits, 




Gaussia luciferase (GLuc) inserted downstream of the structural 
polyprotein stop codon, under control of a duplicated subgenomic 
promoter. GLuc is secreted into cell culture supernatant. ß-globin intron 
is inserted in the capsid region to disrupt a cryptic E.coli promoter. 
Prof Andres Merits, 




zsGreen inserted in the C-terminus of nsP3, it is cleaved from nsP3 
during non-structural polyprotein processing. zsGreen is released into 
the cytoplasm of infected cells. Second marker GLuc is inserted in the 
3’UTR as per SFV4-2SG-GLuc described above. ß-globin intron is 
inserted in the capsid region to disrupt a cryptic E.coli promoter. 
Prof Andres Merits, 









Table 2.5. SFV4 clones generated during this project. 




zsGreen fused to C-terminus of nsP3 protein. GLuc inserted downstream 
of the structural polyprotein stop codon, under control of a duplicated 
subgenomic promoter. GLuc is secreted into cell culture supernatant.   
Adrian Zagrajek, The Roslin 
Institute (see Chapter 4) 




zsGreen fused to C-terminus of nsP3 protein. Recognition element (RE) 
for miR-142-3P inserted in the 3’UTR. 
Adrian Zagrajek, The Roslin 
Institute (see Chapter 4) 
SFV4-3F-zsGreen-             
miR-142-3P Antisense RE 
Infectious clone, 
CMV promoter 
zsGreen fused to C-terminus of nsP3 protein. Antisense RE for miR-
142-3P inserted in the 3’UTR. 
Adrian Zagrajek, The Roslin 
Institute (see Chapter 4) 
SFV4-3F-zsGreen-         
miRNA RE Control 
Infectious clone, 
CMV promoter 
zsGreen fused to C-terminus of nsP3 protein. Control miRNA RE 
inserted in the 3’UTR. 
Adrian Zagrajek, The Roslin 
Institute (see Chapter 4) 




As for SFV4-3F-zsGreen-miR-142-3P RE, but zsGreen is cleaved from 
nsP3 as per SFV4-3H-zsGreen-2SG-GLuc. 
Adrian Zagrajek, The Roslin 
Institute (see Chapter 4) 
SFV4-3H-zsGreen-            
miR-142-3P Antisense RE 
Infectious clone, 
CMV promoter 
As for SFV4-3F-zsGreen-miR-142-3P Antisense RE, but zsGreen is 
cleaved from nsP3 as per SFV4-3H-zsGreen-2SG-GLuc. 
Adrian Zagrajek, The Roslin 
Institute (see Chapter 4) 
SFV4-3H-zsGreen-        
miRNA RE Control 
Infectious clone, 
CMV promoter 
As for SFV4-3F-zsGreen-miRNA RE Control, but zsGreen is cleaved 
from nsP3 as per SFV4-3H-zsGreen-2SG-GLuc. 
Adrian Zagrajek, The Roslin 





As for SFV4-3F-zsGreen-miR-142-3P RE, but GLuc under control of a 
duplicated subgenomic promoter is inserted between the structural 
polyprotein stop codon and the RE. 
Adrian Zagrajek, The Roslin 
Institute (see Chapter 4) 
SFV4-3F-zsGreen-2SG-GLuc-
miR-142-3P Antisense RE 
Infectious clone, 
CMV promoter 
As for SFV4-3F-zsGreen-miR-142-3P Antisense RE, but GLuc under 
control of a duplicated subgenomic promoter is inserted between the 
structural polyprotein stop codon and the RE. 
Adrian Zagrajek, The Roslin 
Institute (see Chapter 4) 
SFV4-3F-zsGreen-2SG-GLuc-
miRNA RE Control 
Infectious clone, 
CMV promoter 
As for SFV4-3F-zsGreen-miRNA RE Control, but GLuc under control 
of a duplicated subgenomic promoter is inserted between the structural 
polyprotein stop codon and the RE 
Adrian Zagrajek, The Roslin 







2.3.2 Chikungunya virus (CHIKV) 
CHIKV clones used in this project were of ICRES1 (LR2006 OPY1) backbone and 
were available as icDNAs. To generate virus stock, CHIKV was rescued from 
icDNAs following the protocol outlined in 2.3.3.  
 
Five clones of CHIKV were available at the beginning of this project. They are 
summarised in Figure 2.2 and Table 2.6. During this project, 4 further clones were 
generated. They are summarised in Table 2.7. Their full design, cloning and testing is 
described in detail in Chapter 5.  
 
Sequence of the unmodified ICRES1 is provided in Annex 14. Sequences of CHIKV 






























Figure 2.2. Schematic representation of CHIKV clones available at the 
beginning of this project. ICRES1 – CHIKV strain LR2006 OPY1; nsP-non-
structural protein; GP – genomic promoter; SGP – subgenomic promoter;            
2SGP – duplicated subgenomic promoter; C – capsid; E1-E3 – envelope 
glycoproteins; RLuc – Renilla luciferase; FLuc – Firefly luciferase; Poly(A) – 
Poly(A) tail; m
7










Table 2.6. CHIKV clones available at the beginning of this project. 
Construct name Construct type Construct details Source 
ICRES1 
Infectious clone,  
SP6 promoter 
Unmodified infectious clone of CHIKV strain LR2006 OPY1. 
Dr Aleksei Lulla and Prof 
Andres Merits,  
University of Tartu 
ICRES1-3F-zsGreen 
Infectious clone,  
SP6 promoter 
zsGreen fused to C-terminus of nsP3 protein. zsGreen is localised to 
replication complexes in the cytoplasm. 
Dr Aleksei Lulla and Prof 
Andres Merits,  
University of Tartu 
ICRES1-3F-zsGreen-2SG-
mCherry 
Infectious clone,  
SP6 promoter 
zsGreen fused to C-terminus of nsP3 protein as in ICRES1-3F-zsGreen. 
mCherry followed by a duplicated subgenomic promoter inserted 
between non-structural and structural ORFs.  
Dr Aleksei Lulla and Prof 
Andres Merits,  
University of Tartu 
ICRES1-3F-RLuc 
Infectious clone,  
SP6 promoter 
Marker gene Renilla luciferase (RLuc) fused to C-terminus of nsP3 
protein. RLuc is localised to replication complexes in the cytoplasm. 
Fusion of RLuc to nsP3 does not inhibit RLuc activity. 
Dr Aleksei Lulla and Prof 
Andres Merits,  
University of Tartu 
ICRES1-3F-RLuc-2SG-FLuc 
Infectious clone,  
SP6 promoter 
Marker gene RLuc fused to nsP3 as in ICRES1-3F-RLuc. Firefly 
luciferase (FLuc) followed by a duplicated subgenomic promoter 
inserted between non-structural and structural ORFs. 
Dr Aleksei Lulla and Prof 
Andres Merits,  












Table 2.7. CHIKV clones generated during this project. 
Construct name Construct type Characteristic Source 
ICRES1-3F-zsGreen-        
miR-142-3P RE 
Infectious clone,  
SP6 promoter 
zsGreen fused to C-terminus of nsP3 protein as per ICRES1-3F-zsGreen. 
RE for miR-142-3P inserted between the non-structural and structural 
ORFs. 
Adrian Zagrajek, The Roslin 
Institute (see Chapter 4) 
ICRES1-3F-zsGreen-         
miRNA RE Control 
Infectious clone,  
SP6 promoter 
zsGreen fused to C-terminus of nsP3 protein as per ICRES1-3F-zsGreen. 
Control miRNA RE inserted between the non-structural and structural 
ORFs. 
Adrian Zagrajek, The Roslin 
Institute (see Chapter 4) 
ICRES1-3F-RLuc-             
miR-142-3P RE 
Infectious clone,  
SP6 promoter 
RLuc fused to C-terminus of nsP3 protein as per ICRES1-3F-RLuc.    
RE for miR-142-3P inserted between the non-structural and structural 
ORFs. 
Adrian Zagrajek, The Roslin 
Institute (see Chapter 4) 
ICRES1-3F-RLuc-          
miRNA RE Control 
Infectious clone,  
SP6 promoter 
RLuc fused to C-terminus of nsP3 protein as per ICRES1-3F-RLuc. 
Control miRNA RE inserted between the non-structural and structural 
ORFs. 
Adrian Zagrajek, The Roslin 
















2.3.3 Virus rescue  
To generate virus stock, both SFV and CHIKV were rescued from icDNAs, as 
described below. A range of DNA expression vectors was used as the backbone for 
icDNAs (e.g. modified pMA vector from GeneArt® was used for all ICRES1 
constructs). In all cases, virus was cloned under control of either the SP6 polymerase 
promoter or the CMV immediate early enhancer/promoter. The type of promoter 
present in the icDNA determined how a particular virus clone was rescued. 
 
2.3.3.1 Virus cloned under control of the SP6 polymerase promoter 
First, 10 µg of an icDNA was linearized by restriction digest as described in 2.16. 
SFV4 icDNAs were cut with SpeI (New England Biolabs, Annex 6) while ICRES1 
were cut with NotI (Roche, Annex 6). Next, linearized DNA was purified using 
NucleoSpin® Gel and PCR Clean-up (Macherey-Nagel, Annex 8) following the 
protocol outlined in 2.15.7. The purified DNA was inspected on an agarose gel as 
outlined in 2.14 to confirm the presence of a single band of the expected size. DNA 





, Annex 10). For subsequent steps, samples with concentration 
of >200 ng/µl and A260/280 of >1.9 were used.  
 
Viral genomic RNA was prepared by in vitro transcription of 1 µg of the purified 
linear icDNA using MEGAscript® SP6 kit (Life Technologies Ambion
TM
, Annex 6). 
Manufacturer’s protocol was followed (September 2010 version; Supplementary 
Data, Appendix 14). Cap analogue M
7
G(S’)ppp(S’)G (Life Technologies Ambion
TM
, 
Annex 6) was added to the reaction mixture at the same final concentration as 
ribonucleotides ATP, CTP and UTP. To facilitate Cap analogue incorporation the 
molar amount of GTP was diluted 1 in 5. Recombinant RNasin
®
 Plus Ribonuclease 
Inhibitor (Promega, Annex 6) was added at 40 U per reaction. The in vitro 
transcription was carried over a period of 1.5-2 hours. Synthesised viral genomic 
RNA was subsequently stored on ice until required, but not longer than 2-4 hours, or 
frozen at -80 ºC. In the latter case, the RNA was first aliquoted and subsequently 







Viral genomic RNA from the in vitro transcription (total reaction volume) was 
electroporated into BHK-21 cells to rescue the virus. In brief, 70-80% confluent 





-free sterile PBS by centrifugation for 5 min at 200 x g and RT, and 
counted. Subsequently, cells were pelleted by centrifugation for 5 min at 200 x g and 




 Life Sciences Gibco
®
, Annex 4) 
at 2 x 10
7
 cells per 800 µl. Viral genomic RNA was mixed gently with 800 μl of the 
cell suspension and incubated on ice for 10 minutes. Next, the cells/RNA mixture 
was transferred into a 0.4 cm cuvette (Bio-Rad, Annex 2) and electroporated using 
the Gene Pulser Xcell
TM
 Electroporation System (Bio-Rad, Annex 10). The 
following square wave protocol was used: 
- Voltage   – 850 V 
- Pulse length   – 4.0 msec  
- Number of pulses  – 2  
- Pulse interval   – 5.0 sec 
 
Electroporated cells were seeded into a T-175 flask in 20 ml of complete GMEM and 
incubated for 48 hours. Cell culture supernatant was collected 24 and 48 hours post-
electroporation and stored at 4 ºC for up to one week. At 24-hour point it was 
replaced with fresh complete GMEM. Next, the collected supernatant was clarified 
by centrifugation for 45 minutes at 4500 x g and 4 ºC. The clarified supernatant was 
aliquoted and frozen at -80 ºC unless further concentration was required (see below).  
 
Viruses were concentrated by ultracentrifugation through a 20% w/v sucrose 
cushion, when required. In brief, 8 ml of 20% w/v sucrose in TNE buffer (Annex 11) 
was added into an Ultra-Clear
TM
 ultracentrifugation tube (Beckman, Annex 2) and 
overlaid with 30 ml of the clarified cell culture supernatant containing the virus. 
Tubes were then ultracentrifuged for 90 min at 86,400 x g and 4 ºC using either L8-
70M Ultracentrifuge and SW28.1 rotor (Beckman Coulter, Annex 10) or Optima
TM
 
L-100K Ultracentrifuge and SW32 Ti rotor (Beckamn Coulter, Annex 10). Finally, 
all liquid was gently discarded, and the virus pellet was re-suspended in TNE buffer 







2.3.3.2 Virus cloned under control of the CMV promoter 
The icDNA was electroporated directly into BHK-21 cells without any processing of 
the plasmid. Only icDNAs with concentration of >500 ng/μl and A260/280 of >1.9 
were used. The protocol outlined in 2.3.3.1 was followed, with one modification. 
Instead of RNA from in vitro transcription, 10 μg of icDNA in Opti-MEM® in total 
volume of 20 μl was mixed with cells prior to electroporation.  
 
2.3.4 Virus stability 
SFV and CHIKV were passaged on BHK-21 cells at a ‘high’ MOI (estimated at 1-5) 
or at a ‘low’ MOI (estimated at 0.01-0.05), in quadruplicates. Depending on the virus 
used and the MOI required, 3 to10 passages were completed. 
 
For a ‘high’ MOI passage, BHK-21 cells were first harvested, counted and seeded 
into T25 flasks at 1 x 10
6
 cells/flask in 5 ml of complete GMEM. After 24 hours, cell 





 and 0.75% w/v Bovine Serum Albumin (PBSA) (Annex 11) was added to 
cells. Flasks were incubated for 1 hour at RT, after which 4 ml of complete GMEM 
was added. Flasks were incubated for 48 hours. Subsequently, 1 ml of the cell culture 
supernatant was collected and frozen at -80 ºC (Passage 1). For each subsequent 
passage 1 µl of the cell culture supernatant from previous passage was added to    
999 μl of fresh PBSA and used to infect new BHK-21 cells, as described above.  
 
For a ‘low’ MOI passage, the procedure described for a ‘high’ MOI was followed, 
however, initial infection was done at MOI=0.001 and for each subsequent passage  
1 µl of 1:100 diluted cell culture supernatant was used.  
 
2.3.5 Virus titration 
SFV and CHIKV were titrated by plaque assay on BHK-21 cells. First, cells were 
harvested, counted and seeded into either 6-well plates at 3 x 10
5
 cells per well in     
2 ml of complete GMEM or into 24-well plates at 6 x 10
4
 cells per well in 0.5 ml of 
complete GMEM. There was no significant difference between virus titres obtained 







Plates were incubated overnight. The desired cell monolayer confluence on the day 
of infection was 80%. Next, 10-fold serial dilutions of virus were performed in 
PBSA. Cell culture medium was aspirated from plates and 400 µl or 125 µl of each 
dilution was added in duplicates to wells in 6- or 24-well plates, respectively. Plates 
were rocked gently for 1-1.5 hour at RT. Plaque assay overlay was prepared by 
mixing GMEM complemented with 2% v/v NBCS, TPB and P/S with melted 4% 
w/v agar (Annex 11) at ration of 3:1 or with 2% w/v carboxymethyl cellulose (CMC) 
(Annex 11) at ratio of 3:2. There was no significant difference between virus titres 
obtained using 4% w/v agar or 2% w/v CMC (data not shown). Next, 3 ml or 1 ml of 
the overlay was added to each well of 6- or 24-well plates, respectively. Finally, 
plates were incubated for 48-72 hours, fixed with 10% v/v neutral buffered formalin 
(Leica Biosystems, Annex 5) for at least 1 hour (SFV) or 4 hours (CHIKV), stained 
with 0.1% toluidine blue (Sigma-Aldrich, Annex 7) for 30 min, washed with tap 
water and inspected for plaques. The titre expressed in Plaque Forming Units (PFU) 
per ml (PFU/ml) was calculated using the following formula: 
 
factordilution   mlin  inoculum of volume





In general, virus stocks were titrated using 6-well plates and experimental samples 
were titrated using 24-well plates. The overlay containing CMC was used in most 
cases. Importantly, all samples within one experiment and samples from all 
experiments to be directly compared with each other used the same format of the 
plaque assay (the type of plates and the type of overlay). 
 
2.3.6 Assessing stability of SFV and CHIKV encoding miR-142-3P RE 
The development and optimisation of this assay is described in detail in 4.15. First, 
Hek 293 miR-142 and Hek 293 Control cells were harvested, counted and seeded 
into 6-well plates at 2.5 x 10
6
 cells/well in 2 ml of complete DMEM with 
doxycycline at 100 ng/ml (Sigma-Aldrich®, Annex 4). Plates were incubated for 24-
26 hours. Next, 10-fold serial dilutions of virus samples were performed in PBSA. In 







miR-142-3P (e.g. SFV4-3F-zsGreen, ICRES1-3F-zsGreen) were performed in 
PBSA, in quadruplicates. The assay overlay was prepared by mixing 3 parts of 
DMEM supplemented with 5% v/v FBS and P/S with 2 parts of 2% CMC. 
Doxycycline was added to the overlay at 100 ng/ml final concentration. Next, cell 
culture medium was aspirated from plates and 650 μl of each dilution was added 
gently to wells in both Hek 293 miR-142 and Hek 293 Control plates, in duplicates. 
Plates were rocked gently by hand and then placed on a flat surface for 1-1.5 hours. 
The volume of inoculum was sufficient to stop the monolayers from drying out 
without constant rocking. However, cells were rocked very gently by hand every 15-
20 minutes to ensure equal distribution of virus inoculum. As cells were not strongly 
adherent, any excessive handling would detach them from the surface of wells. Next, 
virus inoculum was gently pipetted off and discarded, and 3 ml of the overlay was 
added gently to each well. Plates were incubated for 48 hours. Finally, plates were 
fixed overnight with 10% v/v neutral buffered formalin, washed gently with tap 




 per well. Plates were 
inspected microscopically for the presence of virus plaques as indicated by localised 
expression of zsGreen encoded by all tested viruses (see 2.7.1). Any foci of infection 
bigger than 8 cells were treated as a plaque (see Chapter 4 for details). The formula 
described in 2.3.5 was used to calculate the titre of each sample on both Hek 293 
miR-142 and Hek 293 Control cells. Next, the fraction of virus able to replicate in 
the presence of miR-142-3P (in %) was calculated by normalising the titre obtained 
on Hek 293 miR-142 cells to the titre obtained on Hek 293 Control cells. The above 
data were further normalised to the average titres obtained for the control virus (e.g. 
SFV4-3F-zsGreen, ICRES1-3F-zsGreen) to compensate for any differences in the 
infectivity of Hek 293 miR-142 and Hek 293 Control cells. Virus stability was 
expressed as the fraction of virus (in %) unable to form plaques in presence of miR-
142-3P. 
 
2.3.7 One-step growth curves 
BHK-21 cells were harvested, counted and seeded into 24-well plates at 6 x 10
4
 
cells/well, in 0.5 ml of complete GMEM, and incubated overnight. Next, cell 







at MOI of 10, in quadruplicates. Plates were rocked for 1 hour at RT. Next, virus 
inoculum was removed, and 0.6 ml of complete GMEM was added to all wells. 
Plates were rocked gently for 1 minute and 0.1 ml was collected from each well (0 h 
sample), living the final volume of 0.5 ml in all wells. Plates were incubated for 2 
hours. Next, 0.1 ml was removed from each well (2 h samples) and replaced with 0.1 
ml of fresh complete GMEM. Plates were returned to the incubator. The sampling 
was repeated 4, 6, 8, 10, 12, 16, 20 and 24 hours post-infection. Samples were stored 
at 4 ºC until all collections were completed. Then, all samples were frozen at -80 ºC. 
Virus replication was tested by plaque assay (all samples), and luciferase assay if 
available (SFV4 clones expressing GLuc). 
 
2.4 Virus replicon particles (VRPs) 
 
2.4.1 Semliki Forest VRPs 
One clone of SFV replicon was used in this project, SFV1-3F-zsGreen. The replicon 
was of SFV1 backbone, which was based on SFV4. To generate VRP stock, SFV1-
3F-zsGreen was rescued following the protocol outlined in 2.4.3. Split-helper system 
was used. The SFV1-3F-zsGreen and the split-helper constructs used are summarised 
in Figure 2.3 and Table 2.8. Their plasmid sequences are provided in Supplementary 





Figure 2.3. Schematic representation of SFV1-3F-zsGreen replicon. nsP-non-
structural protein; GP – genomic promoter; SGP – subgenomic promoter; Poly(A) – 
Poly(A) tail; m
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Table 2.8. SF replicons and helper constructs used in this project. 




zsGreen fused to C-terminus of nsP3 protein. zsGreen is localised to 
replication complexes in the cytoplasm. Replicon equivalent of SFV4-
3F-zsGreen. 
Dr Rennos Fragkoudis, The 
Pirbright Institute (originally 
from Prof Andres Merits, 




Encodes envelope glycoproteins only under control of the subgenomic 
promoter. 
Dr Rennos Fragkoudis, The 
Pirbright Institute (originally 
from Prof Andres Merits, 




Encodes capsid protein only under control of the subgenomic promoter. 
Dr Rennos Fragkoudis, The 
Pirbright Institute (originally 
from Prof Andres Merits, 















2.4.2 Chikungunya VRPs 
Chikungunya replicons used in this project were of ChikRepl backbone, which was 
based on ICRES1. To generate VRP stock, chikungunya replicons were rescued as 
described in 2.4.3. Split-helper system was used. Five clones of chikungunya 
replicons were available at the beginning of this project. They are summarised in 
Figure 2.4 and Table 2.9. During this project, 4 further clones were generated. They 
are summarised in Table 2.10. Their full design and cloning is described in detail in 
Chapter 5. Sequences of all chikungunya replicons and helper plasmids used in this 




Figure 2.4. Schematic representation of chikungunya replicons available at the 
beginning of the project. nsP-non-structural protein; GP – genomic promoter;    
SGP – subgenomic promoter; RLuc – Renilla luciferase; FLuc – Firefly luciferase; 
m
7















zsGreen fused to C-terminus of nsP3 protein. zsGreen is localised to replication 
complexes in the cytoplasm. Replicon equivalent of ICRES1-3F-zsGreen. 
Prof Andres Merits and Dr 
Aleksei Lulla,           
University of Tartu 




zsGreen fused to nsP3 as in ChikRepl-3F-zsGreen. mCherry inserted 
downstream of the non-structural ORF. mCherry can be used to indirectly 
monitor the activity of the subgenomic promoter in the absence of the structural 
ORF. Replicon equivalent of ICRES1-3F-zsGreen-2SG-mCherry.  
Prof Andres Merits and Dr 
Aleksei Lulla,           




RLuc fused to C-terminus of nsP3 protein. RLuc is localised to replication 
complexes in the cytoplasm. Fusion of RLuc to nsP3 does not inhibit RLuc 
activity. Replicon equivalent of ICRES1-3F-RLuc.  
Prof Andres Merits and Dr 
Aleksei Lulla,           
University of Tartu 




RLuc fused to nsP3 as in ChikRepl-3F-RLuc. FLuc inserted downstream of the 
non-structural ORF. FLuc can be used to indirectly monitor the activity of the 
subgenomic promoter in the absence of the structural ORF. Replicon equivalent 
of ICRES1-3F-RLuc-2SG-FLuc. 
Prof Andres Merits and Dr 
Aleksei Lulla,           
University of Tartu 
Chik-Helper-S Helper Encodes envelope glycoproteins under control of the subgenomic promoter. 
Prof Andres Merits and Dr 
Aleksei Lulla,           
University of Tartu 
Chik-Helper-C Helper Encodes capsid protein under control of the subgenomic promoter. 
Prof Andres Merits and Dr 
Aleksei Lulla,           



















zsGreen fused to C-terminus of nsP3 protein. zsGreen is localised to replication 
complexes in the cytoplasm. RE for miR-142-3P inserted downstream of the 
non-structural ORF. Replicon equivalent of ICRES1-3F-zsGreen-miR-142-3P 
RE. 
Adrian Zagrajek, The Roslin 
Institute (see Chapter 5) 
ChikRepl -3F-zsGreen-       
miRNA RE Control 
Replicon,  
SP6 promoter 
zsGreen fused to C-terminus of nsP3 protein. zsGreen is localised to replication 
complexes in the cytoplasm. Control miRNA RE inserted downstream of the 
non-structural ORF. Replicon equivalent of ICRES1-3F-zsGreen-miRNA RE 
Control. 
Adrian Zagrajek, The Roslin 
Institute (see Chapter 5) 




RLuc fused to C-terminus of nsP3 protein. RLuc is localised to replication 
complexes in the cytoplasm. Fusion of RLuc to nsP3 does not inhibit RLuc 
activity. RE for miR-142-3P inserted downstream of the non-structural ORF. 
Replicon equivalent of ICRES1-3F-RLuc-miR-142-3P RE. 
Adrian Zagrajek, The Roslin 
Institute (see Chapter 5) 
ChikRepl -3F-RLuc-          
miRNA RE Control 
Replicon,  
SP6 promoter 
RLuc fused to C-terminus of nsP3 protein. RLuc is localised to replication 
complexes in the cytoplasm. Fusion of RLuc to nsP3 does not inhibit RLuc 
activity. Control miRNA RE inserted downstream of the non-structural ORF. 
Replicon equivalent of ICRES1-3F-RLuc-miRNA RE Control. 
Adrian Zagrajek, The Roslin 












2.4.3 VRP rescue 
To generate VRP stock, both Semliki Forest and chikungunya replicons were rescued 
as described for infectious virus (see 2.3.3), with minor modifications (see below). 
All Semliki Forest and chikungunya replicons and helper constructs were cloned 
under control of the SP6 polymerase promoter.  Only helper constructs from the 
split-helper system were used to provide virus structural genes in trans during VRP 
generation.  
 
Linearized chikungunya replicon and Helper-C constructs were always tested by 
Polymerase Chain Reaction (PCR) for the presence of CHIKV E1 prior to in vitro 
transcription according to the protocol outlined in 2.11.1. The primers and cycling 
conditions (Annex 12, protocol 1) were adopted from Hoarau et al. (2010).  
 
Replicons and split helper constructs were transcribed in vitro at the same time. The 
RNA from all 3 reaction was mixed and electroporated into BHK-21 cells. VRPs 
were collected 16-20 and then 40-44 hours post-electroporation. VRP stock was 
always concentrated by ultracentrifugation through a 20% w/v sucrose cushion. 
 
2.4.4 VRP titration 
VRP were titrated as described for infectious virus plaque assay, in the 6-well plate 
format (see 2.3.5), with minor changes. BHK-21 cells were fixed 14-18 hours post-
infection with 10% v/v neutral buffered formalin for at least 1 hour (SFV1) or 4 





 (2 ml per well) and observed microscopically for 
cells expressing the fluorescent marker (see 2.7.1). If VRPs did not encode a 
fluorescent marker, the cell monolayer was first immunostained for viral nsP3 (see 
2.6). VRP titre expressed in Infectious Units per ml (IU/ml) was calculated according 
to the formula used to calculate a virus titre (see 2.3.5). 
 
2.4.5 Confirmation of absence of propagating virus in VRP stock 
Virus isolation was performed to confirm that a VRP stock was free of replication-
competent virus. In brief, 50% confluent BHK-21 cells in a T-175 flask were washed 
  









-free PBS, covered with 10 ml of PBSA containing 50 µl of 
a purified VRP stock and incubated at RT for 1 hour. Next, 20 ml of complete 
GMEM was added to the flask. Cells were incubated for 3 days. Next, 10 ml of the 
cell culture supernatant was transferred to a fresh T-175 flask with 50% confluent 
BHK-21 cells in 20 ml of complete GMEM. The second flask was incubated for 4 
days and observed daily for presence of cytopathic effect (CPE). If no CPE was 
observed at the end of day 4, VRP stock was free of replication-competent virus.  
 
However, in case of chikungunya VRPs, all virus-isolation negative VRP stock and 
the cell culture supernatant at the end of virus isolation were further tested by PCR 
for presence of structural genes. The additional layer of control was required as 
presence of any replication-competent virus in the VRP stock would result in ACDP 
HG 3 material being handled in a CL 2 laboratory. In brief, RNA was extracted from 
50 μl of the VRP stock and the cell culture supernatant at the end of virus isolation 
using QIAamp Viral RNA Mini Kit (Qiagen, Annex 8), as described in 2.15.5. Next, 
cDNA was generated from 100 ng of purified RNA as described in 2.12. Finally, the 
cDNA was tested by PCR for CHIKV E1 (Annex 12, protocol 1), CHIKV nsP4-E1 
(Annex 12, protocol 2) and CHIKV nsP4-E3 (Annex 12, protocol 3). The latter two 
assays were developed specifically to test VRPs for recombination between the 
replicon RNA and helper RNAs. Chikungunya VRPs were used only when virus 
isolation and both PCRs were negative.  
 
2.4.6 Preparation of chikungunya replicon RNA for transfection 
First, chikungunya replicon was transcribed in vitro following the protocol outlined 
in 2.4.3. No plasmids encoding CHIKV structural genes were handled at the same 
time. Next, replicon RNA was purified from the reaction mixture using RNeasy® 
Mini Kit as described in 2.15.5. The quality of purified RNA was inspected on a non-
denaturing agarose gel as outlined in 2.14. RNA concentration and purity was 
measured using NanoDrop
TM
 spectrophotometer. Finally, the RNA was aliquoted, 
snap-frozen on dry ice, and moved to -80 ºC freezer. RNA aliquots were thawed only 
once to preserve the RNA integrity. 
 
  





2.5 In vitro infections 
 
2.5.1 Infecting cells (other than MDM) with virus or VRPs 
First, cells were harvested, counted and seeded according to Table 2.11. If required, 
13 mm sterile cover glasses (VWR, Annex 9) were first added to wells of 24-well 
plates. On the day of infection, virus/VRP inoculum was prepared in PBSA at the 
required MOI (the amount of virus was calculated assuming that the cell number 
doubled every 24 hours with the exception of Thp-1 cells, which would not divide 
following the induction with PMA). Cell supernatant was removed and 200 µl and   
33 µl of virus/VRP inoculum was added per well into 24- and 96-well plates, 
respectively. Plates were rocked gently for 1 hour at RT. Special care was paid to 
Hek 293T, Hek 293 miR-142 and Hek 293 miRNA RE Control cells.  These cells 
would detach from the surface of wells/cover glass if not handled carefully. Next, 










-free PBS. Hek 293T, Hek 293 miR-142, Hek 293 miRNA RE Control, NIH 
3T3 and BHK-21 cells were not washed. Finally, 0.6 ml and 0.1 ml of complete 
medium per well was added to 24- and 96-well plates, respectively. Plates were 
incubated for 20 hours, unless otherwise stated. 
 
 
Table 2.11. Seeding cells for virus infections. 
Cells 








IC-21; NIH-3T3 8 x 10
4
  1.3 x 10
4
  24 hours - 
Thp-1 1.6 x 10
5
  2.7 x 10
4
  48 hours 
Complete medium 
supplemented with 20 
ng/ml PMA. 
BHK-21; NHDF 6 x 10
4
  1 x 10
4
  24 hours - 
Hek 293T 1.5 x 10
5
  2.5 x 10
4
  24 hours - 
Hek 293 miR-142-3P; 




  4.2 x 10
4
  24 hours 
Complete medium 
supplemented with 100 
ng/ml doxycycline, if 
required (details in 
Chapter 4). 
  





2.5.2 Collecting and analysing samples post in vitro infection 
At the end of an in vitro experiment all required samples were collected, processed 
and/or stored as described below, unless indicated otherwise. For a plaque assay, cell 
culture supernatant (at least 100 μl) was collected and frozen at -80 ºC as soon as 
feasible. Samples were analysed as described in 2.3.5. For a GLuc assay, cell culture 
supernatant (at least 100 μl) was collected and stored at 4ºC for a short-term storage 
(up to 1 week) or frozen at -80 ºC for a long-term storage. Samples were analysed as 
described in 2.9.3. For RLuc assay (CHIKV), samples were analysed immediately as 
described in 2.9.1. For RLuc assay (ChikRepl), samples were analysed immediately 
as described in 2.9.2. For microscopy, cells were immediately fixed in 10% v/v 
neutral buffered formalin for at least 1 hour (SFV) or 4 hours (CHIKV), processed as 
described in 2.6 and analysed as described in 2.7.1 and 2.7.4. 
 
2.5.3 Generating cell debris from virus-infected cells 
HeLa, 2fTGH or U4C cells were harvested, counted and seeded into T-25 flasks at   
1 x 10
6
 cells/flask in 5 ml of complete DMEM. Flasks were incubated overnight. 




-free PBS and covered with 1 ml of 
virus/VRP diluted in PBSA to give MOI of 5. Flasks were rocked for 1 hour at RT, 
after which they were topped up with 8 ml of complete DMEM and incubated for 72 
hours. Next, cell culture supernatant (approximately 8 ml) was collected and pre-
clarified by centrifugation at 3000 x g and 4 ºC for 10 min. Approximately  75% of 
the supernatant was removed, and passed through 0.2 µm, 0.45 µm or 0.8 µm filter 
(clarified supernatant). The debris pellet was re-suspended in the remaining 25% of 
the supernatant (unclarified supernatant).  
 
2.5.4 Infection of MDMs with cell debris 
MDMs were harvested, counted and seeded into 24-well plates at 1.6 x 10
5
 cells/well 
in 0.5 ml of complete RPMI. After 48 hours, cell supernatant was removed and cells 




-free PBS. Next, clarified or unclarified 
supernatant (see 2.5.3) diluted in complete RPMI with 40 U/ml rhCSF1 was added to 
cells, as described below.  
  





Initial experiments used supernatants diluted 1 in 10 in the final volume of 1 ml per 
well. Plates were incubated for 2-3 days, during which the inoculum was not 
removed. Live cells were inspected microscopically for the expression of the 
fluorescent marker encoded by the virus/VRP every 24 hours using Zeiss Axio 
Observer.D1  inverted microscope (Zeiss, Annex 10) (see 2.7.1). 
 
Later experiments used cell supernatants diluted 1 in 2 in the final volume of 0.5 ml. 
In addition, MDMs were seeded onto sterile cover glasses placed at the bottom of all 
plate wells. Following addition of complete RPMI with cell debris, plates were 
incubated for 6 hours. Next, the cell supernatant was removed and MDMs were 




+-free PBS. Finally, 1 ml of fresh complete RPMI 
with 1 x rhCSF1 was added to each well. Plates were incubated for 2 days. After 24 
hours, live cells were inspected microscopically using Zeiss Axio Observer.D1 
inverted microscope (see 2.7.1). After 48 hours, cells were fixed in 10% v/v neutral 





Next, cover glasses were removed from plates and mounted using VECTASHIELD 
mounting medium with DAPI (Vector Laboratories, Annex 9). Cells were inspected 
microscopically for the expression of the fluorescent marker encoded by the 
virus/VRP using Zeiss Axioskop 2 upright microscope (Zeiss, Annex 10) (see 2.7.1). 
 
2.5.5 Infection of MDMs with purified virus 
MDMs were harvested, counted and seeded into 96-well plates as described in 2.5.4. 





-free PBS. Next, 270 μl of complete RPMI with 40 U/ml rhCSF1 was 
added to each well. Finally, 30 μl of SFV4-steGFP diluted in PBSA to give the 
desired MOI (1, 50,100,500 and 1000) was added directly into the cell supernatant. 
Plates were incubated for 48 hours. Live cells were inspected microscopically for the 
expression of virus-encoded eGFP every 24 hours using Zeiss Axio Observer.D1 









2.5.6 Infection of MDMs with purified virus mixed with cell debris from 
uninfected HeLa cells 
First, cell debris from non-infected cells was generated. In brief, HeLa cells were 










PBS. Flasks were incubated for 72 hours. Clarified and unclarified cell culture 
supernatant was prepared as described in 2.5.3 and then diluted 1 in 2 in complete 
RPMI with 40 U/ml rhCSF. 
 
MDMs were harvested, counted, seeded into 24-well plates and incubated for 48 
hours as described in 2.5.4 (no cover glasses used). Next, MDM supernatant was 




-free PBS. Clarified and 
unclarified supernatants diluted 1:2 in complete RPMI were added to MDMs at 0.5 
ml per well with 40 U/ml rhCSF. Finally, 100 μl of SFV4-steGFP diluted in PBSA to 
give MOI of 50 was added to all wells. Plates were incubated for 48 hours. Live cells 
were inspected microscopically for the expression of eGFP every 24 hours using 
Zeiss Axio Observer.D1 inverted microscope (see 2.7.1). 
 
2.6 Immunostaining (SFV nsP3) 
First, virus-infected cells were fixed for 1-4 hours with 10% v/v neutral buffered 




 for 5 minutes, 
three times. Cells were covered in 0.3% v/v Triton
TM
 X-100 in PBS (Annex 9) for 20 
minutes. Cells were washed with PBS as above and incubated for 30 minutes with 
CAS-BLOCK
TM
 (ZYMED Laboratories, Annex 9). Next, rabbit polyclonal anti-SFV 





 was removed from cells and the primary antibody 
was applied. Cells were incubated at RT for 90 minutes in a humid chamber and 
subsequently washed in PBS for 10 minutes, three times. Donkey anti-Rabbit 
Secondary Antibody conjugated to Alexa Fluor® 488 (Life Technologies, Annex 9) 
was diluted 1:1000 in CAS-BLOCK
TM
 and applied to cells. Next, cells were 
incubated at RT for 45 minutes in a humid chamber and subsequently washed in PBS 
for 10 minutes, three times.  
  





Optionally, cells were incubated with DAPI (Sigma-Aldrich®, Annex 9) in H2O at 
0.1 mg/ml for 15 minutes at RT. If this step was followed, cells were subsequently 
washed with PBS for 10 minutes, three times.  
 
Cells on a cover glass or a glass slide were mounted with VECTASHIELD mounting 
medium with or without DAPI (Vector Laboratories, Annex 9). If cells were on a 




 was added to all 




2.7.1 Epifluorescent microscopy  
Zeiss Axioskop 2 upright microscope and Zeiss Axio Observer.D1 inverted 
microscope were used. Both microscopes were fitted with filters suitable for 
visualisation of DAPI, eGFP, zsGreen, Alexa Fluor® 488, mCherry and Alexa 
Fluor® 594. Zeiss AxioVision 4.8 digital image processing software was used. All 
images taken were saved as uncompressed zvi files.  
 
2.7.2 Confocal microscopy 
The confocal microscopy was done by Dr Pippa Hawes at the Pirbright Institute 
using Leica TCS SP5 confocal microscope. 
 
2.7.3 Transmission electron microscopy (TEM) of cell debris 
First, cell debris from virus/VRP infected cells was prepared as described in 2.5.3, 
with one alteration. Following centrifugation of cell culture supernatant at 3000 x g 
and 4 ºC for 10 min, all supernatant was removed. Next, the debris pellet was re-
suspended in 1 ml of 3% v/v glutaraldehyde in cacodylate buffer (received from 
Steven Mitchell, the University of Edinburgh) and placed on ice. Within 3 hours, 
samples were moved to the Electron Microscope facility of the School of Biological 
Sciences, the University of Edinburgh.  
 
  





Next, samples were processed by Steven Mitchell, the University of Edinburgh. In 
brief, samples were post-fixed in 1% osmium tetroxide in cacodylate buffer, 
dehydrated in acetone, embedded in Araldite resin, sectioned on a Reichert OMU4 
ultramicrotome (Leica) and stained in uranyl acetate and lead citrate. 
 
Finally, samples were viewed and imaged using a Phillips CM120 transmission 
electron microscope and a Gatan Orius CCD camera.  
 
2.7.4 Calculating the proportion of virus-infected cells 
For live cells, 5-10 random areas per each well were screened for adherent cells 
expressing virus-encoded fluorescent marker using fluorescence microscopy at       
10 x magnification. For each well, the proportion of fluorescent marker-positive cells 
in each individual area was estimated (in %), and then averaged. 
 
For cells fixed in 10% v/v neutral buffered formalin, cell nuclei were first stained 
with DAPI (see 2.6). Next, 5 random areas per each well were visualised using 
fluorescence microscopy at 10 x magnification and photographed. Cells expressing 
virus-encoded fluorescent marker and total cells (as indicated by DAPI) were 
counted using ‘Cell counter’ plugin built into ImageJ (Rasband, W.S., ImageJ, U. S. 
National Institutes of Health, Bethesda, Maryland, USA, http://imagej.nih.gov/ij/, 
1997-2014). For each well, the proportion of fluorescent marker-positive cells in 
each individual area was counted, and then averaged. 
 
2.8 Cell viability assay 
CellTiter-Glo® Luminescent Cell Viability Assay (Promega, Annex 6) was used. 
The manufacturer’s protocol was followed (3/15 version; Supplementary Data, 
Appendix 15), with following modifications. Cells were grown in a standard tissue-
culture-treated 96-well plate, with 100 μl of a complete cell culture medium per well. 
Following the addition of CellTiter-Glo® Reagent and the 10 minute incubation at 
RT, 150 μl of the reaction mixture was transferred from each well into a white 
LUMITRAC
TM
200 96-well plate (Greiner Bio-One, Annex 1). The luminescence 
was recorded using GloMax® Microplate Reader (Promega, Annex 10).  
  





2.9 Luciferase assay 
 
2.9.1 Renilla luciferase – CHIKV 
Dual-Glo® Luciferase Assay System (Promega, Annex 6) was used to determine the 
expression of RLuc in CHIKV-infected cells. The manufacturer’s protocol was 
followed (9/11 version, Supplementary Data, Appendix 16), with following 
modifications. Cells were grown in a standard tissue-culture-treated 96-well plate, 
with 100 μl of a complete cell culture medium per well. After the addition of Dual-
Glo® Luciferase Reagent the plate was incubated for 10 minutes at RT. 
Subsequently, Dual-Glo® Stop & Glo® Reagent was added and the plate was 
incubated for further 10 minutes at RT. Next, 150 μl of the reaction mixture was 
transferred from each well into white LUMITRAC
TM
200 96-well plate which was 
subsequently sealed with MicroAmp® Optical Adhesive Film (Life Technologies 
Applied Biosystems®, Annex 2). In addition, a robust and waterproof adhesive tape 
was applied to the edges of the film to ensure that the plate is completely sealed. The 
luminescence was recorded using GloMax® Microplate Reader.  
 
The presence of MicroAmp® Optical Adhesive Film was a biosecurity requirement 
as plates were moved between a CL3 laboratory and a CL2 laboratory, where the 
plate reader was located. The adhesive film reduced the recorded luminescence by 
approximately 10%. This effect was consistent across a wide range of RLuc 
concentration (data not shown).  
 
2.9.2 Renilla luciferase – ChikRepl  
Dual-Luciferase® Reporter Assay System (Promega, Annex 6) was used to 
determine the expression of RLuc in ChikRepl-transfected cells. The manufacturer’s 
protocol was followed (6/11 version; Supplementary Data, Appendix 17). Cells were 
grown in 24-well plates and lysed using the Passive Lysis Buffer. Ten μl of the cell 
lysate was transferred into a white LUMITRAC
TM
200 96-well plate. The 
luminescence was recorded using GloMax® Microplate Reader. Dual Injectors 
System was used to dispense 50 µl of both reagents per well.  
 
  





2.9.3 Gausia luciferase – SFV  
Dual-Luciferase® Reporter Assay System was used to determine the expression of 
GLuc in SFV-infected cells. The protocol outlined in 2.9.2 was followed, however, 
10 µl of a cell culture supernatant and not cell-lysate was tested for each sample 
(GLuc is secreted into cell culture supernatant, lysis of cells is not required). 
 
2.10 Transfection of nucleic acids into mammalian cells 
FuGENE® 6 Transfection Reagent (Promega, Annex 6) was used to transfect DNA. 
Lipofectamine® 2000 Transfection Reagent (Invitrogen
TM
 Life Technologies, Annex 
6) was used to transfect DNA and RNA. 
 
2.10.1 FuGENE® 6 Transfection Reagent (DNA) 
The manufacturer’s protocol was followed (4/11 version; Supplementary Data, 
Appendix 18). Cells to be transfected were grown in a 96-well plate, with 100 μl of a 
complete cell culture medium with no P/S per well. Cells were transfected with     
200 ng of a DNA plasmid in 10 µl of DNA/FuGENE® 6 mixture per well.  
DNA:FuGENE® 6 ratio of 1:3 was used. Cells were incubated for 24-26 hours 
before being assayed. During this time the cell culture supernatant was not changed. 
 
2.10.2 Lipofectamine® 2000 Transfection Reagent (DNA and RNA) 
DNA was transfected following the manufacturer’s protocol (July 2011 version; 
Supplementary Data, Appendix 19). Cells to be transfected were grown in a 6-well 
plate, with 2 ml of a complete cell culture medium with no P/S per well. Cells were 
transfected with 10 µg of DNA plasmids in 500 µl of DNA/Lipofectamine® 2000 
mixture per well. DNA:Lipofectamine® 2000 ratio of 1:3 was used. The cell culture 
supernatant was not changed following the transfection.  
 
RNA was transfected as outlined for DNA. For a 24-well plate, 0.8 µg of purified 
RNA (see 2.15.5) was transfected per well using RNA:Lipofectamine 2000 ratio of 
1:3 in 100 µl of RNA/Lipofectamine® 2000 mixture. The cell culture supernatant 
was not changed following the transfection. 
 
  





2.11 Polymerase Chain Reaction (PCR) 
Venti 96-well Thermal Cycler (Life Technologies Applied Biosystems®, Annex 10) 
was used to amplify DNA via the conventional Polymerase Chain Reaction (PCR) 
using GoTaq® DNA Polymerase (Promega, Annex 6), Vent® DNA Polymerase 
(New England Biolabs, Annex 6) or Pfu DNA Polymerase (Promega, Annex 6). All 
reactions were performed in the final volume of 50 µl. The PCR reaction mixture 
universally included 1 µl of each primer at 10 µM concentration (Sigma-Aldrich® or 
Invitrogen
TM
 Life Technologies), 1 µl of deoxynucleotide (dNTP) solution mixture at 
10 mM concentration each (Bioline, Annex 6), 1 µl of a DNA template at less than 
0.5 µg/µl concentration and nuclease-free water (Sigma-Aldrich®, Annex 6). Thin 
wall 0.2 µl tubes were used (Axygen, Annex 2).  
 
For a new PCR protocol, the annealing temperature was initially tested at 2-3ºC 
below the higher of the two primer melting temperatures (Tm). If required, a range of 
annealing temperatures was subsequently tested, typically in 2 ºC or 3 ºC steps.  
 
Details of all PCR primers and cycling conditions are located in Annex 12. 
 
2.11.1 GoTaq® PCR 
The manufacturer’s protocol was followed (version 3/12; Supplementary Data, 
Appendix 20). The 5x Green GoTaq® Reaction Buffer was used. 
 
2.11.2 Vent® PCR 
The manufacturer’s protocol was followed (Supplementary Data, Appendix 21). The 
Vent® polymerase was added at 0.5 µl (1 unit) per reaction. The PCR reaction was 
not supplemented with MgSO4. 
 
2.11.3 Pfu PCR 
The manufacturer’s protocol was followed (10/09 version; Supplementary Data, 









2.11.4 Primer design 
Eleven primer pairs were designed for control PCRs. In general, the designed 
primers were 18-22 bases long, had GC content of 52.4-61.1% and Tm of 51.1-    
58.6 ºC. Each primer of a pair had the same length, GC content and Tm. All primers 
were design manually by analysing the available sequences (or predicted sequences). 
Whenever possible, the primer pair was designed to amplify a fragment of clearly 
identifiable size (e.g. exactly 400 bp). Finally, all control primers were designed to 
anneal to the template at least 100 bases upstream or downstream of the sequence of 
interest (e.g. cloning site) so that the primers could be used for sequencing.  
 
Fifteen primer pairs were designed to amplify a target sequence for cloning. Overall, 
the designed primers were 26-28 bases long, had GC content of 50-69.2 % and Tm of 
61.1-67.4. All primers were composed of a core section of 17-19 bases that annealed 
to the target sequence (GC content of 41.2-66.7% and Tm of 42.2-54.9). This was 
followed by the sequence of a restriction site to be used for cloning and three random 
bases. The sequence of all cloning primers was dependent on the sequence of the 
restriction sites to be added in addition to the target sequence. Hence, variations in 
GC content and Tm between primers within a pair were occasionally large. The three 
random bases were used to minimise the differences in GC content and Tm between 
primers from one pair and to enhance the recognition of the cleavage site by a 
restriction enzyme. 
 
Primer Tm was calculated using the Wallace formula (Wallace et al. 1979): 
 
𝑇𝑚 =  64.9 + 41 ∗
𝑦𝐺 + 𝑧𝐶 − 16.4
𝑤𝐴 + 𝑥𝑇 + 𝑦𝐺 + 𝑧𝐶
 
 












2.11.5 Colony PCR 
A GoTaq® PCR reaction mixture was set up and aliquoted into PCR tubes (see 2.11 
and 2.11.1). No template DNA was added. Next, a sterile pipette tip was used to pick 
a single bacteria colony from an agar plate and dip it into a tube containing the PCR 
reaction mixture. Next, the tip was removed from the tube and used to streak a fresh 
agar plate containing the required selection antibiotic (see 2.19.1). Finally, PCR was 
run following the applicable protocol (see Annex 12). Samples were analysed by 
agarose gel electrophoresis (see 2.14). 
 
2.11.6 Annealing of oligonucleotides 
Long DNA oligonucleotides (78-81 bases) with 18 bases of a complementary 
sequence were annealed and extended using Vent® DNA polymerase. The standard 
protocol was modified. Both oligonucleotides were added at the concentration of   
100 µM and the amount of dNTPs was doubled. The following cycling conditions 
were used: 
 
Denaturation      –    95 ºC  – 2 min 30 sec x 1 
Annealing      –    55 ºC  – 2 min x 1 
Extension         –    72 ºC  – 5 min x 1 
4 ºC   ∞ 
 
2.12 Reverse Transcription 
First-strand cDNA was synthesised using SuperScript
TM
 III Reverse Transcriptase 
(Invitrogen
TM
 Life Technologies, Annex 6). The manufacturer’s protocol was 
followed (December 2004 version; Supplementary Data, Appendix 23). The reaction 
was set up using 200 ng of purified RNA (see 2.15.4) and oligo(dT)20. Finally, 
cDNA was treated with RNase H (Invitrogen
TM
 Life Technologies, Annex 6). 
 
2.13 Quantitative PCR (qPCR) 
First-strand cDNA was synthesised using High Capacity cDNA Reverse 
Transcription Kit (Life Technologies, Annex 6) in Venti 96-well Thermal Cycler. 
The following reaction mixture in 15 µl final volume was set up for all samples: 
  





- 10 x RT buffer     – 1.5 µl 
- Primer (0.5 µM stock)    – 3 µl 
- dNTPs      – 0.15 µl 
- RNase inhibitor     – 0.19 µl 
- MultiScribeTM reverse transcriptase  – 0.5 µl 
- Nuclease-free water   – up to the final volume of 15 µl  
- RNA      – 200 ng 
 
Reverse transcription was completed using the following thermal cycling conditions: 
 
16 ºC     – 30 min x 1 
42 ºC      – 30 min x 1 
85 ºC       – 2 min x 1 
4 ºC – ∞ x 1 
 
Quantitative PCR (qPCR) was performed using TaqMan® Universal PCR Master 
Mix (Life Technologies Applied Biosystems®, Annex 6) and Rotor-Gene 3000 Real-
Time PCR Machine (Corbett Life Science Qiagen, Annex 10). The following 
reaction mixture in 20 µl final volume was set up for all samples, in triplicates: 
- 2 x Universal Master Mix  – 10 µl 
- Primer-probe mix    – 1 µl 
- RT sample    – 1.5 µl 
- Nuclease-free water  – up to final volume of 20 µl 
 
Quantitative PCR was completed using the following thermal cycling conditions: 
 
50 ºC     – 2 min x 1 
95 ºC      – 10 min x 1 
95 ºC 
60 ºC       
– 15 sec 









2.14 Agarose gel electrophoresis 
In brief, 1-3% w/v agarose gels were prepared by mixing Ultrapure
TM
 Agarose 
(InvitrogenTM Life Technologies, Annex 6) and Tris Acetate-EDTA (TAE) buffer 
(Annex 11) in a glass beaker, and microwaving until the agarose was completely 
dissolved. Next, 5 µl of SYBR® Safe DNA Gel Stain (Life Technologies, Annex 6) 
was added per 100 ml of the gel and mixed well. Still hot gels were casted using a 
UV-transparent gel tray (15 x 10 cm, 15 x 15 cm or 15 x 25 cm) and a Mini-Gel 
Caster (Bio-Rad, Annex 10). Typically, 100 ml of a gel was prepared for the 15 x   
10 cm trey. For trays of other sizes, the gel volume was adjusted accordingly. Combs 
with 15 and 20 wells were used. Solidified gels at RT were moved into Wide Mini-
Sub® Cell GT Cell or Sub-Cell® GT Cell electrophoresis gel tanks (Bio-Rad, Annex 
10) filled with TAE buffer. The buffer volume was subsequently adjusted to ensure 
that the gel was covered with the buffer, but only just.  
 
Next, nucleic acid samples and either a 100 bp or a 1 kb DNA ladder (both Promega, 
Annex 6) were mixed with 6 x Blue/Orange Loading Dye (Promega, Annex 6). This 
was not performed for DNA samples amplified using GoTaq® DNA polymerase as 
the reaction buffer used already contained a loading dye (see 2.11.1). Finally, 5-40 µl 
of each sample or 6 µl of the chosen ladder was loaded per well. Electric current was 
applied using PowerPac
TM
 Basic Power Supply (Bio-Rad, Annex 10). Typically, 
samples were analysed at 90 volts for 45 minutes to 2 hours.  
 
Gels were visualised using DR89 Dark Reader blue transilluminator (Clare Chemical 
Research, Annex 10) or MultiImage Light Cabinet FluorChem HD2 (Alpha 
Innotech, Annex 10). 
 
2.15 Nucleic acid isolation and purification 
 
2.15.1 Measuring the concentration and purity of nucleic acids 
The concentration and purity of eluted DNA and RNA samples were tested using 
NanoDrop
TM
 (Thermo ScientificTM, Annex 10). If required, the integrity of samples 
was tested by agarose gel electrophoresis, as described in 2.14. 
  





2.15.2 Isolation of cellular genomic DNA  
DNeasy® Blood & Tissue Kit (Qiagen, Annex 8) was used. The manufacturer’s 
protocol (spin-column) was followed (July 2006 version; Supplementary Data, 
Appendix 24). DNA was extracted from 1 x 10
6
 of cultured cells. DNA was eluted 
with 200 µl of buffer AE. Purified samples were handled at RT and stored at -20 ºC. 
 
2.15.3 Isolation of cellular total RNA 
TRIzol® Reagent (Life Technologies Ambion
TM
, Annex 6) was used. The 
manufacturer’s protocol was followed (November 2010 version; Supplementary 
Data, Appendix 25). RNA was extracted from 1 x 10
6
 cells. The RNA pellet was air 
dried for 5 minutes and resuspended in 50 µl of nuclease-free water (Sigma-
Aldrich®, Annex 6). Purified RNA was handled on ice and stored at -80 ºC.  
 
2.15.4 Isolation of Viral RNA 
QIAamp Viral RNA Mini Kit (Qiagen, Annex 8) was used. The manufacturer’s 
protocol (spin-column) was followed (June 2006 version; Supplementary Data, 
Appendix 26). RNA was extracted from 50 µl of cell culture supernatant and eluted 
with 60 µl of buffer AVE. Purified RNA was handled on ice and stored at -80 ºC.  
 
2.15.5 Purification of RNA from enzymatic reactions 
RNease® Mini Kit (Qiagen, Annex 8) was used. The manufacturer’s protocol (spin-
column) was followed (September 2010 version; Supplementary Data, Appendix 27). 
RNA was extracted from in vitro transcription reactions (see 2.3.3 and 2.4.3). On-
column DNase digestion was performed using RNase-Free DNase Set (Qiagen, 
Annex 8). RNA was eluted with 30 µl of nuclease-free water. Purified RNA was 
handled on ice and stored at -80 ºC.  
 
2.15.6 Purification of DNA from agarose gels 
A sample of DNA was run on an agarose gel, as described in 2.14. Next, DNA was 
visualised using DR89 Dark Reader blue transilluminator. Required bands were 
removed from the gel using a disposable sterile scalpel (Swann-Morton, Annex 3) 
and put into DNase- and RNase-free 1.5mL screw cap microtubes (Sartsetdt, Annex 
  





2). DNA was purified using NucleoSpin® Gel and PCR Clean-up (Macherey-Nagel, 
Annex 8). The manufacturer’s protocol was followed (January 2012; Supplementary 
Data, Appendix 28). Purified DNA was handled at RT and stored at -20 ºC. 
 
2.15.7 Purification of DNA extracted from enzymatic reactions 
DNA from enzymatic reactions (PCR, restriction digest) was purified using 
NucleoSpin® Gel and PCR Clean-up following manufacturer’s protocol (see 2.15.7). 
 
2.15.8 Small-scale DNA plasmid propagation and isolation (Mini-prep) 
A single colony was picked from an agar plate using a sterile pipette tip. It was used 
to inoculate 5 ml of LB broth (Annex 11) containing the appropriate selective 
antibiotic (See 2.19) in a universal bottle. Standard microbiological practices were 
followed. Next, the bacteria culture was incubated with shaking (250-300 RPM) at 
37 ºC for 16 hours using InnOva
TM
 4300 Incubator Shaker (New Brunswick, Annex 
10). Finally, the plasmid DNA was isolated and purified using ISOLATE Plasmid 
Mini Kit (Bioline, Annex 8). The manufacturer’s protocol was followed (1
st
 edition; 
Supplementary Data, Appendix 29). DNA was eluted in 50 µl of the elution buffer. 
Purified DNA was handled at RT and stored at -20 ºC. 
 
2.15.9 Large-scale DNA plasmid propagation and isolation (Maxi-prep) 
A bacteria culture was prepared as described in 2.15.8 and incubated with shaking 
(250-300 RPM) at 37 ºC for 6-8 hours. Next, 0.5 ml of this culture was transferred 
into a sterile 1 litre glass conical flask containing 250 ml of either LB broth or 
Tryptone Soya Broth (Annex 11) containing the appropriate selective antibiotic (see 
2.19). The culture was incubated with shaking (250-300 RPM) at 37 ºC for 16 or 40 
hours, respectively. Finally, the plasmid DNA was isolated and purified using 
EndoFree® Plasmid Purification Maxi Kit (Qiagen, Annex 8). The manufacturer’s 
protocol was followed (November 2005 version; Supplementary Data, Appendix 30) 
The DNA was resuspended in 0.1-1 ml of either endotoxin-free Buffer TE or DNase- 









2.16 DNA restriction digest 
Restriction enzymes from Promega, New England Biolabs and Roche were used (see 
Annex 6). The activity of all restriction enzymes was expressed in units. One unit 
was defined as the amount of restriction enzyme required to fully digest 1 µg of 
bacteriophage lambda DNA in 1 hour. Each of the enzymes used had specific 
requirements for the optimal activity, including pH, enzyme cofactor(s), salt 
composition and ionic strength. Consequently, the reaction buffer that yielded the 
highest activity for the enzyme (all enzymes, if multiple used) was always chosen 
(typically 100%, no less than 75%). The final concentration of glycerol (typically 
part of a restriction enzyme diluent) was kept below 5% v/v. All DNA substrates 
were first purified as described in 2.15 and had A260/280 ratio of >1.8. 
 
An analytical restriction digest was typically set up as outlined below and 
subsequently incubated for 2 hours at the required temperature (typically 37 ºC): 
- Restriction enzyme(s)    – 5-10 units, each 
- Restriction Enzyme 10 x Buffer   – 2 μl 
- Acetylated BSA, 100 x (Promega, Annex 6)  – 0.2 μl 
- DNA       – 0.5-1 μg 
- Nuclease-free water     – up to 20 μl final volume 
 
The above setup was modified for a cloning restriction digest. In brief, 0.5-20 μg of a 
template DNA was used. The final volume of the reaction mixture depended on the 
amount of template DNA to be digested (10 μl per each 1 μg of DNA, and no less 
than 50 μl). The quantities of the buffer, BSA and water were adjusted accordingly.  
 
Analytical restriction digests were analysed by agarose gel electrophoresis (see 2.14). 
Cloning restriction digests were purified as described in 2.15.7 or 2.15.6. The 
concentration and purity of eluted DNA was tested using NanoDrop
TM
. Purified 










2.17 DNA dephosphorylation 
Cloning vectors linearized by a single restriction enzyme (or blunt-ended) were 
treated with Thermosensitive Alkaline Phosphatase (TSAP) (Promega, Annex 6) to 
remove 5’ phosphate groups from DNA ends and thus prevent the recirculisation of 
linearized vectors during ligation. The following reaction mixture was set up:   
- Linearized DNA    – up to 5 μg 
- TSAP      – 0.5 μl per 1 μg of linearized DNA  
- MULTI-CORETM 10 x Buffer  – 5 μl 
- Nuclease-free water   – up to final volume of 50 μl 
 
The reaction mixture was incubated at 37 ºC for 1 hour. Subsequently, TSAP was 
heat-inactivated at 74 ºC for 15 minutes. DNA was purified as described in 2.15.7. 
 
2.18 DNA ligation 
T4 DNA Ligase (New England Biolabs, Annex 6) was used. DNA was prepared by 
mixing a cloning vector and an insert at the molar ratio of 1 to 3 (100 ng total). The 
following reaction mixture was set up (T4 DNA Ligase was added last): 
- 10 x T4 DNA Ligase Buffer (at RT)   – 2 μl 
- DNA       – 100 ng 
- T4 DNA Ligase     – 1 μl 
- Nuclease-free water     – up to 20 μl final volume 
 
The ligation mixture was incubated at RT for 3 hours. Next, it was either used to 
transform competent bacteria (see 2.19) or it was stored at -20ºC. 
 
2.19 Transformation of competent bacteria with expression vectors 
 
2.19.1 Preparation of selective LB agar plates 
First, LB agar (Annex 11) was slowly melted in a microwave. Next, the melted agar 
was rocked at RT using SSM4 Sea-saw rocker (Stuart, Annex 10) until warm but 
cool enough to handle with unprotected hand. Inside a class II MBSC, a selective 
antibiotic was added. Ampicillin or kanamycin (both Sigma-Aldrich®, Annex 7) 
  





were used at 100 µg/mL and 50 µg/mL final concentrations, respectively. The agar 
was mixed gently (to prevent formation of air bubbles) and then poured into 100 mm 
petri dishes at approximately 15 ml per dish. Finally, petri dishes were cooled to RT 
for approximately 30 minutes and then were stored at 4 ºC for up to 1 month. 
 
2.19.2 SURE® 2 Supercompetent cells (Stratagene, Annex 7) 
The manufacturer’s protocol was followed (Supplementary Data, Appendix 32), 
however, 1.5 ml screw-cap microcentrifuge tubes were used instead of 14 ml round 
bottom tubes. Post-heat-shock, bacteria were diluted in 900 μl of SOC medium 
(Sigma-Aldrich®, Annex 7) and incubated at 37 ºC with shaking (225 RPM) for 1 
hour using Thermomixer® Dry Block Heating Shakers (Eppendorf, Annex 10). 
Finally, the required volume of bacteria (based on anticipated transformation 
efficiency) was spread on selective LB agar plates (see 2.19.1) using disposable 
bacteria spreaders (Gosselin, Annex 2). Standard microbiological practices were 
followed. For volumes larger than 100 μl, bacteria were first pelleted by 
centrifugation at 4000 x g for 5 minutes and then resuspended in 50-100 μl of SOC 
medium. Plates were incubated for at least 16 hours at 37 ºC. 
 
2.19.3 Subcloning EfficiencyTM DH5αTM Competent Cells (InvitrogenTM Life 
Technologies, Annex 7) 
The manufacturer’s protocol was followed (January 2006 version; Supplementary 
Data, Appendix 32). Post-heat-shock, bacteria were diluted in 950 μl of SOC 
medium and incubated for 1 hour as described in 2.19.2. Finally, bacteria were 
spread on selective LB agar plates and incubated as described in 2.19.2. 
 
2.20 DNA Sequencing 
DNA was sequenced by Sanger dideoxy chain terminator method (Sanger et al. 
1977). Commercially available services were used (GATC Biotech, MRC PPU DNA 
Sequencing and Services, and Source Bioscience). Purified PCR products and 
plasmids (circular and linearized) were sequenced. Samples and primers were 
prepared according to the recommendations of the service provider.  
  





Sequences were aligned to a predicted reference sequence using ClustalW version 2 
available at http://www.ebi.ac.uk/Tools/msa/clustalw2/ (Larkin et al. 2007, Goujon et 
al. 2010). Sequencing chromatograms were analysed using BioEdit Sequence 
Alignment tool version 7.1.3.0 (Hall, 1999) to confirm good sequence quality.  
 
2.21 SFV in vivo  
 
2.21.1 Mice 
IFN-α/ß receptor knockout mice of A129/SvEv background (IFNAR mice) sourced 
from B&K Universal were used. Mice were maintained in the Biological Research 
Facility (BRF) at the University of Edinburgh School of Biomedical Sciences. Mice 
were maintained with environmental enrichment, a 12-hour light/dark cycle, and 
food and water ad libitum. Mice were acclimatised for a week prior to any 
experimental procedures. All experiments were carried out under the authority of a 
UK Home Office License. 
 
2.21.2 Infection 
Mice between the age of 4 and 5 weeks were injected intraperitoneally (IP) by Dr 
Rennos Fragkoudis, the Pirbright Institute. In brief, mice were immobilised and 
injected with 0.1 ml of virus inoculum diluted in PBSA at 5 x 10
3
 PFU/animal using 
a 21 G needle (Terumo, Annex 3) inside a class I MBSC.  
 
2.21.3 Sampling 
Mice were euthanized by CO2 overdose according to the Home Office guidelines 
with help from Dr Rennos Fragkoudis, the Pirbright Institute. Next, the animal fur 
was dampened with 70% ethanol. Pulling the abdominal skin with forceps, a small 
incision was made over the caudal half of the abdomen with scissors to expose the 
underlying abdominal wall. Care was taken to not pierce the abdominal wall while 





-free PBS was injected into the caudal half of the peritoneal cavity using a 
25 G needle, bevelled side up (Terumo, Annex 3). The entire body of the mouse was 
gently shaken by hand for approximately 10 seconds. PBS containing resident 
  






peritoneal cells was aspirated using a 19 G needle (Terumo, Annex 3), inserted into 
the cranial half of the peritoneal cavity, bevelled side down. Cell suspension was 
stored on wet ice until processed further (see 2.21.6). Next, the abdominal cavity was 
opened using surgical scissors and the spleen was collected and placed into a bijoux 
tube containing 4% v/v neutral buffered formalin. Finally, using surgical scissors the 
skull was opened, the spinal cord was cut, and the brain was collected and placed 
into a bijoux tube containing 4% v/v neutral buffered formalin. 
 
2.21.4 Processing of tissues and cryosectioning 
Tissues for histology were kept in 4% v/v neutral buffered formalin for 72 hours. 
Next, tissues were submerged in 5 ml of 5% w/v sucrose solutions (Annex 11) for 1 
hour, then in 5 ml of 10% w/v sucrose solution (Annex 11) for 1 hour, and finally in 
5 ml of 20% w/v sucrose solution (Annex 11) overnight. The following day tissues 
were inspected to ensure that they sunk to the bottom of the sucrose solution. Next, 
the tissues were embedded in OCT Cryoembedding Matrix (Thermo Scientific
TM 
Raymond Lamb, Annex 9) using Peel-A-Way Disposable Embedding Molds 
(Thermo Scientific™ Shandon™, Annex 2) and frozen using an isopentane (Sigma-
Aldrich®, Annex 5) bath chilled to approximately -70 ºC with dry ice.  
 
Tissues were sent to the Veterinary Pathology Unit at the University of Edinburgh 
for processing by Mr Neil MacIntyre. In brief, samples were sectioned into 8 μm 
thick sections using a cryomicrotome, placed on polylysine coated slides, and finally 
stored at -80 ºC. 
 
2.21.5 Immunohistochemistry 
Slides were removed from -80 ºC, placed in front of a fan and dried at RT for 
approximately 1 hour. Next, sections were immunostained as described in 2.6, with 
or without 0.3 % v/v Triton
TM
 X-100 treatment step. The following antibodies were 
used: Rat anti-Mouse MARCO primary antibody (AbD Serotec®, Annex 9) at 1:200 
dilution; Rat anti-Mouse CD169 primary antibody, Alexa Fluor® 647 conjugate 
(AbD Serotec®, Annex 9) at 1:100 dilution; Goat anti-Rat IgG secondary antibody, 
Alexa Fluor® 594 conjugate (Life Technologies, Annex 9) at 1:500 dilution. 
  






2.21.6 Peritoneal macrophage flow cytometry 
The suspension of peritoneal cells was centrifuged at 300 x g and 4 ºC for 10 
minutes. One ml of the supernatant was frozen at -80 ºC. If required, cell pellet was 
resuspended in 10 ml of RBC lysis buffer (Annex 11) and incubated at RT for 10 




-free PBS by centrifugation at 




-free PBS and 
mixed with 1 ml of 10% v/v neutral buffered formalin. Cells were fixed for 30 
minutes at RT. Next, cells were centrifuged at 300 x g and 4 ºC for 10 minutes and 




-free PBS, as described above. Finally, cells were 
resuspended in 2 ml of FACS buffer (Annex 11), counted and stored at 4 ºC in dark. 
 
The following day, 1 x 10
6
 cells was resuspended in 100 μl of FACS buffer, and 1 μl 
of PE anti-mouse F4/80 antibody (Biolegend, Annex 9) or 1μl of PE Rat IgG2b, ĸ 
Isotype control (Biolegend, Annex 9) was added. Cell suspension was briefly 
vortexed and incubated in dark at RT for 30 minutes. Next, 1 ml of FACS buffer was 
added and the cells were centrifuged at 300 x g and RT for 5 minutes. Finally, cells 




-free PBS and analysed using BD 
FACSCalibur
TM
 flow cytometer (BD, Annex 10). The data was analysed using 
FlowJo x 10.0.7 software (FlowJo, LLC). 
 
2.22 CHIKV in vivo 
The pathogenesis of a modified CHIKV was tested in a non-human primate model of 
the disease in collaboration with Dr Pierre Roques at the French Alternative Energies 
and Atomic Energy Commission (CEA), Division of Immuno-Virology, Fontenay-
aux-Roses, France. The study was approved by the regional animal care and use 
committee (Comite Regional d’Ethique sur l’experimentation animal Ile de France 
Sud) in accordance with European directive 86/609/EEC. 
 
Handling and sampling of live animals, infection and clinical observations were 
performed by Dr Pierre Roques with assistance from Division of Immuno-Virology 
staff and me. At the end of the study, animals were euthanized by a named 
veterinarian, and samples were collected by Dr Pierre Roques and me.  
  







Naïve, adult (5-8 years old) male cynomolgus macaques (Macaca fascicularis) each 
weighing 8.0-8.5 kg were used. The animals were captive-bred in Mauritius, 
imported to France, and tested negative for simian immunodeficiency virus (SIV), 
simian T lymphotropic virus (STLV), herpes B virus, filovirus, simian type D 
retrovirus (SRV-1), simian retrovirus serotype 2 (SRV-2), measles virus, DENV and 
CHIKV. Animals had been previously infected experimentally with influenza A 
virus, however, they were confirmed to be seronegative for anti-CHIKV neutralising 
antibodies prior to infection with CHIKV. All animals were housed in single cages 
within a purpose-designed CL3 facility. 
 
2.22.2 Infection 
Animals were first sedated with 10 mg/kg of body mass ketamine chlorhydrate 
(Rhône Mérieux, Annex 5) injected intravenously (IV). Next, both wrists were 
shaved and the animals were inoculated sub-cutaneously (SC) on the upper part of 




2.22.3 Clinical observation 
Animals were observed for overt signs of a disease such as loss of appetite and 
lethargy daily. Measurement of body temperature, body weight and wrist swelling 
(site of injection and contralateral) were performed at each time of sampling (2.22.4).  
 
2.22.4 Sampling 
Animals were sedated by ketamine chlorhydrate (see 2.22.2) before any sampling. 
Blood for haematology was collected on days -4, -1, 0 (prior to inoculation), 1, 2, 3, 
4, 5, 7, 14, 18 (pre-euthanasia), 21, 28 and 35 (pre-euthanasia). Full haematology 
was performed using COULTER® HmX Hematology Analyzer (Beckman Coulter, 
Annex 10). Serum was collected on days -4, -1, 0 (prior to inoculation), 1, 3, 5, 7, 14, 
18 (pre-euthanasia), 21, 28 and 35 (pre-euthanasia), aliquoted, and stored at -80 ºC. 
Plasma was collected on days -4, -1, 0 (prior to inoculation), 1, 2, 3, 4, 5, 7, 10, 14, 
18 (pre-euthanasia), 21, 28 and 35 (pre-euthanasia), and stored at -80 ºC. PBMCs 
were collected on days -4, -1, 0 (prior to infection), 2, 4, 7, and 8, and stored in LN2. 
  






Animals were euthanized 18- or 35-days post-infection by IV injection of 10 mg/kg 
of body mass ketamine chlorhydrate followed by IV injection of 100 µg/kg of body 
mass sodium pentothal (Abbot Laboratories, Annex 5). During necropsy, a range of 
muscle, tendon, skin and lymph nodes samples were taken from around the site of 
infection, and contralateral. Samples were preserved in 10% v/v neutral buffered 
formalin for histology or snap-frozen using an isopropanol/dry ice bath for virus and 
RNA isolation. Spleen and liver samples were also collected, cut into smaller 
sections, and then preserved as described above. 
 
2.22.5 Plasma viral RNA quantification (qPCR) 
Viral RNA was isolated from 100 µl of EDTA-anticoagulated, cell-free plasma using 
NucleoSpin® 96 Virus Kit (Macherey-Nagel, Annex 8), in duplicates. The 
Manufacturer’s protocol was followed (April 2014 version; Supplementary Data, 
Appendix 33). RNA was eluted in 100 µl of nuclease-free water and stored at -80 ºC. 
EDTA-anticoagulated, cell-free plasma of a CHIKV-uninfected macaque was used 
as the negative control. To generate a standard curve, CHIKV stock of known titre 
was first diluted in the plasma used for the negative control. Next, serial 10-fold 
dilutions were prepared.  
 
Next, quantitative reverse transcriptase PCR was set up using SuperScript
TM
 III One 
Step Quantitative RT-PCR System (Invitrogen Life Technologies, Annex 6). The 
manufacturer’s protocol was followed (revision B.0; Supplementary Data, Appendix 
34). For each sample, the following reaction mixture was prepared on ice in 25 µl 
final volume, in duplicates: 
- SuperScriptTM III reverse transcriptase/Platinum® Taq  – 0.5 µl 
- 2 x Reaction Mix       – 12.5 µl 
- Forward primer, 10 µM      – 0.5 µl 
- Reverse primer, 10 µM      – 0.5 µl 
- Probe, 10 µM        – 0.5 µl 
- RNase inhibitor (40U/µl)      – 0.5 µl 
- Purified RNA        – 10 µl 
 
  






Primers and probe used were designed by Laurent et al. (2007): 
- Primer F1  – AAGCTCCGCGTCCTTTACCAAG 
- Primer R1 – CCAAATGTCCTGGTCTTCCT 
- Probe   – [FAM]TCTCAACAGCTTGGTCACCGTT[TAM] 
 
Reverse transcription and quantitative PCR were completed using ICycler IQ
TM
 Real 
Time PCR with My IQ
TM
 Real Time Module (Bio-Rad, Annex 10) and the following 
cycling conditions: 
 
Reverse Transcription –    56 ºC  – 30 min x 1 
Denaturation –    95 ºC  – 5 min x 1 
Denaturation      
Annealing and elongation         
–    95 ºC  
–    60 ºC  
– 15 sec 
– 1 min 
x 35 
4 ºC   ∞ 
 
2.23 Statistical analysis and data presentation 
Within an experiment, all infections were done in triplicates (Chapter 3) or 
quadruplicates (Chapter 4 and 5). Data from a representative experiment out of 2-4 
independent repeats (typically 3) are shown, unless specified otherwise. 
 
Results were analysed using Mann-Whitney test, single-tailed. P<0.05 was accepted 
as indicating statistical significance. GraphPad Prism 5.0 (GraphPad Software Inc.) 
and Microsoft Excel 2010 (Microsoft) were used for analysis and graph preparation.  
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The intention for this part of the project was to investigate the interaction of human 
monocyte-derived macrophages (MDMs) with CHIKV. The role of cell debris from 
virus-infected cells in MDMs infection was of a particular interest. However, at the 
time of this study, the CL3 facility at the Roslin Institute was not yet available for 
use. Hence, proof-of-concept experiments were designed and completed using SFV.  
 
There are no published studies investigating if SFV can infect human MDMs. 
However, several studies investigated if SFV could infect mouse macrophages. In 
1976 van der Groen et al. demonstrated that peritoneal macrophages from OF1 mice 
cultured in vitro can get productively infected with SFV strains V13 and A7. Oaten 
et al. (1980) showed that peritoneal macrophages from Swiss/A2G mice were 
productively infected with SFV strain A7(74) and L10 in vivo and in vitro. Finally, 
Fragkoudis et al. (2007) observed a population of virus-positive cells in spleen of 
SFV4-infected IFN-α/ß receptor knockout mice of A129/SvEv background (IFNAR 
mice), in marginal zones between the red pulp and white pulp. These areas are 
known to be rich in macrophages and dendritic cells.  
 
The objectives for this part of the project were as follow: 
 
1) To determine if purified SFV can infect human MDMs in vitro. 
 
2) To determine if the presence of cell debris from SFV-infected human cell lines 
can affect the rate at which SFV infects human MDMs in vitro. 
 
3) To determine if virus particles are required to infect MDMs with SFV.  
 
4) To investigate properties of the cell debris from virus-infected human cell lines 











3.2 Growing viruses and virus replicon particles 
SFV4-steGFP and SFV4-3F-zsGreen were rescued, purified and titrated by Claudia 
Rückert, the University of Edinburgh, as described in 2.3.3 and 2.3.5. SFV1-3F-
zsGreen replicon was rescued and purified as described in 2.4.3. SFV1-3F-zsGreen 
virus replicon particles (VRPs) were titrated as described in 2.4.4. VRP stock was 
confirmed negative for replication-competent virus following the protocol in 2.4.5. 
 
SFV4-steGFP expressed enhanced green fluorescent protein (eGFP) (Cormack et al. 
1996) as part of the virus structural polyprotein (Fragkoudis et al. 2007). The 
fluorescent marker was cleaved from the polyprotein co-translationally leading to its 
release into the cytoplasm of virus-infected cells. SFV4-3F-zsGreen and SFV1-3F-
zsGreen VRPs were fundamentally identical in the non-structural region and they 
both expressed ZsGreen1 (commercially developed by Clontech, herein known as 
zsGreen) as a fusion protein with nsP3. Consequently, ZsGreen1 was localised to 
replication complexes in virus/VRP-infected cells leading to the characteristic foci of 
expression observed microscopically (Figure 3.7). SFV1-3F-zsGreen did not encode 
the structural genes in its genome and therefore VRP-infected cells could not 
produce virus/VRPs.  
 
3.3 Can purified SFV infect human MDMs? 
SFV4-steGFP was used to infect MDMs at multiplicity of infection (MOI) of 1, 50, 
100, 500 and 1000 as described in 2.5.5. Twenty four hours post-infection, the 
percentage of infected (positive for eGFP) cells varied from 0 at MOI=1 to a peak 
value of only 0.06 % at MOI=500. Forty-eight hours post-infection, the percentage of 
infected cells was only marginally above the level of detection (LOD) of 0.01% for 
all MOIs tested. Data are summarised in Figure 3.1. Overall, MDMs did not infect 















Figure 3.1. Infection of MDMs with purified SFV4-steGFP. Cells were observed 
for the expression of virus-encoded eGFP using Zeiss Observer.D1 inverted 
microscope 24- and 48-hours post-infection. MOI range of 1-1000 was tested. 
LOD=0.01%. Data expressed as mean +/- SD. 
 
 
3.4 Can MDMs be transfected with virus or replicon genomic RNA? 
A range of transfection and electroporation protocols was tested to investigate if 
MDMs positive for SFV or SF replicon genome replication can be obtained despite 
the low infection rate achieved with the purified virus. Genomic RNA of SFV4-3F-
zsGreen (virus) and SFV1-3F-zsGreen (replicon) generated in 3.2 was used. Twenty 
four and forty eight hours post-transfection, MDMs were observed microscopically 
for expression of virus- and replicon-encoded zsGreen using Zeiss Observer.D1. 
 
First, MDMs were transfected with Lipofectamine® 2000 Transfection Reagent. In 
brief, MDMs were harvested, counted and seeded into 96-well plates as described in 
2.5.4. After 48 hours, the cell culture supernatant was replaced with a fresh one, and 
MDMs were transfected as described in 2.10.2. Unfortunately, no zsGreen-positive 
MDMs were observed at both time points.   
 
Next, MDMs were electroporated using the Gene Pulser XcellTM Electroporation 
System. In brief, MDMs were harvested and counted as described in 2.5.4, and then 
electroporated as described in 2.3.3.1 (square wave protocol, 850 V, 4 msec pulse 
  






length, 2 pulses with 5 second interval in between). In addition, the protocol was 
modified to follow the exponential decay parameters described by Smale (2010) and 
Ponsaerts et al. (2002) (250-300 V, 150-960 µF).  Similarly to the transfection with 
Lipofectamine® 2000 Transfection Reagent, no zsGreen-positive MDMs were 
observed at both time points.  
  
3.5 Can the presence of cellular debris from SFV-infected human cell lines 
affect the rate at which SFV infects human MDMs? 
The ability of SFV4 to infect MDMs in presence of cellular debris from SFV4-
infected human cell lines HeLa, 2fTGH and U4C was investigated. As discussed 
before, in 2011 Krejbich-Trotot et al. demonstrated that the presence of apoptotic 
debris from CHIKV-infected HeLa cells promoted the infection of primary murine 
macrophages, MM6- and Thp-1-PMA differentiated cells with CHIKV in vitro. 
Hence, HeLa cells were chosen for this study. HeLa are human cervix 
adenocarcinoma epithelial cells that have been used since 1951 (Gey et al. 1952). 
However, these cells are highly aberrant with respect to their genome and gene 
expression (Bottomley et al. 1969, Macville et al. 1999, Adey et al. 2013, Landry et 
al. 2013) and must be used with caution to study any complex biological processes. 
Consequently, 2fTGH and U4C cells were used in this study, in addition to HeLa.  
 
2fTGH is a modified human fibrosarcoma cell line that is characterised by a 
competent IFN system. 2fTGH cells were generated by transfecting human 
fibrosarcoma cell line HT 1080 with a vector containing a selectable marker guanine 
phosphoribosyltransferase regulated by   IFN-α (Pellegrini et al. 1989). The presence 
of the marker allowed selection of  descendant cell lines containing a range of 
mutations in their IFN signalling pathway. U4C cell line is derived from one such 
mutant of 2fTGH cells. U4C cells lack JAK1 kinase and are therefore unresponsive 
to IFN-α/ß/γ (Kohlhuber et al. 1997). In addition, their innate immune response to 
double stranded RNA is defective. The use of U4C cells paired with the parental 
2fTGH cells allowed to directly investigate if the presence of the competent IFN 
system in SFV-infected fibroblast cells can alter the capacity of cell debris derived 
from these cells to mediate infection of human MDMs with the virus. 
  






To generate cellular debris, HeLa, 2fTGH and U4C cells were infected with SFV4-
steGFP as described in 2.5.3. Seventy two hours post-infection, cells were inspected 
microscopically (Figure 3.2). All observed HeLa cells were positive for eGFP. 
Similarly, the majority of U4C cells was positive for eGFP. However, individual 
eGFP-negative U4C cells were also observed. The proportion of eGFP-positive 
2fTGH cells was noticeably smaller, approximately a third of that observed for HeLa 
and U4C cells. The majority of cells expressing eGFP showed cytopathic effect 
(CPE) while little or no CPE was observed in eGFP-negative cells. Based on our 
current knowledge of alphavirus-induced cell death (see 1.4), the cellular debris were 
most likely composed of apoptotic debris. However, cell monolayers and the cellular 
debris were not investigated for the presence of markers of apoptosis (e.g. cleaved 





Figure 3.2. HeLa, 2fTGH and U4C cells infected with SFV4-steGFP. Cells were 
infected at MOI of 5 and incubated for 72 hours. Cells were observed for the 
expression of virus-encoded eGFP using Zeiss Observer.D1 inverted microscope.  
 
  






Unclarified (containing cellular debris) and 0.2 µm-clarified supernatants were 
prepared as described in 2.5.3, diluted 1:10 in complete RPMI, and used to infect 
human MDMs as described in 2.5.4. The inoculum was not removed post-infection. 
Cells were incubated for 48 hours and inspected microscopically for the expression 
of virus-encoded eGFP every 24 hours. SFV4-steGFP titre in unclarified and 0.2 µm-
clarified supernatants was measured as described in 2.3.5.  
 
Infection of MDMs with unclarified supernatant from SFV4-steGFP-infected HeLa 
cells led to a significantly higher proportion of MDMs expressing eGFP in 
comparison to MDMs infected with the clarified supernatant 24- and 48-hours post-
infection (33.0% vs 6.67% and 13% vs 4.33%, respectively) as shown in Figure 3.4c. 
Similar pattern was observed for MDMs infected with 2fTGH and U4C cells-derived 
supernatants (Figure 3.4a and Figure 3.4b, respectively). However, the overall 
number of eGFP-positive MDMs was lower when compared to MDMs infected with 
HeLa-derived supernatants (peak infection rate of 14.67% and 21% for 2fTGH- and 
U4C-derived supernatants, respectively). Importantly, in virus-infected cells eGFP 
was strongly expressed and was distributed across the cytoplasm and nucleus (Figure 
3.3). Consequently, virus infected cells were differentiated from cells that simply 





Figure 3.3. Human MDMs infected with SFV4-steGFP. MDMs were infected via 
0.2 µm-clarified supernatant from SFV4-steGFP-infected HeLa cells and observed 
using Zeiss Observer.D1 microscope 48-hours post-infection. 
  








Figure 3.4. Infection of human MDMs with unclarified or 0.2 µm-clarified 
supernatants from SFV4-steGFP-infected 2fTGH, U4C and HeLa cells.            
(a-c) Cells were observed using Zeiss Observer.D1 inverted microscope 24- and 48-
hours post-infection. LOD=0.01%. The MOIs at which MDMs were infected using 
0.2 µm-clarified supernatants from HeLa, U4C and 2fTGH cells were approximately 
250, 85 and 9, respectively. Data expressed as mean +/- SD; Mann-Whitney test, 
single-tailed; * p<0.05. (d) Supernatants used to infect MDMs on Day 0 were titrated 
on BHK-21 cells by plaque assay. LOD=12.5 PFU/ml.  
 
 
There was no noteworthy difference between SFV4-steGFP titres measured in 













 PFU/ml, respectively) as 
  






shown in Figure 3.4d. However, there was a notable difference between titres 
measured in supernatants derived from different cells. The highest titre was observed 




 PFU/ml). The titre observed in U4C cells 




 PFU/ml) while the titre observed in 





Consequently, the MOI at which MDMs were infected with SFV4-steGFP varied 
substantially between supernatants derived from HeLa, U4C and 2fTGH cells (250, 
85 and 9, respectively, for 0.2 µm-clarified supernatants). Interestingly, the 
proportion of MDMs positive for eGFP observed in this experiment was substantially 
higher than that observed when MDMs were infected with the purified virus at 
comparable MOIs (Figure 3.1). The design of both experiments was comparable. 
 
2fTGH cells were more resistant to SFV4-steGFP infection than U4C and HeLa cells 
when exposed the same inoculum. Fever SFV4-steGFP-infected 2fTGH cells showed 
signs of virus infection, such as CPE or expression of virus-encoded eGFP. As a 
consequence, less cell debris was likely generated from 2fTGH cells in comparison 
to HeLa and U4C cells. However, the exact amount was not compared or quantified. 
In addition, SFV4-steGFP-infected 2fTGH cells released fewer virus particles into 
the cell culture supernatant. This overall reduction in the amount of infectious 
material generated by virus-infected 2fTGH cells was the most likely explanation for 
the difference in the infectivity of MDMs observed between 2fTGH- and U4C-
derived supernatants. It seemed that the presence or absence of a competent IFN 
system in virus-infected human cells did not change the capacity of cell debris 
derived from these cells to infected human MDMs. Consequently, the effects that 
cell debris from HeLa-, 2fTGH- and U4C-infected cells had on human MDMs 
infection with SFV4-steGFP were fundamentally comparable. Importantly, this result 
was observed in spite of the notably different virus titres present in supernatants 
derived from different cells, as discussed above. As the overall effect was the most 
pronounced when HeLa cells-derived supernatants were used, it was decided that 










3.6 Can presence of cell debris from uninfected cells promote infection of 
MDMs with SFV? 
Cell debris from uninfected HeLa cells was generated as described in 2.5.6. 
Unclarified and 0.2 µm-clarified supernatants were prepared and added to human 
MDMs as described in 2.5.6. Next, purified SFV4-steGFP was added at MOI of 50. 
MDMs infected with purified virus alone at MOI of 50 were used as a control. The 
inoculum was not removed post-infection. Cells were incubated for 48 hour and 
inspected microscopically for the expression of virus-encoded eGFP every 24 hours. 
 
Purified SFV4-steGFP infected less than 0.02% of MDMs within the first 24 hours 
and no eGFP-positive cells were observed 48-hours post infection (Figure 3.5). This 
was consistent with previous findings (Figure 3.1). Similar results were obtained 
when the purified virus was mixed with the 0.2 µm-clarified supernatant. In presence 
of the unclarified supernatant, the MDM infection rate increased four-fold. However, 
this still corresponded to less than 0.1% of eGFP-positive MDMs. The data indicated 
that presence of cell debris from uninfected cells was not itself sufficient to increase 
the rate at which SFV infects MDM to levels observed when cell debris derived from 




Figure 3.5. Infection of human MDMs with SFV4-steGFP at MOI of 50 mixed 
with cell debris from uninfected HeLa cells. Cells were observed for the 
expression of virus-encoded eGFP using Zeiss Observer.D1 inverted microscope 24- 
and 48-hours post-infection. LOD= 0.01%. Data expressed as mean +/- SD. 
  






3.7 Can cell debris be infectious to MDMs in absence of virus particles? 
Unclarified and 0.2 µm-, 0.45 µm- and 0.8 µm-clarified supernatants were prepared 
from HeLa cells infected with SFV4-3F-zsGreen and SFV1-3F-zsGreen VRP as 
described in 2.5.3. Supernatants were diluted 1:2 in complete RPMI and MDMs were 
infected as described in 2.5.4, on cover glasses. The inoculum was removed 6 hours 




+-free PBS, and fresh complete 
RPMI was added. Cells were incubated for 48 hours. After 24 hours, live cells were 
inspected microscopically for the expression of virus/VRP-encoded zsGreen. After 
48 hours, cells were fixed in 10% v/v neutral buffered formalin for 1 hour, washed 




+-free PBS, mounted and inspected microscopically for 
the expression of virus/VRP-encoded zsGreen as described in 2.7.  
 
Infections with unclarified supernatant derived from virus- and VRP-infected HeLa 
cells led to comparable numbers of MDMs positive for zsGreen 24 hours post-
infection (32% and 29.67%, respectively). Data are summarised in Figure 3.6a. 
Clarification of the supernatant from virus-infected cells through a 0.2 µm filter 
reduced the proportion of zsGreen-positive MDMs to 4% (Figure 3.6d). The 
difference was statistically significant and consistent with previous findings for 
SFV4-steGFP (Figure 3.4c). Clarification of the supernatant from VRP-infected cells 
through a 0.2 µm filter reduced the proportion of zsGreen-positive MDMs to only 
0.12% (Figure 3.6d). The reduction was significantly larger than that observed for 
the supernatant from virus-infected cells.  
 
Remarkably, 48 hours post-infection the percentage of MDMs infected with the 
replicon via unclarified supernatant from VRP-infected cells doubled and reached the 
value of 72% (Figure3.6a). At the same time the number of MDMs infected with the 
virus via unclarified supernatant from virus-infected cells decreased to below 10%. 
The difference was statistically significant. Altogether, the above data suggested that 














Figure 3.6. Infection of human MDMs with cell debris from SFV4-3F-zsGreen- 
and SFV1-3F-zsGreen VRP-infected HeLa cells. Cells were observed using Zeiss 
Observer.D1 inverted microscope 24-hours post-infection, and using Zeiss Axioskop 
2 upright microscope 48-hours post-infection. LOD=0.01%. (a) Unclarified 
supernatant. (b-d) Supernatant clarified via 0.2 µm, 0.45 µm and 0.8 µm filters. Data 












Interestingly, microscopic observation of replicon-infected MDMs 48 hours post-
infection showed no visual signs of CPE or any change in cell morphology in 
comparison to uninfected MDMs (Figure 3.7). At the same time, virus-infected 
MDMs were observed to round-up and often detach from the surface of plates. 
Importantly, HeLa, 2fTGH and U4C cells infected with SFV1-3F-zsGreen VRPs 
underwent apoptosis within 48 hours post infection (data not shown). Foci of 
zsGreen expression were clearly observed by fluorescent microscopy in both virus- 
and replicon-infected MDMs (Figure 3.7b), indicating the presence of active 





















Figure 3.7. MDMs infected with SFV1-3F-zsGreen replicon via cell debris from 
VRP-infected HeLa cells.  Cells were observed for the expression of replicon-
encoded zsGreen using Zeiss Axioskop 2 upright microscope 48-hours post-
infection. Cell nuclei were stained with DAPI. Red arrows indicate foci of zsGreen 
expression. Strong background auto-fluorescence of MDMs was observed. 
  






3.8 What size of cell debris derived from SFV-infected cells facilitates the 
infection of human MDMs with the virus? 
As described in the previous paragraph, MDMs were infected with 0.2 µm-, 0.45 
µm- and 0.8 µm-clarified supernatant from virus- and VRP-infected HeLa cells. 
Overall, the clarification of a supernatant through 0.2 µm, 0.45 µm and   0.8 µm 
filters led to comparable numbers of zsGreen-positive MDMs (Figure 3.6b,c,d). The 
same pattern was observed for supernatants derived from virus- and VRP-infected 
cells. The results suggested that cell debris >0.8 µm in diameter was the primary 
carrier of infectious material.  
 
3.9 Is infection of MDMs with SFV productive? 
First, SFV4-steGFP thermal inactivation at 37 ºC was investigated. In brief, 10
6.00
 
PFU of SFV4-steGFP was added to 1 ml of complete RPMI in a 24-well plate and 
incubated at 37 ºC for 4 days. Each day, 100 µl of virus was sampled and titrated. 
SFV4-steGFP demonstrated a linear correlation between the measured virus titre and 
the time of incubation at 37 ºC (Figure 3.8a). Approximately 80% of virus was 
inactivated every 24 hours.  
 
Next, unclarified supernatant was prepared from HeLa cells infected with SFV4-
steGFP as described in 2.5.3. The supernatant was diluted 1:10 in complete RPMI 
and MDMs were infected as described in 2.5.4, in 1 ml final volume per well. The 
inoculum was not removed post-infection. Cells were incubated for 72 hours. 
Successful infection of MDMs with SFV4-steGFP was confirmed microscopically. 
Every 24 hours, 100 µl of MDMs supernatant was collected and titrated.  
 
Approximately 25-30% of MDMs expressed eGFP on day 1. A steady decrease in 
MDM supernatant virus titre was observed from day 0 to day 3 (10
6.82
 PFU/ml to 
10
4.20
 PFU/ml). The measured titres were at or below the expected titre calculated 
based on thermal inactivation (Figure 3.8b). The data suggested that MDM infection 
with SFV4-steGFP was either non-productive, or virus replication was below the 
limit of detection established by the thermal inactivation at 37 ºC.  
 
  






This experiment had several notable limitations. Most significantly, the virus 
inoculum was not removed from the MDMs post-infection. As a consequence, the 
limit of detection of this assay was very high, as indicated by the thermal inactivation 
rate of SFV4-steGFP. It is possible that the SFV4-steGFP-infected MDMs were 
producing new virus particles at a low level, but the large amount of virus remaining 
in the supernatant post-infection made it impossible to detect. This experiment was 
designed to investigate production of virus progeny by a single population of MDMs 
that was infected at the same time. However, the continuous presence of the high 
titre virus in the MDM supernatant may have allowed an ongoing infection of new 
cells. This would result in a multiple-step growth curve rather than a single-step 
growth curve as the data would be a combination of the rate at which MDMs produce 
SFV4-steGFP and the virus transmission between cells within the culture. The 
limitations described above do not affect the primary finding that SFV4-steGFP-
infected MDMs produce little or no virus. Permissive cells, such as BHK-21 cells, 




























Figure 3.8. Production of virus progeny by SFV-4-steGFP-infected MDMs.      
(a) SFV4-steGFP thermal inactivation at 37 ºC. Linear regression (least squares) on 
individual data showed as mean +/- SD.  (b) Measured SFV4-steGFP titres in the 
supernatant of virus-infected MDMs compared to the calculated SFV4-steGFP titre 













3.10 Are intact replication complexes present in cell debris from virus- and 
VRP-infected cells? 
Alphavirus replication complexes are very stable structures that remain active even 
during late stages of cell infection (Grimley et al. 1968, Kujala et al. 2001a, 
Kääriäinen et al. 2002, Spuul et al. 2010). Notably, the replication complex are stable 
enough to withstand cell-membrane disruption and immunoprecipitation (Barton et 
al. 1991, Kujala et al. 2001a). Cell debris from SFV4-3F-zsGreen-, SFV4-steGFP- 
and SFV1-3F-zsGreen VRP-infected HeLa cells was observed by transmission 
electron microscopy (TEM) to investigate if they retained intact SFV replication 
complexes that could potentially act as an infectious material. 
 
Sections of cell debris from virus- and VRP-infected HeLa cells confirmed the 
presence of substantially fragmented cells with no identifiable nucleus, and the 
presence of  apoptotic bodies (Figure 3.9). All these were hallmarks of the late stage 
apoptosis (Elmore 2007). There was no notable difference between the cell debris 
generated by eSFV4-steGFP, SFV4-3F-zsGreen and SFV1-3F-zsGreen VRP.  
 
Detailed analysis of the cell debris sections revealed that intact replication complexes 
were indeed present within the cell debris derived from SFV4-steGFP-, SFV4-3F-
zsGreen- and SFV1-3F-zsGreen VRP-infected HeLa cells (Figure 3.10). The size of 
observed replication complexes varied between 0.5 µm and 1.25 µm, and was within 
the expected range (Grimley et al. 1968, Froshauer et al. 1988). Interestingly, little or 




















Figure 3.9. Transmission electron microscopy of cell debris from virus- and 
VRP-infected HeLa cells 3 days post-infection. (a) Uninfected HeLa cells collected 
by trypsinisation. (b) Cell debris from SFV1-3F-zsGreen VRP-infected HeLa cells 
(c) Cell debris from SFV4-steGFP-infected HeLa cells. (d) Cell debris from SFV4-















Figure 3.10. Transmission electron microscopy of SFV replication complexes 
present in cell debris from virus- and VRP-infected HeLa cells 3 days post-
infection. (a) Cell debris from SFV1-3F-zsGreen VRP-infected HeLa cells. (b) Cell 
debris from SFV4-steGFP-infected HeLa cells. (c) Cell debris from SFV4-3F-
zsGreen-infected HeLa cells. Red squares mark the location of replication 
complexes. Photos were analysed independently by Dr Tero Ahola, the University of 












The principal hypothesis behind this part of the project was that human monocyte 
derived macrophages (MDMs) can be infected with SFV by a novel mechanism 
involving apoptotic debris from virus-infected cells. To date there has been no 
evidence in the literature to suggest that SFV can infect human macrophages in vitro.  
 
The work presented in this chapter was preliminary. The long-term aim was to 
confirm these findings with CHIKV and to investigate the interaction of CHIKV and 
human MDMs in much greater detail. This would include in depth characterisation of 
apoptotic cell debris, CHIKV replication in MDMs and cellular responses to virus 
infection in MDMs. However, during the second year of the project its scope 
changed and the intended CHIKV experiments were not completed.  
 
Despite the preliminary nature of this work, several key findings were made: 
 
1. Human MDMs are refractory to infection with purified SFV but can be infected 
via cell debris from SFV-infected HeLa, 2fTGH and U4C cells. 
 
2. The SFV infectious material was contained within cell debris derived from SFV-
infected HeLa, 2fTGH and U4C cells.  
 
3. Intact SFV replication complexes were identified within the HeLa cell debris 72-
hours post SFV or VRP infection.  
 
4. Cell debris derived from uninfected cells do not promote MDM infection in 
presence of a high-titre purified virus.   
 
5. Presence of infectious SFV particles is not required to infect human MDMs via 
cell debris derived from SFV-infected HeLa, 2fTGH and U4C cells.  
 
6. Genomic and subgenomic promoters of SFV are active in SFV-infected MDMs. 
  
  






The data presented in this chapter are the first evidence to demonstrate that SFV can 
infect human macrophages in vitro. Interestingly, purified SFV4-steGFP failed to 
infect human MDMs at MOIs of 1, 50, 100, 500 and 1000. SFV-permissive cells 
such as BHK-21 are readily infected at MOIs as low as 0.001. Importantly, cell 
debris from HeLa, 2fTGH and U4C cells infected with SFV were all successful in 
establishing a notable SFV infection in MDMs. The virus load in the inoculum 
containing the cell debris had no major effect on the MDM infection rate. What is 
more, cell debris derived from uninfected cells did not promote MDM infection in 
presence of a high-titre purified SFV. The above data were consistent with findings 
by Krejbich-Trotot et al. (2011) for CHIKV. They suggested that MDMs are not 
infected with SFV via receptor-mediated endocytosis and that presence of infectious 
SFV particles in the cell supernatant is not required to infect MDMs. Infection of 
macrophages via cellular debris derived from virus-infected cells might be more 
widespread amongst alphaviruses and is not just restricted to CHIKV. 
 
Infection of MDMs using HeLa-derived apoptotic debris produced with VRPs 
provided further insight into the nature of the SFV material infectious to MDMs. It 
showed that the presence of infectious virus particles within the cell debris was not 
required to infect MDMs. The SFV material infectious to MDMs was contained 
primarily within apoptotic debris of >0.8 µm. It was either viral genomic RNA in the 
cytoplasm or viral genomic RNA associated with replication complexes. It is likely 
that macrophages are infected by the virus material contained within apoptotic debris 
via phagosomes. This mechanism of infection may protect virus from antibodies, 
facilitate its spread to neighbouring cells and promote persistent infection in vivo. 
However, the exact mechanism remains unclear.  
 
Human mRNAs are relatively stable inside a cell, with a mean half-life of 
approximately 7 hours (Tani et al. 2012). Thomas et al. (2015) demonstrated that 
during apoptosis cellular mRNAs are rapidly degraded. Human mRNAs and 
alphavirus genomic RNAs share similar structure. Hence, it is likely that virus 
genomic RNAs in the cytoplasm of apoptotic cells are also degraded. Hence, the 
presence of full-length virus RNA in the cytoplasm of apoptotic debris must be 
  






investigated. Presence of intact virus replication complexes in apoptotic debris from 
virus- and VRP-infected HeLa cells was confirmed by transmission electron 
microscopy. These structures should be sufficiently stable to protect viral RNA 
contained within the spherules from degradation during apoptosis (Grimley et al. 
1968, Kujala et al. 2001a, Kääriäinen et al. 2002, Spuul et al. 2010). However, it is 
not known if replication complexes present within apoptotic debris are indeed active. 
Further studies must address this by immunoprecipitation of replication complexes 
from apoptotic debris and then measuring their activity (Barton et al. 1991, Kujala et 
al. 2001b, Kallio et al. 2013) 
 
As discussed previously, there is an ongoing debate as to the sensitivity of human 
macrophages to CHIKV (Schwartz et al. 2010). The data obtained in this chapter 
support the hypothesis that the differences observed by some may be due to the 
quality of the virus inoculum used. The presence of apoptotic debris in a cell-culture-
derived virus inoculum that was not suitably purified (e.g. by ultracentrifugation via 
a sucrose gradient) could promote infection of macrophages with the virus. This must 
always be considered when designing new experimental protocols. 
 
Expression of SFV-encoded fluorescent markers driven by both genomic and 
subgenomic promoters of the virus was observed in SFV4-3F-zsGreen- and SFV4-
steGFP-infected MDMs, respectively. This finding suggested that in SFV-infected 
MDMs non-structural and structural proteins of the virus are produced. 
Consequently, SFV infection of human MDMs may be productive. SFV replicates to 
very high titres in HeLa, 2fTGH and U4C cells. By contrast, no virus production was 
observed in MDMs infected with SFV4-steGFP via cell debris. However, the 
experimental design prohibited detection of low-level virus replication. It is possible 
that small amounts of virus progeny are released from SFV-infected MDMs. This 
would be consistent with previously reported infections of primary mouse 
macrophages with SFV (van der Groen et al. 1976, Oaten et al. 1980). Interestingly, 
CHIKV infection of human MDMs can also be productive in vitro. (Sourisseau  et al. 
2007, Labadie et al. 2010). 
  






Visual observation of MDMs showed that upon infection with SFV they round-up, 
detach from the surface of plates, and likely undergo apoptosis. By contrast, 
replicon-infected MDMs do not seem to demonstrate any morphological changes 
within the same time frame. The above observation should be confirmed by a cell 
viability assay and by inspecting MDMs for hallmarks of apoptosis, such as cleaved 
caspase-3, -8 and -9. The morphological dissimilarity described above may explain 
the difference in MDM infectivity via apoptotic debris produced by virus and by 
VRPs observed 48 hours post-infection (Figure 3.6a). Most likely, a comparable and 
high number of MDMs was initially infected with both. However, while the virus-
infected MDMs were removed from the cell monolayer, the replicon-infected MDMs 
remained in the cell monolayer. This would suggest that apoptotic debris is very 
effective at facilitating MDM infection with SFV. Barry et al. (2010) established that 
SFV envelope glycoproteins trigger the unfolded protein response of the ER that 
accelerates apoptotic cell death. Based on the above data, it is possible that in 
persistently infected macrophages CHIKV/SFV replication is maintained at a low 
level with little or no structural proteins being produced. This should be investigated 
further using modified viruses and replicons that encode marker genes under control 
of both genomic and subgenomic promoters. The relative expression of marker genes 
driven by both promoters in virus/VRP-infected MDMs could be measured over an 
extended period of time, and compared to that observed in a fibroblast infection.  
 
Alphaviruses can infect both dividing and non-dividing cells (Sourisseau et al. 2007). 
However, outcome of an alphavirus infection often depends on a maturation state of 
the cell. Upon infection of mammalian epithelial or fibroblast cells a rapid shutoff of 
host cell transcription and translation is typically observed (Jaffar-Bandjee et al. 
2009, Krejbich-Trotot et al. 2011). Subsequently, cells undergo apoptosis. However, 
terminally differentiated cells, such as mature vertebrate neurons, often do not 
undergo apoptosis when infected with SFV  (Fleming 1977, Fazakerley et al. 1993, 
Oliver et al. 1997, 1998, Allsopp et al. 2000). It is possible that at least in some cases 
the maturation state of CHIKV-infected macrophage may promote persistence by 
inhibiting apoptosis. This must be investigated in further detail.  
 
  






As discussed in 1.4, alphavirus infection of mammalian cells triggers apoptosis both 
in vitro and in vivo. It is safe to assume that the cellular debris derived from HeLa, 
2fTGH and U4C cells were indeed apoptotic bodies. The analysis of Hela cell debris 
by a transmission electron microscope confirmed the presence of hallmarks of late-
stage apoptosis, such as nuclear fragmentation. However, a detailed analysis of the 
cell debris was not performed.  
 
As mentioned at the beginning of this discussion, the work presented in this chapter 
was preliminary. However, many of the findings were intriguing and more detailed 
studies should be planned to investigate them in more depth.  
 
Future work should include: 
1.  Confirmation of data obtained for SFV with CHIKV in human MDMs and 
human fibroblasts; 
2. Characterisation of virus-induced cell debris; 
 size fractioning (gradient centrifugation); 
 identification of the cell debris population that contains the SFV material 
infectious to MDMs (size fractioning combined with bioassays); 
 expression of apoptotic markers (immunostaining); 
 protein composition (proteomics); 
 transcriptome composition (transcriptomics); 
 presence of viral genomic RNA (PCR, qPCR); 
 presence and localisation of virus particles and virus replication 
complexes (immunostaining, marker genes, electron microscopy); 
 protein composition (proteomics; virus encoding a marker); 
 purification of replication complexes (gradient centrifugation, 
immunoprecipitation); 
 measuring the activity of replication complexes; 
 inactivation of unprotected RNA within virus-induced cell debris 
(treatment with RNAses); 
3. Characterisation of virus replication in monocytes, MDMs and Thp-1 cells 
 time course of viral RNA replication (qPCR; 3H-uridine labelling); 
  






 time course of virus protein production (Western blot, 35S-labelled 
methionine, expression of a virus-encoded marker gene); 
 time course of production (release) of infectious virus particles (plaque 
assay, expression of a virus-encoded marker gene, qPCR); 
 differential expression of virus proteins from the genomic and 
subgenomic promoters (reporter virus encoding two marker genes, one 
under control of the genomic promoter and one under control of the 
subgenomic promoter); 
 formation of replication complexes (electron microscopy); 
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As mentioned previously, the scope of the PhD project presented in this thesis 
changed following the completion of work described in Chapter 3. The new objective 
was to investigating the role of monocyte and macrophage infection with CHIKV in 
the nonhuman primate model of chikungunya virus disease. This shift was largely 
dictated by the availability of tools and resources at the time.  
 
The new objective was addressed by harnessing endogenous miR-142-3P to restrict 
virus replication in haematopoietic cells. In context of cynomolgus macaque 
infection with CHIKV this effectively means restricting CHIKV replication in 
monocytes and macrophages as other haematopoietic cells are not readily infected 
with the virus (Labadie et al. 2010). The cell-specific restriction of virus replication 
was attempted by incorporation of a recognition element (RE) with multiple copies 
of target sequences fully complementary to miR-142-3P into the genome of CHIKV.  
 
The work presented in this chapter includes generation of resources and tools 
required to undertake this project, and proof-of-concept experiments completed using 
SFV. The work presented in Chapter 5 includes generation of miR-142-3P-targeted 





















The specific objectives for this part of the project were as follow: 
 
1) To design and generate a recognition element for miR-142-3P, and a suitable 
control. 
 
2) To incorporate miR-142-3P recognition element into the genome of Semliki 
Forest virus. 
 
3) To investigate if replication of Semliki Forest virus encoding miR-142-3P 
recognition element is attenuated in haematopoietic cells.  
 
4) To design, generate and characterise Hek 293 cells that can express miR-142-
3P under control of the tetracycline-inducible promoter. 
 
5) To investigate if replication of Semliki Forest virus encoding miR-142-3P 
recognition element is attenuated in Hek 293 cells that express miR-142-3P, 
but not in Hek 293 cells that do not express miR-142-3P. 
 
6) To design and generate a panel of pcDNATM3.1+ plasmids that express      
miR-142-3P. 
 
7) To investigate if replication of Semliki Forest virus encoding miR-142-3P 
recognition element is attenuated in cells transfected with pcDNA3.1+ 
expressing miR-142-3P, but not in cells transfected with control plasmids. 
 
8) To investigate the stability of miR-142-3P RE in Semliki Forest virus genome 
during serial passage on BHK-21 cells.  
 
9) To investigate if Semliki Forest virus encoding miR-142-3P recognition 










4.2 Designing miR-142-3P recognition element (RE) 
Three miRNA recognition elements (REs) were designed for this study: miR-142-3P 
RE, miR-142-3P Antisense RE and miRNA RE Control. Their sequences are 
provided in Annex 15. The three REs shared a common design (Figure 4.1a).  In 
brief, they were designed as a cassette encoding a 5’ multiple cloning site (MCS), 4 
copies of the miR-142-3P target sequence (TS) separated from each other by 4-
nucleotide spacers, and a 3’ MCS (Figure 4.1a). The overall RE design was 





Figure 4.1. Design of the miRNA REs. (a) Common design shared by all miRNA 
REs: 5’ multiple cloning site (MCS), 4 copies of the target sequence (TS) separated 
from each other by 4 nucleotide spacers, 3’ MCS. (b) Details of each component of 
the miRNA RE cassette. Three out of five different 4-nucleotide spacers (4B) were 
used in each cassette. 
  






Both 5’ and 3’ multiple cloning sites were identical in all miRNA REs. The primary 
difference between the three REs was the type of the target sequence (TS) present in 
the cassette (Figure 4.1b): 
 
1. miR-142-3P RE – miR-142-3P TS, the reverse complement of miR-142-3P 
(perfect target). In an alphavirus encoding this RE, the virus genome would be 
targeted for degradation in all cells that express miR-142-3P. 
 
2. miR-142-3P Antisense RE – miR-142 Antisense TS, the reverse complement of 
miR-142-3P TS. In an alphavirus encoding this RE, the virus antigenome (-ve 
strand, replication intermediate) would be targeted for degradation in all cells that 
express miR-142-3P. 
 
3. miRNA RE Control – Control TS, reverse sequence of miR-142-3P Antisense 
TS (3’ to 5’ sequence but in 5’ to 3’ orientation). In an alphavirus encoding this 
RE, neither the virus genome nor the virus antigenome would be targeted for 
degradation in cells that express miR-142-3P. This construct was used as the 
control for miR-142-3P RE and miR-142-3P Antisense RE. 
 
All miRNA REs were designed to be incorporated into coding and non-coding 
regions of SFV and CHIKV genomes. Consequently, the size of all REs was such 
that they would not cause a frameshift mutation when inserted into an open reading 
frame (i.e. divisible by three). None of the REs contained stop codons in the +1 
frame. To fulfil the above requirements, five different 4-nucleotide spacers were used 
(Figure 4.1b). Furthermore, three additional bases were inserted into miR-142-3P RE 
(two following 5’ MCS and one prior to 3’ MCS). Consequently, the size of miR-
142-3P RE was 141 bp while the size of miR-142-3P Antisense RE and miRNA RE 











The 5’ and 3’ MCSs were 17 base pairs long and contained 3 rare restriction sites, 
each (Figure 4.1b). The MCSs were not intended to be used for cloning of a RE into 
the genomes of SFV or CHIKV. Instead, they were designed to act as a universal 
primer annealing site. This approach ensured that any restriction sites required for 
cloning could be added to all miRNA REs by a single PCR (the same set of primers 
and the same cycling conditions). Also, the entire miRNA RE cassette would always 
remain intact in all viruses, irrespective of the restriction sites used for cloning. 
 
AccIII, MfeI and SacI restriction sites were not present in ICRES1 icDNAs or 
chikungunya replicons. All restriction sites incorporated into the miRNA REs MCSs 
were already present in SFV4 icDNAs. 
 
Finally, SacI and Bsu36I restriction sites were incorporated into the 3’ MCS to allow 
easy-to-interpret control digests of ICRES1 and SFV4 icDNAs, respectively. In brief, 
a miRNA RE could be inserted into the coding region of the alphavirus non-
structural polyprotein, between the nsP3 and nsP4. This locus had been used 
previously to successfully insert marker genes into the genomes of SFV and CHIKV 
(e.g. SFV4-3F-zsGreen, ICRES1-3F-zsGreen). At this location an insert would be 
cloned into the virus genome via a single restriction site, XhoI in SFV4 and SpeI in 
ICRES1. However, the use of a single restriction site for the cloning could result in 
the miRNA RE integrating into the virus genome in either of the two possible 
orientations, only one of which would yield a fully functional construct. In SFV4, 
Bsu36I restriction site was present in two genomic locations. One of them was close 
to the discussed cloning site. A control digest with Bsu36I would yield fragments 
that are different in the size by 114 bp depending on the insert orientation and small 
enough to clearly separate on an agarose gel (Figure 4.2a). Similar was true for 
















Figure 4.2. SFV and CHIKV control digest design. Diagrams represent the 
genomic locations of SFV and CHIKV corresponding to the nsP3 and nsP4.            
(a) Bsu36I digest of SFV4 icDNA with a miRNA RE element inserted in between 
nsP3 and nsP4 would yield a fragment of 518 bp in case of the correct ligation and a 
fragment of 404 bp in case of the incorrect ligation. (b) SacI and AgeI double digest 
of ICRES1 clone with a miRNA RE element inserted in between nsP3 and nsP4 
would yield a fragment of 472 bp in case of the correct ligation and a fragment of 
597 bp in case of the incorrect ligation. 
 
 
4.3  Generating miRNA REs 
Each of the three miRNA REs was synthesised in a form of two 78-81 bp long 
oligonucleotides with 18 bases of a complementary sequence as outlined in Table 
4.1. Next, 1 µl of each oligonucleotides at 100 µM concentration were annealed and 
extended using Vent® DNA polymerase as described in 2.11.6 and outlined in 
Figure 4.3. Double-stranded products were run on a 3% agarose gel as described in 














Table 4.1. Oligonucleotides used to generate the miRNA recognition elements 








































Figure 4.3. Generation of a miRNA RE.  Two oligonucleotides with 18 bases of a 
complementary sequence were aligned and extended using Vent® polymerase.  
  






4.4  Incorporating miRNA REs into the genome of SFV 
SFV4-3H-zsGreen-2SG-GLuc icDNA was modified by incorporation of miRNA 
REs into its genome (Figure 4.4). In this construct, zsGreen was inserted into the 3’ 
terminus of the nsP3 gene. This marker gene was cleaved from the non-structural 
polyprotein post-translationally leading to its released into the cytoplasm of virus-
infected cells. Furthermore, a cassette encoding a duplicated SFV subgenomic 
promoter and Gaussia luciferase (GLuc) was inserted between ApaI and BamHI sites 
into the 3’ UTR of SFV, directly downstream of the structural polyprotein stop 
codon. ß-globin intron was present in the capsid region to disrupt a cryptic E.coli 
promoter. It was removed from the virus genome during its replication (Dr Rennos 
Fragkoudis, the Pirbright Institute, personal communication). Finally, SFV4-3H-
zsGreen-2SG-GLuc was cloned into the icDNA under control of the CMV promoter.  
 
In brief, miRNA REs were incorporated into the 3’ UTR of SFV4-3H-zsGreen-2SG-
GLuc in place of the GLuc as outlined in Figure 4.5. This position is known to be 
genetically stable in SFV (Prof Andres Merits, the University of Tartu, personal 
communication). The resulting SFV4 clones would maintain zsGreen as a marker 
gene and should be small and stable enough to be used in vitro and in vivo. The 
cloning procedure is detailed in Annex 17.  
 
SFV4 constructs encoding miR-142-3P RE, miR-142-3P Antisense RE and miRNA 
RE Control were called SFV4-3H-zsGreen-miR-142-3P RE, SFV4-3H-zsGreen-
miR-142-3P Antisense RE and SFV4-3H-zsGreen-miRNA RE Control, respectively. 
Altogether, these viruses were named SFV4-3H-zsGreen-miRNA RE. Their 


















Figure 4.4. Schematic representation of SFV4-3H-zsGreen-miRNA RE clones. 
miRNA REs were inserted into the 3’ UTR of the virus, between ApaI and BamHI 
restriction sites. Parental virus, SFV4-3H-zsGreen-2SG-GLuc, is shown at the top. 
nsP – non-structural protein; GP – genomic promoter; SGP – subgenomic promoter; 
2SGP – duplicated subgenomic promoter; C – capsid; E1-E3 – envelope 
glycoproteins; GLuc – Gaussia luciferase; vertical dashed line – protein cleavage 
sites; Poly(A) – Poly(A) tail; m
7





















Figure 4.5. Incorporation of a miRNA RE into the genome of SFV4-3H-
zsGreen-2SG-GLuc. Simplified structure of SFV4-3H-zsGreen-2SG GLuc is 
presented. nsP-non-structural protein; GP – genomic promoter; SGP – subgenomic 
promoter; 2SGP – duplicated subgenomic promoter; C – capsid; E1-E3 – envelope 
glycoproteins; GLuc – Gaussia luciferase; vertical dashed line – protein cleavage 
sites; Poly(A) – Poly(A) tail; m
7
GpppA – 5’ CAP; RE – recognition element; MCS – 
multiple cloning site; 4B – 4-nucleotide spacer; TS – target sequence. 
 
 
4.5 Growing SFV-3H-zsGreen-miRNA RE clones 
SFV4-3H-zsGreen-miRNA RE constructs were successfully rescued from icDNAs 
as described in 2.3.3.2. Virus stock (clarified cell culture supernatant) was titrated 
following the protocol outlined in 2.3.5. Expression of zsGreen in icDNA-
electroporated cells was confirmed microscopically 24 hours post-electroporation.  
 
  






4.6 Will SFV4-3H-zsGreen-miR-142-3P RE be attenuated in haematopoietic    
IC-21 cells but not in fibroblast BHK-21 cells? 
The following proof-of-concept experiment was completed only once due to reasons 
explained later. First, BHK-21 cells and haematopoietic IC-21 cells were infected 
with all three SFV4-3H-zsGreen-miRNA RE clones at MOI of 0.01 and 100, 
respectively, in 24-well plates. The protocol described in 2.5.1 was followed. Twenty 
hours post-infection cells were fixed with 10% v/v neutral buffered formalin, washed 
with PBS and observed microscopically for the expression of virus-encoded zsGreen.  
 
The microscopic inspection of IC-21 and BHK-21 cells revealed a complete absence 
of zsGreen expression. Hence, cells were immunostained for SFV nsP3 as described 
in 2.6. Positive staining was observed in virus-infected but not in uninfected cells. 
The proportion of virus-infected cells was calculated as described in 2.7.4. 
 
Similar proportion of BHK-21 cells was infected with all the three viruses (Figure 
4.6b). Approximately 45% of IC-21 cells were infected with SFV4-3H-zsGreen-
miRNA RE Control (figure 4.6a). This was comparable to the infection rate observed 
for SFV4-3H-zsGreen-miR-142-3P Antisense RE. Importantly, less than 1% of IC-
21 cells infected with the virus encoding miR-142-3P RE were positive for SFV 
nsP3. This corresponded to a statistically significant 99% reduction in the number of 
virus-positive cells relative to the control virus (Figure 4.7). These results suggested 
that the presence of miR-142-3P target sequences in the genome of SFV4 but not in 
the antigenome would efficiently restrict virus-replication in haematopoietic cells.  
 
The lack of zsGreen expression in all SFV4-3H-zsGreen-miRNA RE clones was 
very surprising as the marker gene was clearly produced during virus rescue (see 
4.5). Varjak et al. (2010) reported a presence of a functional degradation signal 
within the C-terminal region of SFV nsP3 that significantly accelerated degradation 
of RLuc in a chimeric reporter assay. Its exact role in virus replication is not well 
understood. However, it is believed that in a replication of an unmodified virus the 
nsP3 is stabilised by individual components of the viral replicase. It is also possible 
that SFV replication can inhibit nsP3 degradation. The zsGreen in SFV4-3H-
  






zsGreen-2SG-GLuc construct was fused with C-terminal amino acids of the nsP3. 
Most likely, the presence of the degradation signal led to rapid destruction of the 
virus-encoded zsGreen within hours post-translation. The zsGreen did not have 
sufficient time to accumulate or mature, causing the lack of detectable fluorescent 
signal during microscopic analysis. This effect may perhaps be more pronounced in 
cells where SFV replicates slower (potentially IC-21) in comparison to cells where 
SFV replicates very quickly (e.g. BHK-21). This may explain why zsGreen was 
clearly observed during production of virus stock in BHK-21 cells. As the SFV4-3H-
zsGreen-miRNA RE clones were not fully functional it was decided that they would 
not be used in subsequent experiments. Instead, the three miRNA REs were cloned 














Figure 4.6. Infection of IC-21 and BHK-21cells with SFV4-3H-zsGreen-miRNA 
RE constructs. IC-21 (a) and BHK-21 (b) cells were infected at MOI of 100 and 
0.01, respectively, with SFV4-3H-zsGreen-miR-142-3P RE, SFV4-3H-zsGreen-
miR-142-3P Antisense RE and SFV4-3H-zsGreen-miRNA RE Control. Cells were 
incubated for 20 hours, fixed with 10% v/v neutral buffered formalin, immunostained 
for SFV nsP3 (Alexa Fluor ® 488-conjugated secondary antibody), mounted with 
VECTASHIELD mounting medium containing DAPI and inspected using Zeiss 












Figure 4.7. Infection of IC-21 and BHK-21 cells with SFV4-3H-zsGreen-miRNA 
RE constructs. IC-21 and BHK-21 cells were infected at MOI of 100 and 0.01, 
respectively, with SFV4-3H-zsGreen-miR-142-3P RE, SFV4-3H-zsGreen-miR-142-
3P Antisense RE and SFV4-3H-zsGreen-miRNA RE Control. Cells were incubated 
for 20 hours, fixed, immunostained for SFV nsP3, mounted and inspected using 
Zeiss Axioskop 2 upright microscope. The proportion of nsP3-positive cells was 
calculated. The results were normalised to the infection in BHK-21 cells and to 
SFV4-3H-zsGreen miRNA RE Control virus. Data expressed as relative mean +/- 
relative SD; Mann-Whitney test, single-tailed; * p<0.05. 
 
 
4.7 Generating SFV4-3F-zsGreen-miRNA RE and SFV4-3F-zsGreen-2SG-
GLuc-miRNA RE constructs 
SFV4-3F-zsGreen-2SG-GLuc was modified to incorporate miRNA REs in its 
genome. In this construct, zsGreen was expressed as a fusion protein with the nsP3. 
Consequently, in virus-infected cells zsGreen was localised to replication complexes 
in the cytoplasm. Furthermore, a cassette encoding a duplicated SFV subgenomic 
promoter and GLuc was inserted between ApaI and BamHI sites in the 3’ UTR as 
described previously for SFV4-3H-zsgreen-2SG-GLuc. Finally, SFV4-3F-zsGreen-
2SG-GLuc was cloned into the icDNA under control of the CMV promoter.  
 
Two virus panels were generated based on SFV4-3F-zsGreen-2SG-GLuc. In the first 
one, all three miRNA REs were cloned into the 3’ UTR of the virus, directly 
downstream of the GLuc, between NotI and PmeI restriction sites (Figure 4.8). The 
resulting viruses were designed to study the replication of SFV encoding miR-142-
  






3P RE in vitro. In the second panel, GLuc was replaced by miR-142-3P RE and 
miRNA RE Control (Figure 4.9). Based on the preliminary data obtained using 
SFV4-3H-zsGreen-miR-142-3P Antisense RE (see 4.6) it was decided that miR-142-
3P Antisense RE would not be used. The overall design was similar to that of SFV4-
3H-zsGreen-miRNA RE constructs (see 4.4). The resulting SFV4 clones would 
maintain a functional zsGreen as a marker gene and should be small and stable 





Figure 4.8. Schematic representation of SFV4-3F-zsGreen-2SG-GLuc miRNA 
RE clones. miRNA REs were inserted into the 3’ UTR of the virus, downstream of 
the GLuc, between NotI and PmeI restriction sites. Parental virus, SFV4-3F-zsGreen-
2SG-GLuc, is shown at the top. nsP – non-structural protein; GP – genomic 
promoter; SGP – subgenomic promoter; 2SGP – duplicated subgenomic promoter;   
C – capsid; E1-E3 – envelope glycoproteins; GLuc – Gaussia luciferase; Poly(A) – 
Poly(A) tail; m
7
GpppA – 5’ CAP;  RE – recognition element. 
 
  









Figure 4.9. Schematic representation of SFV4-3F-zsGreen-miRNA RE clones. 
miRNA REs were inserted into the 3’ UTR of the virus. Parental virus, SFV4-3F-
zsGreen, is shown at the top. nsP – non-structural protein; GP – genomic promoter; 
SGP – subgenomic promoter; C – capsid; E1-E3 – envelope glycoproteins; Poly(A) – 
Poly(A) tail; m
7
GpppA – 5’ CAP; RE – recognition element. 
 
 
SFV4-3F-zsGreen-2SG-GLuc constructs encoding miR-142-3P RE, miR-142-3P 
Antisense RE and miRNA RE Control were called SFV4-3F-zsGreen-2SG-GLuc-
miR-142-3P RE, SFV4-3F-zsGreen-2SG-GLuc-miR-142-3P Antisense RE and 
SFV4-3F-zsGreen-2SG-GLuc-miRNA RE Control, respectively. Altogether, these 
viruses were named SFV4-3F-zsGreen-2SG-GLuc-miRNA RE. Their sequences are 
provided in Supplementary Data, Appendix 1. 
 
SFV4-3F-zsGreen constructs encoding miR-142-3P RE and miRNA RE Control 
were called SFV4-3F-zsGreen-miR-142-3P RE and SFV4-3F-zsGreen-miRNA RE 
Control, respectively. Altogether, these viruses were named SFV4-3F-zsGreen-










4.8 Growing SFV encoding miR-142-3P RE and functional marker genes 
zsGreen and GLuc 
SFV4-3F-zsGreen-2SG-GLuc, SFV4-3F-zsGreen-miRNA RE and SFV4-3F-
zsGreen-2SG-GLuc-miRNA RE constructs were successfully rescued from icDNAs 
as described in 2.3.3.2. Virus stock (clarified cell culture supernatant) was titrated 
following the protocol outlined in 2.3.5. Expression of zsGreen in icDNA-
electroporated cells was confirmed microscopically 24 hours post-electroporation.  
 
4.9 Will the presence of miR-142-3P RE affect the rate at which SFV can 
replicate in fibroblast BHK-21 cells? 
Replication of SFV4 (wt), SFV4-3F-zsGreen, SFV4-3F-zsGreen-2SG-GLuc, SFV4-
3F-zsGreen-miRNA RE and SFV4-3F-zsGreen-2SG-GLuc-miRNA RE constructs in 
BHK-21 cells was investigated by completing one-step growth curves. In brief, cells 
were infected at MOI of 10 to ensure an infection rate close to 100%. Virus 
replication was tested by plaque assay (and GLuc, if applicable) every 2-4 hours, for 
24 hours. The protocol described in 2.3.7 was followed.  
 
The results shown in Figure 4.10a suggested that incorporation of marker genes into 
the genome of SFV had a negative effect on virus replication. This was observed at 
all time-points but it was the most pronounced within the first 12 hours post-
infection. The effect was amplified when multiple marker genes were used. This 
could be due to size of modified viruses (larger genome would replicate slower) or 
due to disruptions made in the virus genome during cloning.   
 
Incorporation of a miRNA RE into SFV4 genome did not itself affect virus 
replication. This was observed in SFV4-3F-zsGreen-miRNA RE constructs (Figure 















Figure 4.10. SFV4 one-step growth curves. BHK-21 cells were infected at MOI of 
10 and incubated for 24 hours. The cell supernatant was sampled every 2 hours for 
the first 12 hours, and then every 4 hours. Samples were tested by plaque assay 
(a,b,c) or by GLuc assay (d). Data expressed as mean +/- SD. 
  






The size of plaques produced by SFV4 (wt), SFV4-3F-zsGreen, SFV4-3F-zsGreen-
2SG-GLuc, SFV4-3F-zsGreen-miRNA RE and SFV4-3F-zsGreen-2SG-GLuc-
miRNA RE constructs on BHK-21 cells was investigated using Zeiss AxioVision 4.8 
digital image processing software. All viruses were plaqued as described in 2.3.5, at 
the same time and on the same BHK-21 cells. 
 
The observed plaque sizes (Figure 4.11, 4.12) mirrored the pattern identified by one-
step growth curves (Figure 4.10). SFV4 (wt) produced the largest plaques (2.28 mm, 
SD=0.06) with the most distinctive edge. The size of SFV4-3F-zsGreen plaques was 
reduced by approximately 21% (1.80 mm, SD=0.08) in comparison to SFV4 (wt). 
The reduction was statistically significant (P<0.05). The size of SFV4-3F-zsGreen-
2SG-GLuc was reduced even further, by 32% (1.32 mm, SD=0.06) in comparison to 
SFV4 (wt). The reduction was statistically significant (P<0.05) with respect to both 
SFV4 (wt) and SFV4-3F-zsGreen. Importantly, incorporation of a miRNA RE into a 
virus genome did not itself affect the size of plaques produced by this virus. With the 
exception of SFV4 (wt), all viruses generated plaques that had uneven, serrated 












Figure 4.11. Plaques generated by different SFV4 clones. Cells were incubated for 
48 hours with CMC-based semi-solid overlay, fixed with 10% v/v neutral buffered 
formalin for 1 hour and then stained with 0.1% toluidine blue. 
 
  








Figure 4.12. Size of plaques generated by different SFV4 clones. The size of 
plaques was measured using Zeiss AxioVision 4.8 digital image processing software. 
Data expressed as mean of random 20 individual plaques +/- SD.  
 
 
4.10 Will SFV4-3F-zsGreen-2SG-GLuc-miR-142-3P RE be attenuated in 
haematopoietic IC-21 cells but not in fibroblast BHK-21 cells? 
SFV4-3F-zsGreen-2SG-GLuc-miR-142-3P RE, SFV4-3F-zsGreen-2SG-GLuc-miR-
142-3P Antisense RE and SFV4-3F-zsGreen-2SG-GLuc-miRNA RE Control were 
used to infect BHK-21 cells at MOI of 0.005, and IC-21 cells at MOIs of 10 and 100, 
in 24-well plates. The protocol outlined in 2.5.1 was followed. Fifty µl of the 
supernatant from IC-21 cells was collected 1.5 hours post-infection (samples from 
replicate wells were pooled). Twenty hours post-infection supernatants from virus-
infected cells were collected and cells were observed microscopically for the 
expression of virus-encoded zsGreen. Virus titres and GLuc levels were measured as 
described in 2.3.5 and 2.9.3, respectively.   
 
  






The replication of the three viruses in IC-21 cells could not be accurately measured 
by a plaque assay due to high levels of virus remaining in cell supernatants post-
infection (up to 10
5
 PFU/ml). Twenty hours post-infection, virus titres from IC-21 
cells infected with SFV4-3F-zsGreen-2SG-GLuc-miR-142-3P Antisense RE and 
SFV4-3F-zsGreen-2SG-GLuc-miRNA RE Control were higher (up 10
6
 PFU/ml) and 
comparable to each other suggesting active replication of both viruses in these cells. 
However, the amount of virus present in the supernatant of IC-21 cells infected with 
SFV4-3F-zsGreen-2SG-GLuc-miR-142-3P RE was close to the titre calculated 
according to the SFV4 thermal inactivation (see Figure 3.8). This suggested that the 
full attenuation of SFV4-3F-zsGreen-2SG-GLuc-miR-142-3P RE in IC-21 cells 
could not be measured by a plaque assay in this experiment.  
 
GLuc encoded by all three viruses allowed simple but indirect measurement of virus 
replication. In BHK-21 cells, all three viruses replicated to the same extent (Figure 
4.13). In IC-21 cells, viruses encoding miRNA RE Control and miR-142-3P 
Antisense RE replicated to comparable levels. However, the measured replication of 
SFV4-3F-zsGreen-2SG-GLuc-miR-142-3P RE was reduced by over 99% with 
respect to the control virus at both MOIs. The difference was statistically significant. 
The above data was fully supported by observation of virus-infected cells under a 
microscope. A pattern similar to that shown in Figure 4.7 was observed. 
 
  








Figure 4.13. Replication of SFV4-3H-zsGreen-miRNA RE clones in IC-21 and 
BHK-21 cells.  BHK-21 cells were infected at MOI of 0.005. IC-21 cells were 
infected at MOI of 10 and 100. GLuc was measured in the supernatant from virus-
infected cells 20 hours post-infection. (a) Raw data expressed as mean +/- SD. (b) 
Results normalised to the infection in BHK-21 cells and to SFV4-3F-zsGreen-2SG-
GLuc-miRNA RE Control virus. Data expressed as relative mean +/- relative SD; 














4.11 Designing, generating and characterising Hek 293 cells that express     
miR-142-3P under control of the hybrid CMV/TetO2 promoter 
Stable cell lines that can express miR-142-3P under control of the hybrid 









 293 cells were used. They did not express any 
notable levels of miR-142-3P and they were susceptible to infection by SFV and 
CHIKV. These cells were designed and generated to confirm that the attenuation of 
SFV4 clones encoding miR-142-3P RE in haematopoietic IC-21 cells observed in 4.6 










 293 cells 
contain a single stably integrated minimal (34 bp) Flp Recombination Target (FRT) 
site at a transcriptionally active genomic locus. The FRT site is located immediately 
downstream of ATG initiation codon of lacZ-Zeocin
TM
 fusion gene under the control 
of the SV40 early promoter. In addition, Tet repressor (TetR) is expressed under 
control of the human cytomegalovirus (CMV) immediate early enhancer/promoter 
from a different genomic locus. Next, gene of interest (GOI) is cloned into 
pcDNA
TM
5/FRT/TO expression vector under control of the hybrid CMV/TetO2 
promoter. In addition, the pcDNA
TM
5/FRT/TO plasmid encodes the hygromycin 
resistance gene which lacks a promoter and a start codon but includes a FRT 
sequence in its 5’ end. Upon co-transfection of pcDNA
TM
5/FRT/TO containing the 





293 cells, the pcDNA
TM
5/FRT/TO construct is integrated into the cell genome via 
Flp-mediated homologous recombination between FRT sites in the cell genome and 
the pcDNA
TM
5/FRT/TO. During this process the FRT sites are maintained and the 
SV40 early promoter and ATG initiation codon of the lacZ-Zeocin
TM
 fusion gene are 
donated to hygromycin resistance gene thus inactivating the lacZ-Zeocin
TM
 fusion 
gene. Consequently, stable clones expressing the GOI are resistant to hygromycin but 
are sensitive to Zeocin
TM
 and lack the ß-galactosidase activity. The CMV/TetO2 
promoter upstream of the GOI consists of the CMV immediate early 
enhancer/promoter followed by two copies of 19 nucleotide tet operator 2 (TetO2,  
5’-TCCCTATCAGTGATAGAGA-3’) separate by a 2 base pair spacer. Each TetO2 
  











 293 cells thus repressing the transcription of the GOI. However, 
upon addition of tetracycline, the antibiotic binds to the TetR and changes its 
conformation leading to its dissociation from TetO2 and induction of GOI 
transcription. Consequently, the activity of the CMV promoter driving the expression 
of the GOI can be regulated by presence of tetracycline. 
 
The genomic locus of miR-142-3P on human chromosome 17 has been characterised 
in human K562 cells  by Sun et al. (2010). The transcription start site of the miR-142 
primary transcript was located 308 bases upstream from the 5’ end of the miR-142 
precursor. A polyA signal was located 730 bases downstream of the transcription 
start site. A schematic representation of the miR-142-3P locus (HSA17:5640719-





Figure 4.14. Schematic representation of miR-142-3P locus on human 
chromosome 17. Locations of the transcription start site of the miR-142 primary 
transcript, miR-142 stem loop, miR-142-3P and a polyA signal located on human 
chromosome 17 (HSA17:5640719-56409340[-]) are shown. Fragments of genomic 




 293 cells are indicated.  
  










 293 cells were modified by inserting a sequence from the 
genomic locus of miR-142-3P into their genome, under control of the hybrid 
CMV/TetO2 promoter. Four different constructs were designed (Figure 4.14). Their 
complete sequences are provided in Annex 16.  
 
1. miR-142 ‘Core’ – 293 nucleotide fragment encompassing 103 bp upstream of 
miR-142 stem loop to 103 bp downstream of miR-142 stem loop. 
 
2. miR-142 ‘Short’ – 788 nucleotide fragment encompassing 8 bp upstream of the 
transcription start site of miR-142 primary transcript to 50 bp downstream of 
poly(A) signal. 
 
3. miR-142 ‘Long-3’ – 878 nucleotide fragment encompassing 98 bp upstream of 
the transcription start site of miR-142 primary transcript to 50 bp downstream of 
poly(A) signal. 
 
4. miR-142 ‘Long-5’ - 932 nucleotide fragment encompassing 152 bp upstream of 
the transcription start site of miR-142 primary transcript to 50 bp downstream of 
poly(A) signal. 
 
The cloning details are provided in Annex 19. The resulting cell lines were called 
Hek 293 miR-142 ‘Core’, Hek 293 miR-142 ‘Short’, Hek 293 miR-142 ‘Long-3’, 
Hek 293 miR-142 ‘Long-5’ and Hek 293 Control. Six clones of each cell line were 
sub-cultured. 
 
The expression of miR-142-3P was assayed by qPCR in two clones of each cell line. 
First, each clone was seeded into a 6-well plate at 5 x 10
5
 cells/well in duplicates. 
Doxycycline (an analogue of tetracycline) was added to one well from each pair at 1 
µg/ml final concentration. Cells were incubated for exactly 24 hours. Next, total 
RNA was extracted using TRIzol® reagent as described in 2.15.3. The expression of 
miR-142-3P per 200 ng of RNA was measured using TaqMan® miR-142-3P Assay 
(Life Technologies Applied Biosystems®, Annex 6) as described in 2.13. 
 
  






The qPCR amplification curves were analysed visually (Figure 4.15). All cell lines 
(with the exception of Hek 293 Control) expressed miR-142-3P following the 
addition of doxycycline (DOX). One of the highest expressions of miR-142-3P 
following induction with DOX was observed in Hek 293 miR-142 ‘Core’ cell line. 





 293 cells can efficiently transcribe the miR-142-3P gene in the 
absence of any promoters or control elements present upstream of the miR-142 
primary transcript. In addition, the 293 nucleotide fragment encompassing 103 bp 
upstream of miR-142 stem loop to 103 bp downstream of miR-142 stem loop must 
contain all elements required by the cellular miRNA machinery to process the pri-
miRNA into the mature miR-142-3P.  
 
Evidence of background expression of miR-142-3P was observed in all cell lines 
(with the exception of Hek 293 Control) induced with DOX. This was not 
unexpected as promoters based on tet operator 2 (TetO2) had been shown before to 
be leaky (Senkel et al. 2009). Interestingly, Hek 293 miR-142 ‘Core’ cells 
demonstrated one of the lowest background expressions of miR-142-3P. It is possible 
that the lack of any promoters normally found upstream of the miR-142 primary 
transcript may contribute to the tight control of pri-mRNA expression by the tet 




 293 cells. As a result of the above findings, Hek 293 

















293 cells. qPCR amplification curves from one clone of each cell lines are shown. 
Cells were induced or not with DOX at 1µg/ml final concentration for 24 hours prior 
to RNA extraction. X-axis – qPCR cycle number. Y-axis – Normalised fluorescence. 
The same threshold was used in a,b,c,d and e. 
 
  






The expression of miR-142-3P was assessed by qPCR in all clones of Hek 293 miR-
142 ‘Core’ cell line following the protocol described above. The qPCR amplification 
curves were analysed visually (Figure 4.16). No notable difference was observed 
between the 6 clones. Consequently, clone 1 was chosen for further analysis and the 
resultant cell line was renamed as Hek 293 miR-142. Finally, Hek 293 Control and 
Hek 293 miR-142 cell lines were expanded and frozen in LN2 as described in 2.2.11. 





Figure 4.16. Relative expression of miR-142-3P in 6 clones of Hek 293 miR-142 
‘Core’. No notable difference was observed. Clone 1 was chosen for further analysis 
and the resultant cell line was renamed Hek 293 miR-142. 
 
 
The expression of miR-142-3P relative to miR-16 was subsequently measured in Hek 
293 miR-142 (+/- DOX), Hek 293 (+/- DOX), BHK-21, 3T3, Thp-1 (not treated with 
PMA) and IC-21 cells, in biological triplicates. Hek 293 miR-142 cells (+/- DOX) 
and Hek 293 Control cells (+/- DOX) were prepared as described above. The other 
cell lines were harvested, counted and then 1 x 10
6
 of cells was pelleted by 
centrifugation for 5 min at 200 x g and RT. Total RNA was extracted using TRIzol® 
reagent as described in 2.15.3. The expression of miR-142-3P and miR-16 was 
measured using TaqMan® miR-142-3P Assay and TaqMan® miR-16 Assay, 
respectively (both Life Technologies Applied Biosystems®, Annex 6). The protocol 
described in 2.13 was followed.  
  






The qPCR data are summarised in Figure 4.17. The relative levels of miR-142-3P 
were up to 10,000 higher in haematopoietic cells IC-21 and Thp-1 than in fibroblast 
cell lines 3T3 and BHK-21. High levels of miR-142-3P RE in human Thp-1 cells and 
in mouse IC-21 cells confirmed that this miRNA is conserved in humans and mice. 
As expected, the level of miR-142-3P expression in Hek 293 Control cells was low 
and not dependent on the induction with DOX. As expected, a strong background 
expression of the miRNA was observed in Hek 293 miR-142 cells not induced with 
DOX. Importantly, following the induction with DOX the expression of miR-142-3P 
in Hek 293 miR-142 cells increased over 14-fold and was only slightly smaller than 





Figure 4.17. miR-142-3P expression normalised to miR-16 in a range of 
haematopoietic and non-haematopoietic cell lines. Data expressed as 15-ΔΔCq, 
mean of 3 biological replicates +/- SD. Hek 293 miR-142 (+DOX) and Hek 293 
Control (+DOX) cells were induced with DOX at 1µg/ml final concentration for 24 
hours prior to RNA extraction. Dox – doxycycline; Cq – quantification cycle.  
 
 
In all subsequent experiments, Hek 293 miR-142 and Hek 293 Control cells were 
treated with DOX at 100 ng/ml. This concentration of DOX was sufficient to fully 
induce the expression of miR-142-3P in Hek 293 miR-142 cells (data not shown). 
 
  






 Susceptibility of Hek 293 miR-142 and Hek 293 Control cells to SFV was 
investigated. In brief, both cell lines were harvested, counted and seeded into 24-well 
plates (with or without DOX at 100 ng/ml final concentration) as described in 2.5.1. 
After 24 hours of incubation, cells were infected with SFV4-3F-zsGreen-2SG-GLuc-
miRNA RE Control at MOI of 0.1 and 1 as described in 2.5.1. Twenty hours post-
infection the supernatant from virus-infected cells was collected. Virus titres and 





Figure 4.18. Infection of Hek 293 miR-142 and Hek 293 Control cells with 
SFV4-3F-zsgreen-2SG-miRNA RE Control. Hek 293 miR-142 (+DOX) and Hek 
293 Control (+DOX) cells were induced with DOX at 100 ng/ml final concentration 
for 24 hours prior to infection. Cells were infected at MOI of 0.1 and 1. Data 
expressed as mean +/- SD. 
 
 
As shown in Figure 4.18, SFV4-3F-zsGreen-2SG-GLuc successfully infected       
Hek 293 miR-142 and Hek 293 Control cells. Interestingly, the virus replicated 
marginally better in Hek 293 miR-142 cells than in Hek 293 Control cells. This 
difference was more pronounced when cells were infected at the higher MOI. Similar 
results were observed for CHIKV (data not shown). Overall, treatment of cells with 
doxycycline did not change the susceptibility of these cells to the control virus. 
  






4.12 Will SFV encoding miR-142-3P RE be attenuated in non-haematopoietic 
cells expressing miR-142-3P? 
Hek 293 miR-142 and Hek 293 Control cells were harvested, counted and seeded 
into 24-well plates (with or without DOX at 100 ng/ml final concentration) as 
described in 2.5.1. After 24 hours of incubation, cells were infected with SFV4-3F-
zsGreen-2SG-miR-142-3P RE, SFV4-3F-zsGreen-2SG-GLuc-miR-142-3P Antisense 
and SFV4-3F-zsGreen-2SG-GLuc-miRNA RE Control at MOI of 0.1 and 1 as 
described in 2.5.1. Twenty hours post-infection the supernatant from virus infected 
cells was collected and the cells were observed microscopically for the expression of 
virus-expressed zsGreen. Virus titres and GLuc levels were measured as described in 
2.3.5 and 2.9.3, respectively.   
 
In Hek 293 Control cells that were either induced with DOX or not, all three viruses 
replicated to the same extent at both MOIs as demonstrated by both virus production 
(Figure 4.19) and by GLuc expression (Figure 4.20). This confirmed that the pre-
treatment of cells with DOX in itself did not selectively alter virus replication. 
Replication of all three viruses in Hek 293 miR-142 cells not induced with DOX was 
comparable to that observed in Hek 293 Control cells, suggesting that the 
background expression of miR-142-3P (see Figure 4.17) was not sufficient to alter 
the replication of any of these viruses. In Hek 293 miR-142 cells that were pre-
treated with DOX, the replication of viruses encoding miRNA RE Control and miR-
142-3P Antisense RE was not affected. However, the measured replication of SFV4-
3F-zsGreen-2SG-GLuc-miR-142-3P RE was reduced by over 95% with respect to 
the control virus at both MOIs. This was demonstrated by virus production (Figure 
4.19) and by GLuc expression (Figure 4.20). In both assays the observed attenuation 
of SFV was statistically significant. The above results were fully supported by 
observation of virus-infected cells under the microscope. Altogether, the above data 
confirmed that the replication of SFV4 encoding miR-142-3P target sequences in its 
genome but not in its antigenome was attenuated in cells that express miR-142-3P. 
 
The close correlation between production of viable virus particles and expression of 
virus-encoded GLuc observed in Figures 4.19 and 4.20 suggested that miR-142-3P 
  






attenuated SFV4-3F-zsGreen-2SG-GLuc-miR-142-3P RE by interfering with the 
replication of its RNA genome during early stages of infection. As described in 1.3.2, 
alphavirus RNA is replicated inside replication complexes that shield it from cellular 
factors. Once replication complexes are established and matured, large amounts of 
newly synthesised viral RNA are released into the cytoplasm. At this stage, 
alphavirus RNA encoding a miRNA RE would quickly saturate the cellular miRNA 
machinery and render it non-effective. Consequently, the alphavirus RNA encoding a 
miRNA RE may be the most vulnerable to targeting by cellular miRNAs 
immediately after the nucleocapsid disassembly, when the unprotected genomic 
RNA is released into the cytoplasm. However, relatively high background levels of 
miRNA expression may be required to efficiently degrade alphavirus RNA during 
the brief period before the replication complexes are established. This was supported 
by the lack of attenuation of SFV4-3F-zsGreen-2SG-miR-142-3P RE in Hek 293 
miR-142 cells not induced with DOX which demonstrated a background expression 
of miR-142-3P (138-fold higher than those observed in Hek 293 Control cells).  
 
The pre-treatment of Hek 293 miR-142 cells with DOX led to only 14-fold increase 
in the expression of miR-142-3P in comparison to cells that were not induced. 
However, the effect of this moderate increase in miR-142-3P expression on SFV4-
3F-zsGreen-2SG-GLuc-miR-142-3P RE replication was significant. The relationship 
between the levels of miR-142-3P expression and the attenuation of SFV4 encoding 
the miR-142-3P RE was further investigated using Hek 293 miR-142-3P cells 
induced with a range of DOX concentrations. In brief, Hek 293 miR-142 cells were 
harvested, counted and seeded into 24-well plates with increasing amounts of DOX 
(0-1000 ng/ml, 0.2 ng/ml or 10-fold steps) as described in 2.5.1. After 24 hours of 
incubation, cells were infected with SFV4-3F-zsGreen-2SG-miR-142-3P RE and 
SFV4-3F-zsGreen-2SG-GLuc-miRNA RE Control at MOI of 1 as described in 2.5.1. 
Twenty hours post-infection the cells were observed microscopically for the 
expression of virus-encoded zsGreen. The supernatant from virus infected cells was 
collected, and cellular RNA was extracted as described in 2.15.3. Virus titres and 
GLuc levels were measured as described in 2.3.5 and 2.9.3, respectively.   
 
  








Figure 4.19. Virus production in SFV4-3F-zsGreen-2SG-GLuc-miRNA RE-
infected Hek 293 miR-142 and Hek 293 Control cells. Hek 293 miR-142 (+DOX) 
and Hek 293 Control (+DOX) cells were induced with DOX at 100 ng/ml final 
concentration for 24 hours prior to infection. Cells were infected at MOI of 0.1 and 
1. (a) Raw data expressed as mean +/- SD. (b) Results normalised to the infection in 
Hek 293 Control (-DOX) cells and to SFV4-3F-zsGreen-2SG-GLuc-miRNA RE 
Control virus. Data expressed as relative mean +/- relative SD; Mann-Whitney test, 
















Figure 4.20. GLuc production in SFV4-3F-zsGreen-2SG-GLuc-miRNA RE-
infected Hek 293 miR-142 and Hek 293 Control cells. Hek 293 miR-142 (+DOX) 
and Hek 293 Control (+DOX) cells were induced with DOX at 100 ng/ml final 
concentration for 24 hours prior to infection. Cells were infected at MOI of 0.1 and 
1. (a) Raw data expressed as mean +/- SD. (b) Results normalised to the infection in 
Hek 293 Control (-DOX) cells and to SFV4-3F-zsGreen-2SG-GLuc-miRNA RE 
Control virus. Data expressed as relative mean +/- relative SD; Mann-Whitney test, 













The induction of Hek 293 miR-142-3P cells with DOX did not affect the replication 
of SFV4-3F-zsGreen-2SG-GLuc-miRNA RE Control as demonstrated by both virus 
production (Figure 4.21a) and by GLuc expression (Figure 4.21c). This confirmed 
that the pre-treatment of cells with DOX in itself did not affect SFV replication. 
SFV4-3F-zsGreen-2SG-GLuc-miR-142-3P RE was attenuated when Hek 293 miR-
142 cells were pre-treated with DOX at concentration of above 0.1 ng/ml. The 
maximum effect was achieved with DOX at concentrations of above 10 ng/ml. This 
was demonstrated by both virus production (Figure 4.21a) and GLuc expression 
(Figure 4.21c). The extent of virus attenuation observed in this experiment was 
comparable to that shown in Figure 4.19 (virus production) and Figure 4.20 (GLuc 
expression). A more detailed analysis revealed that the majority of virus attenuation 
took place when Hek 293 miR-142 cells were induced with DOX at a narrow range 
of concentrations between 0.4 and 1.2 ng/ml. Again, this was confirmed by virus 
production (Figure 4.21b) and by GLuc expression (Figure 4.21d).  
 
At the time of writing this thesis the relative levels of miR-142-3P expression in Hek 
293 miR-142-3P cells generated during this experiment were not yet tested. Hence, it 
was impossible to investigate the exact correlation between levels of miR-142-3P 
and SFV4-3F-zsGreen-2SG-GLuc-miR-142-3P RE replication. However, the sharp 
decrease in the virus replication observed when Hek 293 miR-142 cells were pre-
treated with DOX at the concentration range of 0.4-1.2 ng/ml may further indicate 
that a threshold level of a miRNA expression is required to efficiently degrade viral 
RNA before replication complexes can be established. It is also possible that the 
CMV/TetO2 driving the transcription of miR-142-3P pri-miRNA becomes active at 


















Figure 4.21. Attenuation of SFV4-3F-zsGreen-2SG-GLuc-miR-142-3P RE and 
SFV4-3F-zsGreen-2SG-GLuc-miRNA RE Control in HEK 293 miR-142 cells 
induced with DOX at concentrations ranging from 0 to 1000 ng/ml. a) 
Comparison of both viruses (virus production). b) Comparison of both viruses (GLuc 
expression). c) Detailed analysis of SFV4-3F-zsGreen-2SG-GLuc-miR-142-3P RE 
attenuation (virus production). d) Detailed analysis of SFV4-3F-zsGreen-2SG-GLuc-














4.13 Designing and generating pcDNATM3.1+ plasmids that express miR-142-
3P in non-haematopoietic cell lines 
When Hek 293 miR-142 and Hek 293 Control cells were designed it was uncertain 
whether they would work. Hence, a panel of pcDNA
TM
3.1+ expression plasmids was 
generated in parallel to allow transient expression of miR-142-3P in non-
haematopoietic cells. The multiple cloning sites in pcDNA
TM
3.1+ vector and 
pcDNATM5/FRT/TO vector were identical. All constructs used to generate Hek 293 
miR-142 cells (miR-142 ‘Core’, ‘Short’, ‘Long-3’ and ‘Long-5’) were cloned into 
pcDNA
TM
3.1+ as described in 4.11. The sequencing results for the chosen clones are 
provided in Supplementary Data, Appendix 11. The resulting plasmids were called 
pcDNA3.1+ miR-142 ‘Core’, pcDNA3.1+ miR-142 ‘Short’, pcDNA3.1+ miR-142 
‘Long-3’ and pcDNA3.1+ miR-142 ‘Long-5’, respectively. Their sequences are 
provided in Supplementary Data, Appendix 5. 
 
In addition, pcDNA3.1+ miR-142 ‘Core’ and pcDNA3.1+ miR-142 ‘Short’ were 
further modified to co-express a marker gene mCherry. The resulting constructs were 
called pcDNA3.1+ miR-142 ‘Core’ mCherry and pcDNA3.1+ miR-142 ‘Short’ 
mCherry. Plasmid sequences are provided in Supplementary Data, Appendix 5. The 
cloning details are provided in Annex 20. The expression of mCherry in plasmid-
transfected cells was confirmed microscopically (Figure 4.22). The expression of 
miR-142-3P in plasmid-transfected cells was not measure. 
  








Figure 4.22. Expression of mCherry in BHK-21 cells transfected with the panel 
of cloned pcDNA3.1+ plasmids encoding mCherry. Cells were observed 24 hours 
post-transfection using Zeiss Axioskop 2 upright microscope. Cell nuclei were 
stained with DAPI. 
 
 
4.14 Will SFV encoding miR-142-3P RE be attenuated in cells transfected with 
pcDNA
TM
3.1+ plasmids expressing miR-142-3P, but not in cells 
transfected with control plasmids? 
The following experiment was completed only once. Hek 293T cells were harvested, 
counted, and seeded into 96-well plates at 2.5 x 10
4
 cells per well as described in 
2.5.1. Complete medium with no P/S was used. After 24 hours of incubation, cells 
were transfected with all plasmids generated in 4.13 using FuGENE® 6 as described 
in 2.10.1. Unmodified pcDNA
TM
3.1+ was transfected as a control. Twenty-four 
hours post-transfection, cells were inspected microscopically for the expression of 
mCherry, and then infected with SFV4-3F-zsGreen-2SG-GLuc-miR-142-3P and 
SFV4-3F-zsGreen-2SG-GLuc-miRNA RE Control at MOI of 0.1. Twenty hours 
post-infection the supernatant from virus infected cells was collected. GLuc levels 
were measured as described in 2.9.3.   
 
  






As shown in Figure 4.23, both viruses replicated to the same levels in Hek 293T cells 
transfected with control plasmids (pcDNA
TM
3.1+ and pcDNA3.1+ mCherry). In all 
Hek 293T cells transfected with pcDNA3.1+ plasmid modified to express miR-142-
3P, the measured replication of SFV4-3F-zsGreen-2SG-GLuc-miR-142-3P RE was 
significantly reduced with respect to the control virus. Overall, the above results 
were consistent with previous observations on IC-21 and Hek 293 miR-142 cells.  
 
In cells transfected with pcDNA3.1+ miR-142-3P ‘Core’ plasmid, the replication of 
SFV4-3F-zsGreen-2SG-GLuc-miR-142-3P RE was reduced by 90%. The attenuation 
of this virus was less prominent in cells transfected with pcDNA3.1+ miR-142-3P 
‘Short’, pcDNA3.1+ miR-142-3P ‘Long-3’ and pcDNA3.1+ miR-142-3P ‘Long-5’ 
plasmids (83%, 75% and 76%, respectively). Notably, there was a clear relationship 
between the extent of virus attenuation and the length of the miR-142-3P construct 
expressed by the plasmid. In brief, the shorter the construct, the more attenuated 
virus replication was. Furthermore, cells transfected with plasmids expressing miR-
142-3P were less permissive to virus replication than cells transfected with plasmids 
co-expressing the same miR-142-3P construct and mCherry. The difference in 
measured virus replication was 2-fold for the pair of miR-142-3P ‘Core’ plasmids, 
and 2.5-fold for the pair of miR-142-3P ‘Short’ plasmids.  
 
The attenuation of SFV4-3F-zsGreen-2SG-GLuc-miR-142-3P RE in cells transfected 
with pcDNA3.1+ miR-142-3P ‘Core’ plasmid was not as high as that observed on 
Hek 293 miR-142 cells induced with DOX (Figure 4.20). However, the efficacy of 
plasmid transfection was only 75-80% (as indicated by expression of mCherry in 
pcDNA3.1+ mCherry-transfected cells). The observed variation in the capacity of 
different plasmids to attenuate SFV4-3F-zsGreen-2SG-GLuc-miR-142-3P RE 

















Figure 4.23. Replication of SFV4-3F-zsGreen-2SG-GLuc in Hek 293T cells 
transfected with pcDNA3.1+ plasmids expressing miR-142-3P. Transfected cells 
were infected at MOI of 0.1. (a) Raw data expressed as mean +/- SD. (b) Results 
normalised to the infection in cells transfected with pcDNA
TM
3.1+ and to SFV4-3F-
zsGreen-2SG-GLuc-miRNA RE Control virus. Data expressed as relative mean +/- 










4.15 Designing a functional bioassay to test the stability of miR-142-3P RE in 
SFV genome using Hek 293 cells modified to express miR-142-3P 
A bioassay in the form of a modified plaque assay was designed to assess the 
stability of miR-142-3P RE inserted into the genome of SFV and CHIKV. In 
principle, a virus encoding miR-142-3P RE was titrated on Hek 293 miR-142 cells 
(+DOX) and on Hek 293 Control cells (+DOX). The two titres were compared and 
the fraction of virus unable to form plaques in presence of miR-142-3P was 
calculated. This assay did not investigate the stability of a miR-142-3P RE at the 
molecular level. The complete protocol is described in 2.3.6. 
 
Hek 293 miR-142 and Hek 293 Control cells were not strongly adherent. However, 
cells seeded into 6-well plates were more robust than cells seeded into 24- or 12-well 
plates. Hence, the assay was optimised for 6-well plates. To investigate the optimal 
number of cells needed to seed plates, Hek 293 miR-142 and Hek 293 Control cells 
were plated at 2 x 10
6
, 2.5 x 10
6
 and 3 x 10
6
 cells/well with 100 ng/ml DOX and 
incubated for 24 hours. Next, cells were fixed with 10% v/v neutral buffered 
formalin, cell nuclei were stained with DAPI and monolayers were inspected 
microscopically. Cells seeded at 2.5 x 10
6
 cells/well showed the best balance 
between an under confluent monolayer and formation of cell clumps (Figure 4.24). 
 
To optimise the incubation time post-infection, cells were seeded at 2.5 x 10
6
 
cells/well with 100 ng/ml of DOX and incubated for 24 hours. Next, the cell 
supernatant was removed and 3 ml of semi-solid overlay (see 2.3.6) was added. After 
24-, 48- and 72-hours incubation cells were fixed with 10% v/v neutral buffered 
formalin, cell nuclei were stained with DAPI and monolayers were inspected 
microscopically. The optimal incubation time was identified as 48 hours as longer 
incubation led to a notable deterioration of Hek 293 miR-142 and Hek 293 Control 















Figure 4.24. Hek 293 miR-142 stability bioassay - optimising the seeding density. 
Cells were seeded at 2 x 10
6
, 2.5 x 10
6
 and 3 x 10
6
 cells/well with 100 ng/ml 
doxycycline. Cells were inspected microscopically 24 hours later. Cell nuclei were 
stained with DAPI.  
 
  









Figure 4.25. Hek 293 miR-142 stability bioassay - optimising the incubation time 
post-infection. Cells were seeded at 2.5 x 10
6
 cells/well with 100 ng/ml of 
doxycycline. After 24 hours, the cell supernatant was removed and 3 ml of semi-
solid overlay was added. Cells were inspected microscopically after 24-, 48- and 72-
hours of incubation. Cell nuclei were stained with DAPI.  
 
  






To investigate the formation of SFV plaques, Hek 293 miR-142 and Hek 293 Control 
cells were seeded at 2.5 x 10
6
 cells/well with 100 ng/ml of DOX and incubated for 24 
hours. Next, cells were infected with 650 µl of SFV4-3F-zsGreen per well and 
incubated at room temperature for 90 minutes.  The volume of virus inoculum was 
sufficient to completely cover cell monolayers and therefore minimise the need to 
rock plates. Next, 3 ml of a semi-solid overlay with 100 ng/ml of DOX was added. 
After 24, 48 and 72 hours cells were fixed with 10% v/v neutral buffered formalin. 
Cell nuclei were stained with DAPI and monolayers were inspected microscopically 
for the expression of virus-encoded zsGreen or stained with 0.1% toluidine blue. The 
virus did not form large-enough plaques to allow counting by eye (Figure 4.26). 
Microscopical inspection of cell monolayers revealed that SFV4-3F-zsGreen formed 
plaques of comparable sizes on both Hek 293 miR-142 and Hek 293 Control cells 
(Figures 4.27 and 4.28). All plaques were very small. Twenty four hours post-
infection the average size of a plaque was only 0.1 mm in diameter. This increased to 
only 0.2 and 0.25 mm in diameter 48 and 72 hours post-infection, respectively.  
 
To investigate formation of plaques by a virus encoding miR-142-3P RE in the 
presence of miR-142-3P, the protocol described above was followed. However, Hek 
293 miR-142 and Hek 293 Control cells were infected with both SFV4-3F-zsGreen 
and SFV4-3F-zsGreen-miR-142-3P RE. Plates were incubated 48 hours post-
infection. The results are summarised in Figures 4.29 and 4.30. SFV4-3F-zsGreen 
and SFV4-3F-zsGreen-miR-142-3P RE produced plaques of comparable sizes on 
Hek 293 Control cells (0.20 mm and 0.17 mm in diameter, respectively). Plaques 
formed by SFV4-3F-zsGreen on Hek 293 miR-142 cells were similar in size to those 
formed on Hek 293 Control cells (0.19 mm in diameter). Not surprisingly, SFV4-3F-
zsGreen-miR-142-3P RE did not plaque readily on Hek 293 miR-142-3P cells. 
Plaques were only observed at low virus dilutions and they were smaller than that 
witnessed on Hek 293 Control cells. In addition, two distinctive plaque phenotypes 
were present. Small plaques were on average 0.4 mm in diameter. However, any foci 
of infection larger than 8 cells were counted as a plaque. Larger plaques were on 
average 0.1 mm in diameter. Virus capable on forming plaques on Hek 293 miR-142 
cells induced with DOX must have lost or significantly mutated the miR-142-3P RE.  
  









Figure 4.26. Hek 293 miR-142 stability bioassay – formation of virus plaques 
observed visually. Cells were seeded at 2.5 x 10
6
 cells/well with 100 ng/ml of 
doxycycline. After 24 hours, cells were infected with SFV4-3F-zsGreen and a semi-
solid overlay was added. Cells were fixed with 10% v/v neutral buffered formalin 
and stained with 0.1% toluidine blue 24, 48 and 72 hours post-infection. Uninfected 
cell monolayers and cell monolayers containing 280-320 plaques per well (confirmed 













Figure 4.27. Hek 293 miR-142 stability bioassay - formation of virus plaques 
observed microscopically. Cells were seeded at 2.5 x 10
6
 cells/well with 100 ng/ml 
of doxycycline. After 24 hours, cells were infected with SFV4-3F-zsGreen and a 
semi-solid overlay was added. The formation of plaques was observed 
microscopically after 24, 48 and 72 hours of incubation. Cell nuclei were stained 
with DAPI.  
 
  









Figure 4.28. Hek 293 miR-142 stability bioassay – plaque size. Cells were seeded 
at 2.5 x 10
6
 cells/well with 100 ng/ml of doxycycline. After 24 hours, cells were 
infected with SFV4-3F-zsGreen and a semi-solid overlay was added. The formation 
of plaques was observed microscopically after 24, 48 and 72 hours of incubation. 
The size of SFV4-3F-zsGreen plaques was measured using Zeiss AxioVision 4.8 
digital image processing software. Data expressed as mean of random 20 individual 














Figure 4.29. Hek 293 miR-142 stability bioassay – formation of plaques by a 
virus encoding miR-142-3P RE. Cells were seeded at 2.5 x 10
6
 cells/well with 100 
ng/ml of doxycycline. After 24 hours, cells were infected with SFV4-3F-zsGreen and 
SFV4-3F-zsGreen-miR-142-3P RE, and a semi-solid overlay was added. The 
formation of plaques was observed microscopically 48 hours post-infection. Cell 













Figure 4.30. Hek 293 miR-142 stability bioassay – formation of plaques by a 
virus encoding miR-142-3P RE. Cells were seeded at 2.5 x 10
6
 cells/well with 100 
ng/ml of doxycycline. After 24 hours, cells were infected with SFV4-3F-zsGreen and 
a semi-solid overlay was added. The formation of plaques was observed 
microscopically after 24, 48 and 72 hours of incubation. The size of SFV4-3F-
zsGreen plaques was measured using Zeiss AxioVision 4.8 digital image processing 
software. Data expressed as mean of random 20 individual plaques +/- SD. 
 
 
4.16 Will miR-142-3P RE be stable in the genome of SFV that has been 
passaged in vitro on BHK-21 cells? 
The genetic stability of miR-142-3P RE incorporated into the genome of SFV4-3F-
zsGreen-miR-142-3P RE was investigated in vitro. The virus was passaged 5 times 
on BHK-21 cells at two distinct MOIs. The virus was passaged in absence of the 
selective pressure from miR-142-3P. The detailed protocol is described in 2.3.4. 
  
For the ‘high’ MOI passage, BHK-21 cells were first infected with SFV4-3F-
zsGreen-miR-142-3P RE at MOI of 0.1. Next, the virus-infected BHK-21 cells were 
incubated for 48 hours. Then, the cell culture supernatant containing BHK-21-
derived progeny of SFV4-3F-zsGreen-miR-142-3P RE was collected (Passage 1 
stock). Next, 1 µl of the collected supernatant was used to infect fresh BHK-21. The 
remaining supernatant was frozen at -80 ºC. As previously, the virus-infected    
  






BHK-21 cells were incubated for 48 hours. Subsequently, the BHK-21 cell culture 
supernatant containing new BHK-21-derived virus progeny was collected (Passage 2 
stock). This procedure was repeated for each consecutive virus passage.  
 
For the ‘low’ MOI passage, the procedure described above was followed. However, 
the initial infection of BHK-21 cells was done at MOI of 0.001. All subsequent 
infections of BHK-21 cells were completed using 1 µl of the supernatant from the 
previous passage that had been diluted 1 in 100 in PBSA. Retrospective titration on 
BHK-21 cells of all collected samples revealed that the ‘low’ MOI was equal to 0.01-
0.05 while the ‘high’ MOI was equal to 1-5.  
 
The genetic stability of miR-142-3P RE in the passaged SFV4-3F-zsGreen-miR-142-
3P RE was investigated using the bioassay developed in 4.15. The detailed protocol 
is available in 2.3.6. Each passage stock of SFV4-3F-zsGreen-miR-142-3P RE was 
titrated on both Hek 293 miR-142 cells (+DOX) and Hek 293 Control cells (+DOX). 
In principle, all viable SFV4-3F-zsGreen-miR-142-3P RE was able to form plaques 
on Hek 293 Control cells. However, only virus that had lost or significantly mutated 
the miR-142-3P RE was capable of forming plaques on Hek 293 miR-142 cells 
induced with DOX.  
 
To calculate the fraction of virus unable to form plaques in presence of miR-142-3P, 
the virus titre obtained on Hek 293 miR-142 cells was compared to the virus titre 
obtained on the Hek 293 Control cells for each passage stock of the virus. The results 
were expressed as a proportion of the total virus population present in the sample that 
was unable to form plaques in presence of miR-142-3P. Hence, a virus that was 
completely unable to plaque on Hek 293 miR-142 cells induced with DOX would 
have a stability of 100% while a virus that was not at all attenuated on Hek 293 miR-
142 cells induced with DOX would have a stability of 0%. The results were 
normalised to SFV4-3F-zsGreen to account for any differences in the infectivity of 
Hek 293 miR-142 and Hek 293 Control cells that may have been present at the time 
of the assay.  
 
  






Remarkably, 3.09% of infectious virus particles present in SFV4-3F-zsGreen-miR-
142-3P RE unpassaged stock were able to form plaques in the presence of miR-142-
3P (Figure 4.31). This proportion was much higher than anticipated. With each 
consecutive passage, the stability of the virus was gradually and markedly reduced. 
After 5 passages only 80.15-83.06% of the virus particles were still inhibited by the 
expression of miR-142-3P. Altogether, the above data suggested that the SFV4-3F-
zsGreen-miR-142-3P RE was not a genetically stable construct. 
 
Surprisingly, the stability of SFV4-3F-zsGreen-miR-142-3P RE was not affected by 
the MOI at which the virus was passaged. In a high MOI infection the majority of 
cells in a monolayer are infected at once and therefore a single cycle of infection 
takes place. In a low MOI infection, multiple cycles of virus replication are required 
to infect all cells. Hence, a virus passaged at a low MOI should effectively undergo 
more cycles of replication than a virus passaged at high MOI, increasing the 
likelihood of mutants arising. BHK-21 cells are very permissive to infection with 
SFV. It is possible that the difference in the inoculum dose of SFV was not 





Figure 4.31. SFV4-3F-zsGreen-miR-142-3P RE stability in vitro. The virus was 
passaged on BHK-21 cells at high MOI (estimated at 1-5) or at low MOI (estimated 
at 0.01-0.05). Virus stability (%) was defined as the proportion of the total virus 
population that was unable to form plaques in presence of miR-142-3P. Data 
expressed as relative mean +/- relative SD. 
  






4.17 Will SFV encoding miR-142-3P RE be attenuated in vivo in IFN-α/ß 
receptor knockout mice? 
As mentioned earlier, Fragkoudis et al. (2007) observed a population of virus-
positive cells in spleen of SFV4-infected IFN-α/ß receptor knockout mice of 
A129/SvEv background (IFNAR  mice), in marginal zones between the red pulp and 
white pulp. These areas are known to be rich in macrophages and dendritic cells. 
Hence, the pathogenesis of SFV4-3F-zsGreen-miR-142-3P RE and SFV4-3F-
zsGreen-miRNA RE Control viruses was investigated in IFNAR mice in a pilot 
proof-of-concept experiment, as described below. 
 
In brief, 7 IFNAR mice were divided into two groups of 3 animals each, and 1 group 
of 1 animal. The two groups of 3 animals were inoculated with either SFV4-3F-
zsGreen-miR-142-3P RE (group B) or with SFV4-3F-zsGreen-miRNA RE Control 
(group C) at 5 x 10
3
 PFU/animal. The protocol outlined in 2.21.2 was followed. The 
one animal in the last group was inoculated with PBSA only (group A).  
 
Animals were euthanized 28 hours post-infection. Peritoneal macrophages, brain and 
spleen were collected from all animals as described in 2.21.3. One ml of peritoneal 
wash was collected as described in 2.21.6 and tested for virus load following 2.3.5. 
Virus titre in the peritoneal cavity was calculated based on the assumption that 50 µl 
of peritoneal fluid was initially present in each animal. The stability of miR-142-3P 
RE in SFV4-3F-zsGreen-miR-142-3P RE recovered from peritoneal wash was 
assessed as described in 2.3.6. Brain and spleen samples were processed and 
sectioned using a cryomicrotome as described in 2.21.4. Spleen sections were 
immunostained for murine macrophage cell surface receptors CD169 and 
Macrophage receptor with collagenous structure (MARCO) as described in 2.21.5. 
Sections were imaged using confocal microscopy as described in 2.7.2. Peritoneal 
F4/80-positive cells were analysed by flow cytometry as described in 2.21.6.  
 
All virus-infected animals demonstrated a high viral load in the peritoneal cavity 
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animals infected with SFV4-3F-zsGreen-miR-142-3P RE. There was no overall 
difference between the two groups.  
 
Virus isolated from all animals infected with SFV4-3F-zsGreen-miR-142-3P RE 
demonstrated reduced stability in comparison to the inoculum (Figures 4.31 and 
4.32b). The stability observed in animals B1 and B2 (84.84% and 88.80%, 
respectively) was comparable to the stability of this virus observed after 5 passages 
on BHK-21 cells in vitro in absence of the selective pressure from miR-142-3P 
(Figure 4.31). On the other hand, only 65% of virus isolated from animal B3 was 
unable to form plaques in presence of miR-142-3P.  
 
Stability of any RNA virus construct is dependent on many factors, including the size 
of an insert, the nature of an insert, the location of an insert within a virus genome, 
presence of a selective pressure, individual characteristics of infected cells, virus titre 
and physiological conditions. Most of these factors are relatively easy to control 
during an in vitro passage of a virus. Consequently, stability data from an in vitro 
passage of a virus are often very clear, with individual replicates behaving in a 
similar fashion as shown in Figure 4.31. Replication of a virus in vivo is a much 
more complex process. Many of the conditions listed above may vary from one 
infected animal to another. In addition, the availability of permissive cells is large, 
allowing many rounds of virus replication. As a result, stability of an RNA virus 
observed in vivo can be much more variable than that observed in vitro. It is difficult 
to dissect why the virus isolated from animal B3 was less stable than viruses isolated 
from the other two animals. Cells of the haematopoietic lineage are not the primary 
site of SFV replication in mice. Hence, a virus encoding miR-142-3P RE would not 
normally be exposed to a significant selective pressure from the presence of miR-
142-3P. However, if by chance SFV4-3F-zsGreen-miR-142-3P RE was exposed to 
miR-142-3P early during infection, it could accelerate the loss of miR-142-3P RE 
from the virus genome, or its mutation. The results from animals B1 and B2 may 
suggest, however, that in vitro passaging of a virus can provide some indication of its 
in vivo stability. Unfortunately, the limited number of animals available in this study 
does not allow to draw any definite conclusions. 
  








Figure 4.32. Analysis of virus isolated from the peritoneal cavity of virus-
infected IFNAR mice. (a) Titre of virus present in the peritoneal cavity. (b) Stability 
of the virus present in the peritoneal cavity expressed as the proportion of the total 
virus population unable to form plaques in presence of miR-142-3P (in %). 
 
 
The analysis of F4/80-positive peritoneal macrophages by flow cytometry showed no 
zsGreen-positive cells in either of the two cohorts of virus-infected animals. Data are 
not shown.  
 
MARCO and CD169 are cell surface receptors expressed in murine splenic marginal 
zone macrophages (Ito et al. 1999, Prestwood et al. 2012). However, all 
immunostainings of spleen sections using anti-mouse CD169 and anti-mouse 
MARCO primary antibodies failed. Due to lack of available time the 
immunostaining protocol was not optimised. Without any troubleshooting data 
available, it was difficult to hypothesise why the immunostainings failed.  
 
Nevertheless, when spleen sections were imaged by confocal microscopy a 
difference was observed between animals infected with SFV4-3F-zsGreen-miR-142-
3P RE and the control virus (Figures 4.33 and 4.34). In spleen sections from animals 
infected with SFV4-3F-zsGreen-miRNA RE Control, there was a visible population 
  






of zsGreen-positive cells in what was presumed to be marginal zones between the red 
pulp and the white pulp. The spleen sections were not stained with haematoxylin and 
eosin as this would interfere with the signal from zsGreen. However, the white pulp 
of spleen typically has a higher cell density than the surrounding areas of spleen. 
This could be observed as a localised increase in the concentration of DAPI-stained 
nuclei. Hence, marginal zones were identified as zones immediately surrounding 
areas of localised increase in the concentration of DAPI-stained nuclei. The number 
of zsGreen positive cells per 1000 of total cells present in this region of spleen varied 
between 18.80 and 34.45 in individual animals (Figure 4.34). Based on previous 
findings by Fragkoudis et al. (2007) it is likely that these cells were splenic 
macrophages. However, their identity was not confirmed by immunostaining for 
macrophage-specific markers due to technical issues described previously.  
 
Most importantly, almost no zsGreen-positive cells were observed in marginal zones 
of spleens from animals infected with SFV4-3F-zsGreen-miR-142-3P RE (Figures 
4.33 and 4.34). As those animals experience similar viraemia to animals infected 
with SFV4-3F-zsGreen-miRNA RE Control (Figure 4.32a), the difference was 
tissue-specific and not systemic. However, the relative replication of the two viruses 
was not investigated in other tissues permissive to SFV infection, such as pancreas. 
Interestingly, the attenuation of virus replication observed in these cells was present 
in spite of the loss of virus stability described in Figure 4.32b. It is possible that cells 
in marginal zones of spleen were infected early during infection, when the virus 
stability was still relatively high. It is also possible that any attenuation of virus 













Figure 4.33. Sections of spleens from SFV4-infected IFNAR mice collected 28 
hours post-infection. Representative comparison of marginal zones in spleen 
sections from animals infected with SFV4-3F-zsGreen-miR-142-3P RE and the 
control virus. (a) Sections from animals that had high virus load in the peritoneum. 
(b) Sections from animals that had low virus load in the peritoneum. Sections were 
imaged by Dr Pippa Hawes, the Pirbright Institute, using Leica TCS SP5 confocal 
microscope. 
  








Figure 4.34. Prevalence of zsGreen positive cells in sections of spleens from 
SFV4-infected IFNAR mice collected 28 hours post-infection. Number of zsGreen 
positive cells and DAPI-stained nuclei was counted in 10 high power fields. Data 











The principal objective of the work presented in this chapter was to harness 
endogenous haematopoietic-specific miR-142-3P to restrict replication of Semliki 
Forest virus in monocytes and macrophages. The cell-specific restriction of virus 
replication was attempted by incorporation of a recognition element (RE) with 
multiple copies of a target sequences fully complementary to miR-142-3P into the 
genome of SFV.  
 
The work presented in this chapter laid foundation to the objective of Chapter 5, 
which was to investigating the role of monocyte and macrophage infection with 
CHIKV in the nonhuman primate model of chikungunya virus disease. It included 
generation of resources and tools required to undertake this project, and proof-of-




1. Two RE for miR-142-3P, and one control RE, were successfully designed, 
generated and cloned into genomes of multiple SFV clones. 
 
2. Hek 293 cell line that expressed miR-142-3P under control of the tetracycline-
inducible hybrid CMV/TetO2 promoter was designed and generated.  
 
3. Presence of target sequences to miR-142-3P in the genome (but not antigenome) 
of SFV restricted replication of this virus in all cells expressing miR-142-3P. 
 
4. Replication of SFV encoding the RE for miR-142-3P was restricted in 
haematopoietic cells not only in vitro, but also in vivo.  
 
5. SFV encoding a RE for miR-142-3P was reverting slowly to its non-attenuated 
phenotype following serial passage on BHK-21 cells and in vivo. However, it 
was sufficiently stable to demonstrate a difference in pathogenesis in vivo.  
 
  






Three miRNA REs were successfully designed and generated. Any of the three 
miRNA REs was inserted into the 3’ UTR of the virus, directly downstream of the 
structural polyprotein ORF. In SFV, this position is typically stable (Tsetsarkin et al. 
2006, Prof Andres Merits, the University of Tartu, personal communication). 
Furthermore, it corresponds to a common location of a miRNA target sequence in a 
cellular mRNA.  
 
Replication of SFV encoding miR-142-3P target sequences in its genome was 
significantly restricted in mouse macrophage IC-21 cells, but not in fibroblast BHK-
21 cells. The extent of virus attenuation was comparable or better to that observed by 
Pham et al. (2012) in a similar study on dengue virus. The restriction of virus 
replication was further confirmed in non-haematopoietic Hek 293 cells modified to 
express miR-142-3P, and in non-haematopoietic Hek 293T cells transfected with 
plasmids expressing miR-142-3P. The above data clearly demonstrated that the 
attenuation of SFV encoding miR-142-3P RE in cells expressing miR-142-3P was 
specifically due to the action of miR-142-3P and that the presence of a miR-142-3P 
RE had no effect on virus replication in non-haematopoietic cells.  
 
Interestingly, the presence of miR-142-3P target sequences in the antigenome of the 
virus had no effect on virus replication in presence of miR-142-3P. Most likely, the 
SFV antigenome is shielded from cellular miRNAs and the cellular silencing 
machinery by virus replication complexes (Kallio et al. 2013). In fact, the number of 
alphavirus antigenomes corresponds to the total number of replication complex 
spherules present in a virus-infected cell (Dr Tero Ahola, the University of Tartu, 
personal communication). This suggests that all copies of an alphavirus antigenome 
are associated with replication complexes in virus-infected cells and are therefore 
protected from degradation via cellular miRNAs. Based on the above data, miR-142-
3P Antisense RE was not incorporated into the genome of CHIKV for the subsequent 










SFV encoding miR-142-3P RE was progressively reverting to a non-attenuated 
phenotype following serial passage on BHK-21 cells. After 5 passages only 80% of 
the virus was still unable to form plaques in presence of miR-142-3P. The above data 
suggested that SFV4-3F-zsGreen-miR-142-3P RE was not a genetically stable 
construct. However, these findings were similar to other studies that used a cellular 
miRNA to restrict virus tissue tropism (Pham et al. 2012, Heiss et al. 2012). The 
molecular mechanism responsible for the reversion of the virus to a non-attenuated 
phenotype was not investigated. 
 
In a pilot study, the replication of SFV encoding miR-142-3P RE was investigated in 
IFN-α/ß receptor knockout mice of A129/SvEv background (IFNAR mice). In these 
animals, SFV encoding miR-142-3P RE and the control virus replicated to 
comparable titres. In spleen sections from animals infected with the control virus, 
there was a visible population of zsGreen-positive cells in marginal zones between 
the white pulp and the red pulp. These cells were most likely macrophages, however, 
this was not confirmed by immunostaining for macrophage-specific markers due to 
technical issues. The above observation was consistent with previous findings by 
Fragkoudis et al. (2007). Significantly, almost no zsGreen-positive cells were 
observed in marginal zones of spleens from animals infected with SFV4 encoding 
the RE for miR-142-3P. This suggests that this virus was restricted in haematopoietic 
cells not only in vitro, but also in vivo. The in vivo stability of SFV4-3F-zsGreen-
miR-142-3P RE was much more variable than that observed in vitro. However, it 
was sufficient to demonstrate a difference in pathogenesis in IFNAR mice.   
 
As mentioned previously, some of the work presented in this chapter was continued 
in Chapter 5 with CHIKV. However, more detailed studies should be planned to 
investigate some of the findings presented in this chapter.  
 
Future work should include: 
1. In-depth characterisation  of Hek 293 miR-142 cells; 
 Expression of miR-142-3P following induction with variable concentration 
of DOX (qPCR); 
  






 Time course of miR-142-3P expression following induction with DOX; 
 Cell line stability over time; 
2. Characterisation of miR-142-3P levels produced in cells transfected with 
plasmids expressing miR-142-3P; 
3. In-depth characterisation of SFV4-3F-zsGreen-miR-142-3P RE population that 
reverted to a non-attenuated phenotype; 
 Deep sequencing of the virus population; 
 Plaque purification of individual virus clones; 
4. Optimisation of the protocols used to immunostain splenic macrophages; 
5. Detailed characterisation of SFV4-3F-zsGreen-miR-142-3P RE pathogenesis in 
IFNAR mice; 
 Six animals per group per sampling time point; 
 Two time points at which animals are sacrificed and samples are collected, 
24 and 40 hours post-infection; 
 Collection of blood for virus titration and the assessment of virus stability; 
 Collection of multiple organs (spleen, brain, kidneys, pancreas and hart) for 
virus titration, RNA extraction and immunohistopathology; 
 Analysis of virus replication in different tissues (plaque assay, qPCR, 
immunohistopathology); 
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The objectives for this part of the project were as follow: 
 
1) To incorporate miR-142-3P recognition element into the genome of 
chikungunya replicons and chikungunya virus. 
 
2) To investigate if chikungunya replicon encoding miR-142-3P recognition 
element is attenuated in cells that express miR-142-3P. 
 
3) To investigate if chikungunya virus encoding miR-142-3P recognition element 
is attenuated in haematopoietic cells. 
 
4) To investigate if chikungunya virus encoding miR-142-3P recognition element 
is attenuated in Hek 293 cells that express miR-142-3P, but not in Hek 293 
cells that do not express miR-142-3P. 
 
5) To investigate if chikungunya virus encoding miR-142-3P recognition element 
is attenuated in cells transfected with pcDNA3.1+ expressing miR-142-3P, but 
not in cells transfected with control plasmids. 
 
6) To investigate the stability of miR-142-3P RE in chikungunya virus genome 
during serial passage on BHK-21 cells.  
 
7) To investigate if chikungunya virus encoding miR-142-3P recognition element 
















5.2 Incorporating miRNA REs into chikungunya replicons 
Chikungunya VRPs provided a useful tool to study chikungunya virus attenuation in 
vitro. Importantly, chikungunya VRPs could be handled at containment level (CL) 2 
while replication-competent chikungunya virus had to be handled at CL3.   
 
Two panels of chikungunya replicons were cloned. First one was based on ChikRepl-
3F-zsGreen-SG-mCherry (Figure 5.1). In this construct, zsGreen was expressed as a 
fusion protein with the nsP3. Hence, in replicon-infected cells zsGreen was localised 
to replication complexes in the cytoplasm. In addition, a second marker gene 
mCherry was inserted after the non-structural ORF between AvrII and PmeI sites, 
under control of the CHIKV subgenomic promoter. To generate the panel of 
replicons, miR-142-3P RE and miRNA RE Control were inserted between AvrII and 
PmeI sites in place of mCherry. The cloning procedure is detailed in Annex 21.  
 
Replicons encoding miR-142-3P RE and miRNA RE Control were called ChikRepl-
3F-zsGreen-miR-142-3P RE and ChikRepl-3F-zsGreen-miRNA RE Control, 





















Figure 5.1. Schematic representation of ChikRepl-3F-zsGreen-miRNA RE 
clones. miRNA REs was inserted after the non-structural ORF, between AvrII and 
PmeI restriction sites. nsP – non-structural protein; GP – genomic promoter; SGP – 
subgenomic promoter; Poly(A) – Poly(A) tail; m
7




The second panel of chikungunya replicons was based on ChikRepl-3F-RLuc-SG-
FLuc (Figure 5.2). In this construct, Renilla luciferase (RLuc) was expressed as a 
fusion protein with the nsP3. Consequently, in replicon-infected cells RLuc was 
localised to replication complexes in the cytoplasm. However, fusion of RLuc to 
nsP3 did not inhibit RLuc activity. Furthermore, Firefly luciferase (FLuc) was 
inserted after the non-structural ORF between AvrII and PmeI sites, under control of 
the CHIKV subgenomic promoter. To generate the panel of replicons, miR-142-3P 
RE and miRNA RE Control were inserted between AvrII and PmeI sites in place of 
FLuc. The protocol described earlier was followed.  
 
Resulting replicons encoding miR-142-3P RE and miRNA RE Control were called 
ChikRepl-3F-RLuc-miR-142-3P RE and ChikRepl-3F-RLuc-miRNA RE Control, 
respectively. Their sequences are provided in Supplementary Data, Appendix 4. 
 
  







Figure 5.2. Schematic representation of ChikRepl-3F-RLuc-miRNA RE clones. 
miRNA RE was inserted after the non-structural ORF, between AvrII and PmeI 
restriction sites. nsP – non-structural protein; GP – genomic promoter; SGP – 
subgenomic promoter; Poly(A) – Poly(A) tail; m
7




5.3 Growing chikungunya VRPs  
ChikRepl-3F-zsGreen, ChikRepl-3F-zsGreen-miR-142-3P RE and ChikRepl-3F-
zsGreen-miRNA RE Control replicons were successfully rescued as described in 
2.4.3. However, a replication-competent virus was identified in all VRP stocks 
following the protocol in 2.4.5. The replicon rescue was attempted twice more, 
however, each time a replication-competent virus was isolated. Hence, the decision 
was made to not use VRPs in the subsequent experiments (with the exception of 5.4).  
 
All plasmids and molecular biology reagents used to generate the VRPs were 
confirmed to be free of full-length virus icDNA by PCR. The generation of the 
replication-competent virus was likely a consequence of recombination between the 
replicon RNA and the two helper RNAs. Split-helper systems used to rescue VRPs 
are specifically designed to minimise the likelihood of this happening. The 
theoretical frequency of producing a replication-competent virus using the SFV split-
  






helper system was calculated to be <1.9 x 10
-13
 (Smerdou et al., 1999). This 
frequency is not known for the chikungunya split-helper system. Some of its design 
features may unexpectedly promote the recombination. The analysis of plasmid 
sequences revealed that there is a relative large complementarity between individual 
components of the system. Molecular analysis of the replication-competent virus 
may provide information necessary to identify the way by which it was generated. 
 
5.4 Will a chikungunya replicon encoding miR-142-3P RE be attenuated in 
non-haematopoietic cells expressing miR-142-3P? 
This experiment was completed only once due to reasons explained in 5.3. First,  
Hek 293 miR-142 and Hek 293 Control cells were harvested, counted and seeded 
into 24-well plates in complete DMEM with no P/S (with or without DOX at        
100 ng/ml final concentration) as described in 2.5.1. After 24 hours of incubation, 
cells were transfected with ChikRepl-3F-RLuc, ChikRepl-3F-RLuc-miR-142-3P RE 
and ChikRepl-3F-RLuc-miRNA RE Control replicons as described in 2.4.3 
(generation of replicon RNA), 2.15.5 (RNA purification) and 2.10.2 (transfection 
using Lipofectamine® 2000). Twenty four hours post-infection the levels of 
replicon-expressed RLuc were measured as described in 2.9.2.   
 
In Hek 293 Control cells that were either induced with doxycycline or not, all three 
replicons replicated to the same extent as demonstrated by the expression of RLuc 
(Figure 5.3). In Hek 293 miR-142 cells not induced with DOX, the replication of the 
control replicons ChikRepl-3F-RLuc and ChikRepl-3F-RLuc-miRNA RE Control 
was not affected. However, the measured replication of ChikRepl-3F-RLuc-       
miR-142-3P RE was reduced by over 60% with respect to ChikRepl-3F-RLuc-
miRNA RE Control. The difference was statistically significant. In Hek 293 miR-142 
cells induced with DOX a similar pattern was observed. However, the measured 
replication of ChikRepl-3F-RLuc-miR-142-3P RE was reduced by over 80% with 
respect to ChikRepl-3F-RLuc-miRNA RE Control. Interestingly, attenuation of 
SFV4-3F-zsGreen-2SG-GLuc-miR-142-3P RE on Hek 293 miR-142 cells not 
induced with DOX was never observed (Figure 4.19, Figure 4.20). 
 
  









Figure 5.3. RLuc expression in ChikRepl-3F-RLuc-miRNA RE-transfected Hek 
293 miR-142 and Hek 293 Control cells. Hek 293 miR-142 (+DOX) and Hek 293 
Control (+DOX) cells were induced with DOX at 100 ng/ml final concentration for 
24 hours prior to infection. Replicon RNA was transfected using Lipofectamine® 
2000. (a) Raw data expressed as mean +/- SD. (b) Results normalised to the 
replication in Hek 293 Control (-DOX) cells and to ChikRepl-3F-RLuc-miRNA RE 
Control replicon. Data expressed as relative mean +/- relative SD; Mann-Whitney 











5.5 Incorporating miRNA REs into CHIKV 
Two panels of chikungunya viruses that mirrored the replicon designs were cloned. 
First one was based on ICRES1-3F-zsGreen-2SG-mCherry. In this virus, zsGreen 
was expressed as a fusion protein with the nsP3 and mCherry was inserted after the 
non-structural ORF between AvrII and PmeI sites, under control of the CHIKV 
subgenomic promoter. The subgenomic promoter was duplicated downstream of 
mCherry to drive the expression of the structural polyprotein. In brief, miR-142-3P 
RE and miRNA RE Control were inserted between AvrII and PmeI sites (Figure 5.4, 
Figure 5.5). The protocol described in 5.2 was followed, however, the colony PCR 
was completed using a different set of primers (Annex 12, protocol 4).  
 
Resulting CHIKV encoding miR-142-3P RE and miRNA RE Control were called 
ICRES1-3F-zsGreen-miR-142-3P RE and ICRES1-3F-zsGreen-miRNA RE Control, 





Figure 5.4. Schematic representation of ICRES1-3F-zsGreen-miRNA RE clones. 
miRNA RE was inserted after the non-structural ORF, between AvrII and PmeI 
restriction sites. nsP – non-structural protein; Poly(A) – Poly(A) tail; GP – genomic 
promoter; SGP – subgenomic promoter; m
7
GpppA – 5’ CAP. 
  









Figure 5.5. Incorporation of a miRNA RE into the genome of ICRES-3F-
zsGreen-2SG-mCherry. nsP-non-structural protein; GP – genomic promoter; SGP – 
subgenomic promoter; 2SGP – duplicated subgenomic promoter; C – capsid;          
E1-E3 – envelope glycoproteins; vertical dashed line – protein cleavage sites; 
Poly(A) – Poly(A) tail; m
7
GpppA – 5’ CAP; RE – recognition element; MCS – 
multiple cloning site; 4B – 4-nucleotide spacer; TS – target sequence. 
 
 
The second panel of CHIKV was based on ICRES-3F-RLuc-2SG-FLuc (Figure 5.6). 
In this construct, RLuc was expressed as a fusion protein with the nsP3 and FLuc 
was inserted after the non-structural ORF between AvrII and PmeI sites, under 
control of the CHIKV subgenomic promoter. The fusion of RLuc to nsP3 did not 
inhibit RLuc activity. In brief, miR-142-3P RE and miRNA RE Control were 
inserted between AvrII and PmeI sites in place of FLuc. The protocol described 
earlier was followed.  
  






Resulting CHIKV encoding miR-142-3P RE and miRNA RE Control were called 
ICRES1-3F-RLuc-miR-142-3P RE and ICRES1-3F-RLuc-miRNA RE Control, 





Figure 5.6. Schematic representation of ICRES1-3F-RLuc-miRNA RE clones. 
miRNA RE was inserted after the non-structural ORF, between AvrII and PmeI 
restriction sites. nsP – non-structural protein; GP – genomic promoter; SGP – 
subgenomic promoter; Poly(A) – Poly(A) tail; m
7




5.6 Growing CHIKV clones  
ICRES1-3F-zsGreen, ICRES1-3F-zsGreen-miR-142-3P RE, ICRES1-3F-zsGreen-
miRNA RE Control, ICRES1-3F-zsGreen-2SG-mCherry, ICRES1-3F-RLuc, 
ICRES1-3F-RLuc-miR-142-3P RE, ICRES1-3F-RLuc-miRNA RE Control, 
ICRES1-3F-RLuc-2SG-FLuc and ICRES1 (wt) were successfully rescued from 
icDNAs as described in 2.3.3.1. Virus stock (purified by ultracentrifugation through 
a 20% w/v sucrose cushion) was titrated following the protocol outlined in 2.3.5.  
 
  






5.7 Will the presence of miR-142-3P RE affect the rate at which CHIKV can 
replicate in fibroblast BHK-21 cells? 
Replication of ICRES1-3F-zsGreen, ICRES1-3F-zsGreen-miR-142-3P RE, ICRES1-
3F-zsGreen-miRNA RE Control, ICRES1-3F-zsGreen-2SG-mCherry, ICRES1-3F-
RLuc, ICRES1-3F-RLuc-miR-142-3P RE, ICRES1-3F-RLuc-miRNA RE Control, 
ICRES1-3F-RLuc-2SG-FLuc and ICRES1 (wt) was investigated by completing one-
step growth curves. In brief, cells were infected at MOI of 10 to ensure an infection 
rate close to 100%. Virus replication was tested by plaque assay every 2-4 hours, for 
24 hours. The protocol described in 2.3.7 was followed.  
 
The results shown in Figure 5.7a suggested that incorporation of marker genes into 
the genome of ICRES1 had a negative effect on virus replication. This was observed 
at all time-points. The effect was amplified when multiple marker genes were used. 
Interestingly, viruses expressing RLuc as a fusion protein with nsP3 were replicating 
slower than corresponding viruses expressing zsGreen (Figure 5.7a). This difference 
was likely related to the size of both marker proteins, and their genes. RLuc (36 kDa) 
is a larger protein than zsGreen (25 kDa). When fused to nsP3, both markers can 
affect the processing of the non-structural polyprotein into its individual components, 
formation of replication complexes and activity of the virus replicase. However, the 
larger RLuc has the capacity to cause more steric hindrance than zsGreen and 
therefore affect the formation, maturation and activity of the virus replicase more 
significantly than zsGreen.  In addition, the RLuc gene is 240 nucleotides longer than 
the zsGreen gene. Typically, the speed of virus genome replication is proportionally 
reduced as the length of the inserted gene increases. Notably, the size-dependent 
attenuation of a virus is not always evident in vivo. However, it may lead to 
decreased replication and pathogenicity. Hence, CHIKV constructs encoding 
zsGreen should be used in preference to constructs encoding RLuc in vivo. 
 
Incorporation of a miRNA RE into ICRES1 genome did not itself affect virus 
replication. This was observed in ICRES1-3F-zsGreen-miRNA RE constructs 
(Figure 5.7b) and in ICRES1-3F-RLuc-miRNA RE constructs (Figure 5.7c).  
  








Figure 5.7. ICRES1 one-step growth curves. BHK-21 cells were infected at MOI 
of 10 and incubated for 24 hours. The cell supernatant was sampled every 2 hours for 
the first 12 hours, and then every 4 hours. Samples were tested by plaque assay. Data 
expressed as mean +/- SD. 
 
  






The size of plaques produced by ICRES1-3F-zsGreen, ICRES1-3F-zsGreen-miR-
142-3P RE, ICRES1-3F-zsGreen-miRNA RE Control, ICRES1-3F-zsGreen-2SG-
mCherry, ICRES1-3F-RLuc, ICRES1-3F-RLuc-miR-142-3P RE, ICRES1-3F-RLuc-
miRNA RE Control, ICRES1-3F-RLuc-2SG-FLuc and ICRES1 (wt) was 
investigated. All viruses were plaqued as described in 2.3.5, at the same time and on 
the same BHK-21 cells.  
 
As shown in Figures 5.8 and 5.9, ICRES1 (wt) produced plaques of the largest size 
(2.74 mm, SD=0.10). However, the size of plaques formed by ICRES1-3F-zsGreen 
(2.62 mm, SD=0.13), ICRES1-3F-zsGreen-miR-142-3P RE (2.57 mm, SD=0.10), 
ICRES1-3F-zsGreen-miRNA RE Control (2.54 mm, SD=0.12), ICRES1-3F-RLuc-
miR-142-3P RE (2.63 mm, SD=0.15) and ICRES1-3F-RLuc-miRNA RE Control 
(2.53 mm, SD=0.14) was only mildly reduced. Plaques of significantly smaller sizes 
were produced by ICRES1-3F-zsGreen-2SG-mCherry (2.04 mm, SD=0.15) and 
ICRES1-3F-RLuc-2SG-FLuc (1.19 mm, SD=0.04). This observation was consistent 
with one-step growth curves. Importantly, incorporation of a miRNA RE into a virus 
genome did not itself affect the size of plaques produced by this virus.  
 
Interestingly, ICRES1-3F-RLuc yielded a mixed population of plaques (Figures 5.8 
and 5.9). Large plaques (20% of the total population) were comparable in size (2.61 
mm, SD=0.05) to those formed by ICRES1-3F-zsGreen, ICRES1-3F-zsGreen-miR-
142-3P RE, ICRES1-3F-zsGreen-miRNA RE Control, ICRES1-3F-RLuc-miR-142-
3P RE, ICRES1-3F-RLuc-miRNA RE Control and ICRES1 (wt). Small plaques 
(80% of the total population) were comparable in size (1.36 mm, SD=0.21) to those 
formed by ICRES1-3F-RLuc-2SG-FLuc. To exclude the possibility of virus cross-
contamination, ICRES1-3F-RLuc icDNA was purified and re-grown as described in 
2.19.2 and 2.15.9. Fresh virus stock was generated from the new icDNA as described 
in 2.3.3. However, the new stock of ICRES1-3F-RLuc was still characterised by the 
mixed plaque phenotype. This finding suggested that there could be an inherent 
molecular issue with this particular CHIKV construct that resulted in production of 
two slightly different virus populations during virus rescue. Molecular differences 
between these two populations of ICRES1-3F-RLuc were not characterised.  
  










Figure 5.8. Plaques generated by different ICRES1 clones. Cells were incubated 
for 72 hours with CMC-based semi-solid overlay, fixed with 10% v/v neutral 

























Figure 5.9. Size of plaques generated by different ICRES1 clones. The size of 
plaques was measured using Zeiss AxioVision 4.8 digital image processing software. 






















5.8 Will ICRES1-3F-RLuc-miR-142-3P RE be attenuated in haematopoietic 
IC-21 and Thp-1 cells but not in fibroblast 3T3 and NHDF cells? 
ICRES1-3F-RLuc-miR-142-3P RE and the control virus were used to infect IC-21 
cells at MOI of 100 and 1000, Thp-1  cells (PMA-induced) at MOI of 100 and 1000, 
3T3 cells at MOI of 1 and NHDF cells at MOI of 1, in 96-well plates. The above 
cells were selected to provide a panel of species-matched fibroblast and macrophage 
cell lines (human Thp-1 and NHDF, mouse IC-21 and 3T3). The protocol outlined in 
2.5.1 was followed. Twenty hours post-infection, RLuc levels were measured as 
described in 2.9.1.   
 
RLuc encoded by all three viruses allowed simple but indirect measurement of virus 
replication. In 3T3 and NHDF cells, the two viruses replicated to comparable levels 
(Figure 5.10). The minor differences observed were most likely due to inaccurate 
titration of the virus stock. In IC-21 cells infected at MOI of 100 and 1000, the 
replication of ICRES1-3F-RLuc-miR-142-3P RE was reduced with respect to the 
control virus by approximately 90% and 98%, respectively. The difference was 
statistically significant. In Thp-1 cells, an almost identical effect was observed. The 
results clearly demonstrated that the replication of ICRES1 encoding miR-142-3P 
target sequences in its genome was attenuated in haematopoietic cells. The results 























Figure 5.10. Replication of ICRES1-3F-RLuc-miRNA RE clones in IC-21,    
Thp-1, 3T3 and NHDF cells.  IC-21 and Thp-1 cells (PMA-induced) were infected 
at MOI of 100 and 1000. 3T3 and NHDF cells were infected at MOI of 1 and 100, 
respectively. RLuc was measured 20 hours post-infection. (a) Raw data expressed as 
mean +/- SD. (b) Virus replication in IC-21 or Thp-1 cells was normalised to virus 
replication in 3T3 or NHDF cells, respectively. The resulting relative replication of 
ICRES1-3F-RLuc-miR-142-3P RE was normalised to the relative replication of 
ICRES-3F-RLuc-miRNA RE Control. Data expressed as relative mean +/- relative 
SD; Mann-Whitney test, single-tailed; * p<0.05. 
 
  






5.9 Will CHIKV encoding miR-142-3P RE be attenuated in non-
haematopoietic cells expressing miR-142-3P? 
Hek 293 miR-142 and Hek 293 Control cells were harvested, counted and seeded 
into 24-well plates and into 96-well plates (with or without DOX at 100 ng/ml final 
concentration) as described in 2.5.1. After 24 hours of incubation, cells were infected 
at MOI of 1 and 10 with ICRES1-3F-zsGreen-miR-142-3P RE and ICRES1-3F-
zsGreen-miRNA RE Control (24-well plates), and with ICRES1-3F-RLuc-miR-142-
3P RE and ICRES1-3F-RLuc-miRNA RE Control (96-well plates). Twenty hours 
post-infection the supernatant from cells infected with ICRES1-3F-zsGreen-miRNA 
RE viruses was collected. Cells were observed microscopically for the expression of 
virus-encoded zsGreen. Virus load was measures as described in 2.3.5. Furthermore, 
RLuc levels were measured in ICRES1-3F-RLuc-miRNA RE-infected cells as 
described in 2.9.1. 
 
In Hek 293 Control cells that were either induced with doxycycline or not, all viruses 
replicated to the same extent as demonstrated by both virus production (Figure 5.11) 
and by RLuc expression (Figure 5.12). In Hek 293 miR-142 cells not induced with 
DOX, the replication of viruses encoding miR-142-3P RE was reduced by 20-30% 
with respect to the control viruses as demonstrated by both virus production and by 
RLuc expression. This effect suggested that the background expression of miR-142-
3P present in these cells may have been sufficient to partially affect replication of 
CHIKV encoding miR-142-3P RE. In Hek 293 miR-142 cells induced with DOX, 
the replication of ICRES1-3F-zsGreen-miR-142-3P RE and ICRES1-3F-RLuc-miR-
142-3P RE was reduced by statistically significant 99% and 90%, respectively, as 
demonstrated by virus production and by RLuc expression. 
 
The above results were fully supported by observation of virus-infected cells under 
the microscope (data not shown). Altogether, the above data confirmed that the 
replication of ICRES1 encoding miR-142-3P target sequences in its genome was 
attenuated in cells that express miR-142-3P. The results were in agreement with 
previous findings for SFV. 
 
  









Figure 5.11. Virus production in ICRES1-zsGreen-miRNA RE-infected Hek 293 
miR-142 and Hek 293 Control cells. Hek 293 miR-142 (+DOX) and Hek 293 
Control (+DOX) cells were induced with DOX at 100 ng/ml final concentration for 
24 hours prior to infection. Cells were infected at MOI of 1 and 10. (a) Raw data 
expressed as mean +/- SD. (b) Results normalised to the infection in Hek 293 
Control (-DOX) cells and to ICRES1-3F-zsGreen-miRNA RE Control virus.       


















Figure 5.12. RLuc expression in ICRES1-3F-RLuc-miRNA RE-infected Hek 
293 miR-142 and Hek 293 Control cells. Hek 293 miR-142 (+DOX) and Hek 293 
Control (+DOX) cells were induced with DOX at 100 ng/ml final concentration for 
24 hours prior to infection. Cells were infected at MOI of 1 and 10. (a) Raw data 
expressed as mean +/- SD. (b) Results normalised to the infection in Hek 293 
Control (-DOX) cells and to ICRES1-3F-RLuc-miRNA RE Control virus.            














The relationship between the levels of miR-142-3P expression and the attenuation of 
CHIKV encoding miR-142-3P RE was further investigated using Hek 293 miR-142-
3P cells induced with a range of DOX concentrations. In brief, Hek 293 miR-142 
cells were harvested, counted and seeded into 96-well and 24-well plates with 
increasing amounts of DOX (0-1000 ng/ml, 0.2 ng/ml or 10-fold steps) as described 
in 2.5.1. After 24 hours of incubation, cells were infected at MOI of 10 with 
ICRES1-3F-zsGreen-miR-142-3P RE (24-well plates), and with ICRES1-3F-RLuc-
miR-142-3P RE (96-well plates). Cellular RNA was extracted from uninfected cells 
(24-well plates) as described in 2.15.3. Twenty hours post-infection the supernatant 
from cells infected with ICRES1-3F-zsGreen-miR-142-3P RE was collected. Cells 
were observed microscopically for the expression of virus-encoded zsGreen and the 
virus load was measures as described in 2.3.5. Furthermore, RLuc levels were 
measured in ICRES1-3F-RLuc-miR-142-3P RE-infected cells as described in 2.9.1. 
 
ICRES1 clones encoding miR-142-3P RE were attenuated when Hek 293 miR-142 
cells were pre-treated with DOX at concentration higher than 0.1 ng/ml (Figure 
5.13). The majority of virus attenuation took place when Hek 293 miR-142 cells 
were induced with DOX at a narrow range of concentrations between 0.4 and 1.0 
ng/ml. This was observed by virus production (Figure 5.13a) and by RLuc 
expression (Figure 5.13b). The extent of virus attenuation observed in this 
experiment was comparable to that shown in Figure 5.11 (virus production) and 
Figure 5.12 (RLuc expression). Importantly, the results mirrored exactly the 
behaviour of SFV4-3F-zsGreen-2SG-GLuc-miR-142-3P observed in an equivalent 
experiment (Figure 4.21). At the time of writing this thesis the relative levels of miR-
142-3P expression in Hek 293 miR-142-3P cells generated during this experiment 
were not yet tested. Hence, it was impossible to investigate the exact correlation 
between levels of miR-142-3P and the replication of ICRES1 clones encoding miR-
142-3P RE. However, the similarity between data obtained for SFV and CHIKV 
suggested that miR-142-3P restricted replication of both SFV and CHIKV in a 













Figure 5.13. Attenuation of ICRES1-3F-zsGreen-miR-142-3P RE and ICRES1-
3F-RLuc-miR-142-3P RE in HEK 293 miR-142 cells induced with DOX at 
concentrations ranging from 0 to 1000 ng/ml. a) Detailed analysis of ICRES1-3F-
zsGreen-miR-142-3P RE attenuation (virus production). d) Detailed analysis of 
ICRES1-3F-RLuc-miR-142-3P RE attenuation (RLuc expression). Data expressed as 















5.10 Will CHIKV encoding miR-142-3P RE be attenuated in cells transfected 
with pcDNA
TM
3.1+ plasmids expressing miR-142-3P, but not in cells 
transfected with control plasmids? 
The following experiment was completed only once. Hek 293T cells were harvested, 
counted, and seeded into 96-well plates at 2.5 x 10
4
 cells per well as described in 
2.5.1. Complete medium with no P/S was used. After 24 hours of incubation, cells 
were transfected with all plasmids generated in 4.13 using FuGENE® 6 as described 
in 2.10.1. Unmodified pcDNA
TM
3.1+ was transfected as a control. Twenty-four 
hours post-transfection, cells were inspected microscopically for the expression of 
mCherry, and then infected with ICRES1-3F-zsGreen-miR-142-3P and ICRES1-3F-
zsGreen-miRNA RE Control at MOI of 0.1. Twenty hours post-infection the RLuc 
levels in virus-infected cells were measured as described in 2.9.1.   
 
As shown in Figure 5.14, both viruses replicated to the same levels in Hek 293T cells 
transfected with pcDNA
TM
3.1+. In all Hek 293 cells transfected with pcNDA3.1+ 
modified to express miR-142-3P, the measured replication of SFV4-3F-zsGreen-
2SG-GLuc-miR-142-3P RE was significantly reduced with respect to the control 
virus. Overall, the attenuation of ICRES1-3F-zsGreen-miR-142-3P RE was not as 
high as that observed on Hek 293 miR-142 cells induced with doxycycline. 
However, the efficacy of plasmid transfection was only 75% (as indicated by 
expression of mCherry in pcDNA3.1+ mCherry-transfected cells). The above results 
were consistent with previous observations on IC-21 and Hek 293 miR-142 cells.  
 
Interestingly, the results did not fully mirror the behaviour of SFV4-3F-zsGreen-
2SG-GLuc-miR-142-3P RE observed in an equivalent experiment (Figure 4.23). 
Most notably, the attenuation of CHIKV replication was less pronounced than the 
attenuation of SFV. In addition, the extent of SFV attenuation varied in cells 
transfected with different plasmids. This was not observed in this experiment. As 
both experiments were performed only once, it is difficult to discuss why the 
differences were present. It is likely that they may have resulted from small 
variations in the experimental conditions that were not suitably controlled for.  
 
  









Figure 5.14. Replication of ICRES1-3F-RLuc-miRNA RE in Hek 293T cells 
transfected with pcDNA3.1+ plasmids expressing miR-142-3P. Transfected cells 
were infected at MOI of 0.1. (a) Raw data expressed as mean +/- SD. (b) Results 
normalised to the infection in cells transfected with pcDNA
TM
3.1+ and to ICRES1-
3F-zsGreen-miRNA RE Control virus. Data expressed as relative mean +/- relative 












5.11 Will miR-142-3P RE be stable in the genome of CHIKV that has been 
passaged in vitro on BHK-21 cells? 
The genetic stability of miR-142-3P RE incorporated into the genome of ICRES1-
3F-zsGreen-miR-142-3P RE was investigated in vitro. The virus was passaged 5 
times on BHK-21 cells at a ‘high’ MOI. The virus was passaged in absence of the 
selective pressure from miR-142-3P. The results were expressed as a proportion of 
the total virus population present in the sample that was unable to form plaques in 
presence of miR-142-3P. Detailed description of this experiment is located in 4.16. 
 
Interestingly, only 0.2% of ICRES1-3F-zsGreen-miR-142-3P RE stock virus 
(inoculum) was able to form plaques in the presence of miR-142-3P (Figure 5.15). 
The stability of ICRES1-3F-zsGreen-miR-142-3P RE did not change significantly 
between passages 0 (inoculum) and 5. After 10 passages, almost 95% of the virus 
was still unable to form plaques in presence of miR-142-3P. The results indicated 
that ICRES1-3F-zsGreen-miR-142-3P was genetically stable in the absence of a 
selective pressure from miR-142-3P. 
 
The above findings were notably different from the stability of SFV4-3F-zsGreen-
miR-142-3P RE observed in an equivalent experiment (Figure 4.31). With each 
consecutive passage, the stability of SFV4-3F-zsGreen-miR-142-3P RE was 
gradually and markedly reduced. After 5 passages only 80.15% of the virus particles 
were still inhibited by the expression of miR-142-3P. Consequently, SFV4-3F-
zsGreen-miR-142-3P RE was not considered to be a genetically stable construct. In 
spite of that, the replication of SFV4-3F-zsGreen-miR-142-3P RE was restricted in 
haematopoietic cells not only in vitro, but also in vivo. Altogether, the above findings 
strongly suggested that ICRES1-3F-zsGreen-miR-142-3P RE was sufficiently stable 















Figure 5.15. ICRES1-3F-zsGreen-miR-142-3P RE stability in vitro. The virus 
was passaged on BHK-21 cells at high MOI (estimated at 1-5). Virus stability (%) 
was defined as the proportion of the total virus population that was unable to form 
plaques in presence of miR-142-3P. Data expressed as relative mean +/- relative SD. 
 
 
5.12 Investigating the role of monocyte and macrophage infection with CHIKV 
in the non-human primate model of chikungunya disease 
 
Two adult cynomolgus macaques (see 2.22.1) were inoculated with 10
6
 PFU of 
ICRES1-3F-zsGreen-miR-142-3P RE as described in 2.22.2. No control group was 
included, historic data (published and unpublished) were used for comparison.  
Animals were observed for clinical signs of disease as described in 2.22.3. Whole 
blood, PBMC, plasma and serum samples were collected as described in 2.22.4. 
Viral load in plasma was evaluated by qPCR as described in 2.22.5. Animals 31065 
and 30856 were euthanised 18 and 35 days post-infection, respectively. During 
necropsy, samples from muscles, tendons, lymph nodes, liver, spleen, skin and joint 
tissue were collected as described in 2.22.4. 
 
Both animals were successfully infected with CHIKV (Figure 5.16). The peak 
viraemia of approximately 10
6
 CHIKV genome copy number per ml of plasma was 
observed on Day 2 post-infection. No virus was detected in the plasma of infected 
animals from Day 4 post-infection. The above results were notably different from 
  






published kinetics of CHIKV replication in cynomolgus macaques (Labadie et al. 
2010). Typical viraemia in cynomolgus macaques infected with a comparable dose 





genome copy number per ml of plasma was typically observed 2 days post-infection. 
Altogether, the above results indicated that CHIKV encoding a marker gene zsGreen 
and a recognition element for miR-142-3P was attenuated in the non-human primate 
model of chikungunya virus disease. Unfortunately, at the time of writing this thesis 





Figure 5.16. CHIKV infection in adult cynomolgus macaques. Two adult 
macaques were infected with 10
6
 PFU of ICRES1-3F-zsGreen-miR-142-3P RE. 
Viral load in plasma was evaluated by qPCR. LOD=500 CHIKV genome copy 

















The principal objective of the work presented in this chapter was to generate CHIKV 
that was restricted in monocytes and macrophages but could replicate normally in 
other cells and tissues. This virus was used to investigate the role of monocyte and 
macrophage infection with CHIKV in the non-human primate model of chikungunya 




1. Presence of target sequences to cellular miR-142-3P in the genome of CHIKV 
restricted replication of this virus in all cells expressing miR-142-3P. 
 
2. CHIKV encoding the RE for miR-142-3P was shown to be stable in vitro 
following serial passage on BHK-21 cells in the absence of selective pressure 
from miR-142-3P.  
 
3. The pathogenesis of CHIKV encoding the RE for miR-142-3P was investigated 
in the non-human primate model of chikungunya virus disease. Preliminary data 
indicated that CHIKV encoding the RE for miR-142-3P was attenuated in 
cynomolgus macaques.  
 
Replication of CHIKV encoding miR-142-3P target sequences in its genome was 
significantly restricted in haematopoietic IC-21 and Thp-1 cells, but not in fibroblast 
3T3 and NHDF cells. The restriction of virus replication was further confirmed in 
non-haematopoietic Hek 293 cells modified to express miR-142-3P and in non-
haematopoietic Hek 293T cells transfected with plasmids expressing miR-142-3P. 
The above data were in full agreement with previous findings for SFV. 
 
In CHIKV, miR-142-3P RE or miRNA RE Control were inserted into the J region of 
the virus. This overall design was different to that of SFV. However, in CHIKV this 
position was believed to be more genetically stable than the 3’ UTR (Tsetsarkin et al. 
2006, Prof Andres Merits, the University of Tartu, personal communication).  
Indeed, the stability of CHIKV was superior to that observed for SFV. After 5 
  






passages, over 98% of the virus was still unable to form plaques in presence of miR-
142-3P. This was reduced to 95% after 10 passages. The above data suggested that 
ICRES1-3F-zsGreen-miR-142-3P RE was genetically stable in absence of the 
selective pressure from miR-142-3P. Importantly, non-haematopoietic fibroblasts 
and myoblasts are the primary sites of CHIKV replication in vivo. Hence, the 
majority of virus observed in the plasma of infected humans and animals is produced 
in absence of selective pressure from miR-142-3P. Consequently, this virus was 
expected to be relatively stable in vivo.  
 
Both cynomolgus macaques were successfully infected with the modified CHIKV. 
Consequently, this study represents the first successful attempt to directly study the 
importance of monocyte and macrophage infection with CHIKV in the non-human 
primate model of the disease. Both animals demonstrated very comparable viraemia 
that lasted approximately 3 days. The duration of viraemia was 3-4 days shorter than 
expected based on historic data (Labadie et al. 2010). The peak viraemia of 10
6
 
CHIKV genome copy number per ml of plasma was observed on day 2 post-
infection. It was approximately 2 log10 lower than expected based on historic data 
(Labadie et al. 2010).  
 
The above results suggested that CHIKV encoding a recognition element for miR-
142-3P was attenuated in the non-human primate model of chikungunya virus 
disease. None of the in vitro experiments indicated that the modified virus was 
attenuated in non-haematopoietic cells. Hence, the observed attenuation was likely 
due to restriction of virus replication in monocytes and macrophages. It is possible 
that an initial infection of monocytes circulating the in the blood is required to 
efficiently disseminated CHIKV. Similar role of monocytes in human CHIKV 
infection was proposed by Her et al. (2010). At the time of writing this thesis no 
further data were available.  
 
Cynomolgus macaque model of CHIKV infection is very complex. Restriction of 
CHIKV tissue tropism does not simply promote survival of infected animals. Hence, 
a large proportion of disease-associated markers must be investigated to fully assess 
  






the role of monocyte and macrophage infection with CHIKV in cynomolgus 
macaques. These include antibody responses, cytokine expression profiles, 
chemokine expression profiles, growth factors expression profiles, haematology, 
clinical observation, T cell responses  and tissue immunohistochemistry. Fortunately, 
good historic data exist (published and unpublished) that can be used as the 
reference.  
 
The results of this study will provide a valuable and unique insight into the 
mechanism of CHIKV pathogenesis in non-human primates, and in humans. 
However, a significant amount of further work is needed to complete this work: 
 
1. Characterisation of ICRES1-3F-zsGreen-miR-142-3P RE replication in 
peripheral blood mononuclear cells (FACS, immunohistochemistry, qPCR, 
plaque assay); 
2. Analysis of virus replication in collected tissues (muscles, tendons, skin, 
cartlidge, liver, spleen, lymph nodes) (immunohistochemistry, plaque assay, 
qPCR); 
3. Characterisation of cytokine expression profiles (IFN-γ, IL-2, IL-4, IL-5, IL-
13, IL-17, TNF-α, IL-1ra, IL1β, IL-6, IL-8, IL-10); 
4. Characterisation of chemokine expression profiles (MIP-1α, MIP-1β); 
5. Characterisation of growth factor profiles (e.g. GM-CSF); 
6. Characterisation of T-cell responses (e.g. IFN-γ ELISPOT) ; 
7. Characterisation of antibody responses; 






















































The immunobiology of viral arthritides is complex and not well understood. Virus 
replication or presence of a pathogen (or pathogen-derived material) may induce 
innate or adaptive immune responses that mediate cell damage (Suhrbier et al. 2009). 
Virus infections have been proposed to induce autoimmune responses (Suhrbier et al. 
2009). This can be achieved via molecular mimicry or activation of self-reactive 
lymphocytes by inflammatory conditions at the site of infection. It is possible that 
phagocytosis of apoptotic debris containing virus material by antigen-presenting cells 
leads to robust and uncontrolled immune response that induces autoimmunity against 
self-antigens present in apoptotic debris (Krejbich-Trotot et al. 2011). Autoimmune 
response can also be induced by presence of viral antigens and nucleic acids in 
affected joints (Suhrbier et al. 2009). Cell damage is then usually mediated by 
adaptive immune response against viral antigen, which may cause inflammation and 
long-term arthritis. Interestingly, double stranded RNA (dsRNA), which is an 
intermediate in alphavirus replication, may stimulate inflammation when present in 
synovial fluid (Bokarewa et al. 2008). CHIKV dsRNA, however, is not normally 
observed in synovial fluid in patients suffering from arthritis (Grivard et al., 2007).  
 
In this study, the interaction of human MDMs with SFV was investigated. The 
results demonstrated that human MDMs are refractory to infection with purified SFV 
but can be infected via apoptotic debris from virus-infected cells. Importantly, virus 
particles are not required to infect human MDMs via apoptotic debris from virus-
infected cells. The SFV infectious material contained within apoptotic debris is viral 
genomic RNA either in the cytoplasm or associated with replication complexes. 
 
Macrophages are one of the major cell populations that infiltrates joint tissue in 
polyarthritis (Assunção-Miranda et al. 2010). They are part of innate and adaptive 
immune responses that are activated in response to virus infection. As described 
previously, proinflammatory factors associated with CHIKV arthralgia/arthritis 
include  MCP-1, IL-6, IL-8, IFN-α, IL-6, IL-12 and GM-CSF (Hoarau et al. 2010, 
Chow et al. 2011). These cytokines and chemokines suggest that rheumatic disease is 
associated at least in part with macrophage recruitment and activation (Suhrbier & 
Mahalingam, 2009). Furthermore, long-term presence of IgM and elevated levels of 
  






IL-12 and IFN-α suggests that CHIKV virus infection might be persistence in PBMC 
(Hoarau et al. 2010). Lack of increased levels of TNF-α is surprising. It is possible, 
however, that TNF-α is expressed locally, at the site of inflammation. It has been 
suggested that chronic infection of macrophages by some viruses affects their 
differentiation, which results in an alternative phenotype different from M1/M2 
characteristics that contributes to tissue fibrosis (Hoarau et al. 2010). This has not yet 
been investigated in detail. 
 
In this study, the role of monocyte and macrophage infection with CHIKV was 
investigated. The tissue tropism of CHIKV was restricted by insertion of target 
sequences to haematopoietic-specific miR-142-3P into the virus genome. Replication 
of modified CHIKV was restricted in haematopoietic cells and the virus was shown 
to be very stable in vitro. The pathogenesis of CHIKV encoding the RE for miR-142-
3P was investigated in the cynomolgus macaque model of CHIKV disease. At the 
time of writing this thesis the majority of samples were not yet analysed. Once 
available, the results of this study will provide a valuable insight into CHIKV 
pathogenesis in non-human primates, and in humans. 
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ANNEX 1: Cell culture flask and multidishes 
 
Type Details Manufacturer 
Catalogue 
number 
TC Flask, 175 cm
2
 
 NunclonTM Delta surface 








TC Flask, 80 cm
2
 
 NunclonTM Delta surface 








TC Flask, 25 cm
2
 
 NunclonTM Delta surface 
































100 mm cell culture 
dish 
 Round  
 100 mm x 20 mm 
 TC Treated 
Corning 430167 
100 mm petri dish 
 Sterile 











96-well plates, white 
 Sterile 
 Suitable for measurement of 
luminescence 




















ANNEX 2: Plasticware 
 
Name Details Manufacturer 
Catalogue 
number 
Syringe 60 ml  





Syringe 20 ml 
 Luer Lock Tip 




Syringe 2 ml 






 Internal thread 









1.5mL Screw Cap 
Microtube 
 Sterile 





 DNase-, RNase-free 
Axygen MCT-175-C 
PCR Tubes 
 0.2ml Thin Wall 
 Flat Cap 
Axygen PCR-02-C 
50 ml centrifuge tube 
 Conical base 
 Sterile 
 DNase-, RNase-free 
 Non-pyrogenic, non-
cytotoxic 
Greiner Bio-One 227261 
50 ml centrifuge tube 
 Skirted base 
 Sterile 
 DNase-, RNase-free 
 Non-pyrogenic, non-
cytotoxic 






 38.5 ml 
 25 x 89 mm 
Beckman 344058 
Bijoux bottle 























 50 ml  Sigma-Aldrich® 
Z679968-
100EA 
Syringe filter 0.20 µm  Hydrophilic Sartorious 16534 
Syringe filter 0.45 µm  Hydrophilic Sartorious 16555 
Stericup-GP Filter Unit  
 0.22 µm Millipore 
Express PLUS (PES) 
membrane 
 250 ml capacity 
Millipore SCGPU02RE 
  






5 ml Serological Pipettes 
 Sterile and certified non-
pyrogenic 







10 ml Serological Pipettes 
 Sterile and certified non-
pyrogenic 








25 ml Serological Pipettes 
 Sterile and certified non-
pyrogenic 







TipOne Filter Pipette Tip, 
XL, 10µl 
 Sterile, RNase-, DNase, 
DNA- and pyrogene-free 
 Filtered 
Starlab S1120-3810 
TipOne Filter Pipette Tip, 
20µl 
 Sterile, RNase-, DNase, 
DNA- and pyrogene-free 
 Filtered 
Starlab S1120-1810 
TipOne Filter Pipette Tip, 
200µl 
 Sterile, RNase-, DNase, 
DNA- and pyrogene-free 
 Filtered 
Starlab S1120-8810 
TipOne Filter Pipette Tip, 
XL, 1000µl 
 Sterile, RNase-, DNase, 




 90 mm 








Bacteria Spreader  L-form with curved end Gosselin ETAR-01 
Disposable forceps 
 Sterile 






 4.7 x 8 mm 






  1.0 to 2.0 ml tubes Thermo Scientific
TM






 0.4 cm gap Bio-Rad 165-2088 
Parafilm 
 2" Wide 

















Half Area 96 well UV 
microplate 
 Non-sterile 
 DNase- and RNase-free 
Corning 3679 
Aluminium film for PCR 
plates 
 For molecular biology Dominique Dutscher 016925 
Reservoir, quarter 
 40 ml 
 Sterile 
Beckman Coulter 372790 
  






ANNEX 3: Sharps 
 
Name Details Manufacturer 
Catalogue 
number 
Needle 25 G  25 G x 1 ½” Terumo NN-2538R 
Needle 21 G  21 G x 1 ½” Terumo NN-2138R 
Needle 19 G  19 G x 1 ½” Terumo NN-1938R 
Disposable scalpels 


























ANNEX 4: Cell culture media components and 
supplementary reagents 
 
Name Details Manufacturer 
Catalogue 
number 
Dulbecco's Modified Eagle 
Medium (DMEM) 
 4mM L-glutamine 
 4.5 g/L glucose 







Glasgow Minimum Essential 
Medium (GMEM) 
 2mM L-glutamine 







Roswell Park Memorial 
Institute 1640 (RPMI 1640) 









 Reduced Serum 
Media 
 HEPES 









Foetal bovine serum (FBS) 













 1 M in H2O (238 g/L 
HEPES in H2O) 











Tryptose Phosphate Broth 
(TPB) 










 100 x concentrated 
 5000 U/ml penicillin 















Phosphate Buffered Saline 
(PBS) 
 pH 7.4 







Phosphate Buffered Saline 
(PBS) 
 pH 7.1-7.5 




 ≥99% (TLC) Sigma-Aldrich® P8139-5MG 
  






Recombinant human colony 
stimulating factor 1 (rhCSF-1) 
 Storage stock 
 1 x 108 U/mL 
Received from Prof 
David Hume, The 
Roslin Institute 
N/A 
Albumin, from bovine serum 
(BSA) 
 ≥98% (agarose gel 
electrophoresis)  
 lyophilized powder 
Sigma-Aldrich® A7030-100G 
Collagenase, Type I 





Dimethyl sulfoxide (DMSO)  ≥99.9% Sigma-Aldrich® D8418 
Hygromycin B 
 From Streptomyces sp. 
 Sterile-Filtered 
Solution in 25 mM 
HEPES 
Calbiochem 400053 
Doxycycline hyclate  ≥98% (TLC) Sigma-Aldrich® D9891-5G 




 pH 8.0 
 0.5 M in H2O 


























ANNEX 5: Chemicals 
 
Name Details Manufacturer 
Catalogue 
number 
Citrate-dextrose solution (ACD)  Sterile Sigma-Aldrich® 029K8712 
Carboxymethylcellulose sodium 
salt (CMC) 
 High viscosity Sigma-Aldrich® C5013-500G 
EDTA powder 









 ACS reagent 
 ≥99.8% 
Sigma-Aldrich® 252859-500G 
TRIS-HCl  pH=7.0 Sigma-Aldrich® T2413 
Tris-Acetate-EDTA (TAE) buffer, 
50 x  
 50 x  
 0.22 μm filtered  
Life Technologies B49 
Sodium chloride (NaCl) 
 ACS reagent 
 ≥99.5% 
Sigma-Aldrich® S9888-5KG 
Sodium hydroxide (NaOH) 
solution 






Hydrochloric acid (HCl) solution 






10% Neutral Buffered Formalin  
 10% v/v formalin 




Toluidine Blue N/A Sigma-Aldrich® T3260 
Ethanol 
 Molecular biology 




















Imalgène® 1000 (ketamine 
chlorhydrate) 
N/A Rhône Mérieux N/A 
Sodium pentothal 





Silicone Vacuum Grease N/A Beckman Coulter 335148 
Ammonium chloride, NH4Cl  Powder Sigma-Aldrich® 254134-100G 
Potassium bicarbonate, KHCO3 










ANNEX 6: Molecular biology kits and reagents 
 
Name Details Manufacturer 
Catalogue 
number 
Dual-Glo® Luciferase Assay 
System 
 No lysis required 




 Lysis required 
 RLuc, GLuc, FLuc 
Promega E1960 
CellTiter-Glo® Luminescent 
Cell Viability Assay 
 10 × 10ml 
 Based on quantitation 
of the ATP present 
Promega G7571 
Nuclease-free water (H2O) 
 Miolecular biology 
grade 
 RNase-, DNasae-free 
Sigma-Aldrich® W4502 




















FuGENE® 6 Transfection 
Reagent 
 0.5 ml Promega E2693 




100bp DNA Ladder  For 50 lanes Promega G2101 
1kb DNA Ladder  For 100 lanes  Promega G5711 
6 x Blue/Orange Loading Dye 
 6 x loading dye 












SYBR® Safe DNA Gel Stain  400 µL Life Technologies S33102 
GoTaq® DNA Polymerase  500 Units Promega M3005 
KOD Hot Start DNA 
Polymerase 




Pfu DNA Polymerase  500 Units Promega M774B 





 25mM each 
 2 x 500 µl 
Bioline BIO-39029 















 40 mM  






RNasin® Plus RNase Inhibitor  10,000 Units Promega N2615 
SuperScript™ III Reverse 
Transcriptase 
 10,000 Units 
 200 Units/µl 








 III Platinum 
One Step Quantitative RT-
PCR System 












High Capacity cDNA Reverse 
Transcription Kit 





FastStart SYBR® Green 
Master Mix 
 50 reactions Roche 04673484001 
TaqMan® Universal PCR 
Master Mix 





TaqMan® miR-142-3P Assay 
 Assay ID: 000464 





TaqMan® miR16 Assay 
 Assay ID: 000391 







 100 Units Promega M9910 
T4 DNA Ligase 
 20,000 Units 




Bovine Serum Albumin 
(BSA), Acetylated 
 Enzyme stabiliser 
 10 mg/ml 
Promega R3961 
SpeI 
 500 Units 





 200 Units 
 10 Units/µl 
Roche 11014714001 
AvrII 
 100 Units 





 500 Units 





 5,000 Units 
 10 Units/µl 
Promega R6361 
BamHI 
 2,500 Units 
 10 Units/µl 
Promega R6021 
SacI 
 2,000 Units 












 500 Units 





 3,000 Units 
 10 Units/µl 
Promega R6161 
EcorV 
 2,000 Units 
 10 Units/µl 
Promega R6351 
BglII 
 500 Units 
 10 Units/µl 
Promega R6081 
MluI 
 1,000 Units 
 10 Units/µl 
Promega R6381 
XbaI 
 2,000 Units 
 10 Units/µl 
Promega R6181 
NdeI 
 4,000 Units 





 100 Units 





 2,500 Units 
 10 Units/µl 
Promega R6085 
EcorV 
 2,000 Units 
























ANNEX 7: Competent bacteria and supplementary 
reagents 
 




DH5α™ Competent Cells 






SURE® 2 Supercompetent 
Cells 
 10 x 100 µl Stratagene 200152 
SOC medium 
 5 ml aliquots 






 Agar - BD  214010 













 50 mg/ml (1000x 
concentration) 
Sigma-Aldrich® K1876-5G 
LB Broth  
 Miller (Luria-Bertani) 
formulation 






 Miller (Luria-Bertani) 
formulation 























ANNEX 8: Nucleic acid extraction and purification kits 
 
Name Details Manufacturer 
Catalogue 
number 
DNeasy® Blood & Tissue Kit  For 50 samples Qiagen 69504 
RNeasy® Mini Kit  For 50 samples Qiagen 74104 
RNase-Free DNase Set 
 For 50 samples  
 DNase treatment with 
Qiagen RNA purification 
kits 
 On-column treatment 
Qiagen 79254 
QIAamp Viral RNA Mini Kit  For 50 samples Qiagen 52904 
NucleoSpin® Gel and PCR 
Clean-up 
 For 50 samples 
 Binding capacity 25 µg 
 Optimal recovery of 
fragments <15 µg and 









 PCR DNA 
and Gel Band Purification Kit 
 For 100 samples GE Healthcare 45-001-489 
ISOLATE Plasmid Mini Kit 
 For 50 samples 
 Binding capacity 13 µg 
Bioline BIO-52026 
EndoFree® Plasmid 
Purification Maxi Kit 
 For 10 samples Maxi-
Prep Kit 
 Endotoxin-free 
 Binding capacity 500 µg 
Qiagen 12362 
NucleoSpin® 96 Virus 
 96-well plates format 
 < 150 µL cell-free 




















ANNEX 9: Immunobiology reagents 
 
Name Details Manufacturer 
Catalogue 
number 
CD14 MicroBeads  Against human CD14 Millenyi Biotec 130-050-201 
MACS MS Separation 
columns 
 25 columns Millenyi Biotec 130-042-201 
Microscope slides  76 x 26 mm Knittle Glass - 
Cover glass 
 13 mm diameter 
 Thickness No. 1 
 Boroslilicate glass 
VWR 631-0149 
VECTASHIELD® Mounting 
Medium with DAPI 





Antifade Mounting Medium 







 10 mg 
Life Technologies D1306 
CAS BLOCK
TM




PE Rat anti-mouse F4/80 
antibody 
 1:100 dilution for flow 
cytometry 
Biolegend 122616 
PE Rat IgG2b 
 1:100 dilution for flow 
cytometry 
 ĸ Isotype control 
Biolegend 400608 








 X-100  Laboratory grade Sigma-Aldrich ® X100-500ML 
Rabbit anti-SFV nsP3 primary 
antibody 
 Polyclonal 




Donkey anti-Rabbit secondary 
Antibody, Alexa Fluor® 488 
conjugate 
 Polyclonal, IgG 
 Conjugated to Alexa 
Fluor® 488 
Life Technologies R37118 
Goat anti-Rat IgG (H+L) 
secondary antibody, Alexa 
Fluor® 594 conjugate 
 Polyclonal, IgG (H+L) 
 Conjugated to Alexa 
Fluor® 594 
Life Technologies A-11007 
Rat anti-Mouse MARCO 
primary antibody 
 Monoclonal  
 Clone ED31 
 IgG1 
AbD Serotec® MCA1849T 
Rat anti-Mouse CD169 
primary antibody, Alexa 
Fluor® 647 conjugate 
 Monoclonal  
 Clone MOMA-1 
 IgG2a 
AbD Serotec® MCA947A647 
  






ANNEX 10: Equipment 
 
Name Details Manufacturer 
Zeiss Observer.D1 
 Inverted microscope 
 Hal 100 halogen illuminator 
 Colibri LED illumination system 
 AxioCam MRc camera 
Carl Zeiss 
Zeiss Axioskop 2 
 Upright microscope 
 HBO 100 illuminator - 100-watt high-pressure 
mercury plasma arc-discharge lamp 
 HAL 100 halogen illuminator 
 Supply unit Ebq 100 ISOLATED for 100 W 
high-pressure mercury burner 
 AxioCam MRc camera 
Carl Zeiss 
Venti 96-well Thermal 
Cycler 
 Innovative VeriFlex™ Blocks allow for precise 
PCR optimization and enable you to run up to 
6 independent assays 
 Sample Ramp Rate - ± 3.35 °C⁄se 
 Block Temperature Range - 4.0-99.9 °C 
 Temperature Accuracy - ±0.25°C (35°C to 
99.9°C) 







 4.19 Megapixel camera with 16-bit A/D, 
cooled to -25ºC absolute and regulated 
 Manual 28-70 mm F2.8 zoom lens 
 Orange Filter —for gels stained with ethidium 
bromide, coomassie blue, or SYPRO® Orange. 
590/55 nm. 
 Green Filter —for gels or plates with GFP, 
SYBR® Safe, SYBR® Gold, Fluorescein, 
SYBR® Green. 537/35 nm 
 Red Filter —used for gels stained with 
SYPRO® Red, SYPRO® Ruby, Texas Red, or 
Rhodamine. 620/40 nm 
Alpha Innotech  
L8-70M Ultracentrifuge 
 Max Speed – 70,000 RPM 






 Max Speed – 100,000 RPM 
 SW32 Ti Swing Bucket Rotor (6 x 38.5 ml) 
Beckman Coulter 
3 S-R Bench Top 
Centrifuge 
 Refrigerated 
 Swing-out rotor for 4 buckets (20 x 50 ml tubes 
or 48 x 15 ml tubes) 
 Max RCF – 3,800 x g 








5810 R Centrifuge 
 Refrigerated  
 Rectangular swing-out rotor for 4 buckets (20 x 
50 ml tubes or 64 x 15 ml tubes) 
 Max RCF -  3,100 x g 
 Max Speed – 4,000 RPM 
Eppendorf 
  









 Fixed-angle rotor for 30 microfuge tubes, 
1.5/2.0 ml 
 Swing-out rotor for 4 buckets (12 x 50 ml tubes 
or 28 x 15 ml tubes) 
 Max RCF (fixed-angle rotor) – 21,930 x g 
 Max RCF (swing-out rotor) – 3,960 x g 
 Max Speed (fixed angle rotor) – 14,000 RPM 







 24 x 1.5/2.0 ml Fixed-Angle Rotor 
 Max RCF - 17,000 x g 









 Fixed-angle rotor for 24 microfuge tubes, 
1.5/2.0 ml tubes 
 Max RCF - 16,100 x g 






 200 µl-tube strips or 200 µl tubes 
 Maximum RCF - 2,810 x g   







 8-tube 200 µl-tube strips or 1.5/2.0 ml  tubes 







 Temp control range and fluctuation - ambient 
temp +5 to +50, ±0.1 °C 
 Temperature uniformity - ±0.25°C 
 CO2 control range - 0-20% 
Panasonic 
Rotor-Gene 3000 Real-
Time PCR Machine 
 Centrifugal rotary format 
 Uniformity – ± 0.01°C 






Time PCR  
 My IQTM Real Time Module  






 Power supply for gel electrophoresis. Bio-Rad 
Wide Mini-Sub® Cell 
GT Cell 
 Electrophoresis gel tank 
 15 x 10 cm gel trays 
Bio-Rad 
Mini-Sub® Cell GT 
Cell 
 Electrophoresis gel tank 
 7 x 10 cm gel trays 
Bio-Rad 
Sub-Cell® GT Cell 
 Electrophoresis gel tank 














QBT2 Digital Block 
Heater 
 Temperature range Ambient + 5 °C to 150 °C 
 Setting range 15 °C to 150 °C 
 Stability at 37 °C ± 0.1 °C 
Grant 
Hotplate Stirrer CB302 
 Plate size - 30x30cm 
 Max. plate temperature - 300°C 
 Stirrer speed – 100-1,500 RPM 
Stuart 
Thermomixer® Dry 
Block Heating Shakers 
 Thermoblock for 24 x 1.5 ml tubes 
 Temperature control range - 4°C above room 
temperature to 99°C 
 Mixing frequency - 300-1,400 RPM 
 Incubating accuracy - ±1°C from values set 
between 20 and 45°C 
Eppendorf 
PIPETMAN Classic™ 
 0.2-2.0 µl 
 1.0-10.0 µl 
 2.0-20 µl 
 20-200 µl 





























Vortex/Shaker SA8  Speed range – 200-2,500 RPM Stuart 
WhirliMixer
TM
 vortex  Speed range – 200-1,400 RPM Fisher Scientific 
InnOva
TM
  4300 
Incubator Shaker  
 Speed range - 25-500 RPM 
 Temperature range - 5C above ambient to 60C 




 Full spectrum spectrophotometer  
(220nm-750nm) 
 Nucleic acid concentration and purity of 






SSM4 Sea-saw rocker 
 Speed range - 5 to 70 RPM 
 Angle of tilt - 7° 
Stuart 
DR89 Dark Reader blue 
transilluminator 
 Multiple high intensity blue LEDs 
 Visible light – no DNA damage 
 Suitable for visualising SYBR® Green, GelStar, 
GelGreen, SYPRO® Ruby, ProQ Diamond, 






 Vacuum range from -300 to -600 mbar 
 Pump flow rate - 8 l/min (air) 













 Luminescence, fluorescence, absorbance 
 Dual injectors 
 Detector - head-on photomultiplier tube (PMT) 
for photon-counting 
 Detection Limit - 3 x 10-21 moles of Luciferase 
or 1 x 10-18moles of AT 
 Linear Dynamic Range - > 8 logs 






 Automatic temperature compensation (ATC) Mettler Toledo 
Milli-Q® Water 
Purification System and 
Q-POD Water Delivery 
Unit 
 High quality, ultrapure water, free of 
particulates, bacteria, pyrogens, RNAse, DNase, 
proteases, VOCs, endocrine disruptors and 







 Main unit, CE module and  a ShockPod™ 
cuvette chamber   
Bio-Rad 







 Dual-laser design (air-cooled argon laser and red 
diode laser) – high sensitivity, minimal need for 
compensation and flexibility 




 75 samples-per-hour throughput 
 Continuous auto-loading for complete walkaway 
operation 







 My IQTM Real Time Module 
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1. MACS Buffer (2mM EDTA and 1% w/v FBS in PBS) 
 448 ml of Mg2+- and Ca2+-free PBS (Sigma-Aldrich®, Annex 4) 
 2 ml of 0.5 M EDTA (Life Technologies, Annex4) 
 5 ml of FBS (InvitrogenTM Life Technologies, Annex 4) 
 
2. 10 x TNE buffer (0.5 M Tris-HCl, 1.0 M NaCl, 1.0 mM EDTA, pH=7.4) 
 500 ml of 1.0 M Tris-HCl (Sigma-Aldrich®, Annex 5) 
 58.5g of NaCl (Sigma-Aldrich®, Annex 5) 
 100 ml of 1.86g in EDTA solution in 500 ml of H2O (Sigma-Aldrich®, 
Annex 5) 
 Milli-Q H2O up to 1000 ml total volume (Merck Millipore, Annex 10) 
 NaOH or HCl to adjust pH to 7.4 (Sigma-Aldrich®, Annex 5) 
 Autoclave at 121ºC for 15 minutes 
 
3. 1 x TNE buffer (50 mM Tris-HCl, 100 mM NaCl, 0.1 mM EDTA, pH=7.4) 
 100 ml of 10 x TNE buffer 
 Milli-Q H2O up to 1000 ml total volume (Merck Millipore, Annex 10) 
 NaOH or HCl to adjust pH to 7.4 (Sigma-Aldrich®, Annex 5) 
 Autoclave at 121ºC for 15 minutes 
 
4. 20% w/v sucrose in TNE buffer 
 100 ml of 10 x TNE buffer 
 200 g of sucrose (Sigma-Aldrich®, Annex 5) 
 Milli-Q H2O up to 1000 ml total volume (Merck Millipore, Annex 10) 
 Autoclave as per sugar cycle 
 
5. 5% w/v sucrose in H2O 
 50 g of sucrose (Sigma-Aldrich®, Annex 5) 
 Milli-Q H2O up to 1000 ml total volume (Merck Millipore, Annex 10) 
 Autoclave as per sugar cycle 
 
  






6. 10% w/v sucrose in H2O 
 100 g of sucrose (Sigma-Aldrich®, Annex 5) 
 Milli-Q H2O up to 1000 ml total volume (Merck Millipore, Annex 10) 
 Autoclave as per sugar cycle 
 
7. 20% w/v sucrose in H2O 
 200 g of sucrose (Sigma-Aldrich®, Annex 5) 
 Milli-Q H2O up to 1000 ml total volume (Merck Millipore, Annex 10) 
 Autoclave as per sugar cycle 
 
8. Tryptone Soya Broth 
 30 g of Tryptone Soya Broth (Thermo ScientificTM OxoidTM, Annex 7) 
 Milli-Q H2O up to 1000 ml total volume (Merck Millipore, Annex 10) 
 Autoclave at 121ºC for 15 minutes 
 
9. LB Broth 
 25 g of LB Broth (BD, Annex 7) 
 Milli-Q H2O up to 1000 ml total volume (Merck Millipore, Annex 10) 
 Autoclave at 121ºC for 15 minutes 
 
10. LB Agar 
 40 g of LB Broth (BD, Annex 7) 
 Milli-Q H2O up to 1000 ml total volume (Merck Millipore, Annex 10) 
 Autoclave at 121ºC for 15 minutes 
 
11. 2% w/v CMC in PBS 
 10 g of CMC (Sigma-Aldrich®, Annex 5) 
 PBS with Mg2+ and Ca2+ up to 500 ml total volume (Sigma-Aldrich®, 
Annex 4)  










12. 0.75% w/v PBSA 
 7.5 g BSA (Sigma-Aldrich®, Annex 4) 
 PBS with Mg2+ and Ca2+ up to 1000 ml total volume(Sigma-Aldrich®, 
Annex 4) 
 Filtered through 0.22µl membrane (Millipore, Annex 2) 
 
13. 4% w/v Agar 
 4 g of BactoTM Agar (BD, Annex 7) 
 PBS with Mg2+ and Ca2+ up to 100 ml total volume (Sigma-Aldrich®, 
Annex 4) 
 Autoclave at 121ºC for 15 minutes 
 
14. 1 x TAE 
 20 ml of 50 x TAE buffer (Life Technologies, Annex 5) 
 Milli-Q H2O up to 1000 ml total volume (Merck Millipore, Annex 10) 
 
15. 0.3% v/v TritonTM X-100 in PBS 
 1.5 ml TritonTM X-100 (Sigma-Aldrich®, Annex 9) 
 498.5 ml PBS with Mg2+ and Ca2+ (Sigma-Aldrich®, Annex 4) 
 
16. RBC lysis buffer 
 8.29 g of NH4Cl (Sigma-Aldrich®, Annex 5) 
 1 g of KHCO3 (Sigma-Aldrich®, Annex 5) 
 32.7 mg EDTA (Sigma-Aldrich®, Annex 5) 
 Milli-Q H2O up to 1000 ml total volume (Merck Millipore, Annex 10) 
 
17. FACS buffer 
 99 ml of Mg2+- and Ca2+-free PBS (Sigma-Aldrich, Annex 4) 
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1. CHIKV E1 Control (Go-Taq®) 
 
CHIKV E1 For (22 bases; 54.5% GC; Tm=56.7 ºC): 
AAGCTCCGCGTCCTTTACCAAG 
 
CHIKV E1 Rev (21 bases; 47.6% GC; Tm=52.4 ºC): 
CCAAATTGTCCTGGTCTTCCT 
Fragment size    –    209 bp 
Denaturation      –    95 ºC  – 2 min x 1 
Denaturation      
Annealing         
Elongation 
–    95 ºC  
–    60 ºC  
–    72 ºC  
– 30 sec 
– 30 sec 
– 30 sec 
x 35 
Elongation         –    72 ºC  – 5 min x 1 
4 ºC   ∞ 
 
2. CHIKV nsp4-E1 Recombination Control (Go-Taq®) 
 
CHIK nsp4 For (19 bases; 52.6% GC; Tm=51.1 ºC): 
GCTCCAGATCCAACTTCGA  
 
CHIK E1 Rev (19 bases, 52.6% GC; Tm=51.1 ºC): 
GCAGCTGAGAATTCCCTTC 
Fragment size    –    3,614 bp 
Denaturation      –    95 ºC  – 2 min x 1 
Denaturation      
Annealing         
Elongation 
–    95 ºC  
–    55 ºC  
–    72 ºC  
– 30 sec 
– 30 sec 
– 4 min 
x 35 
Elongation         –    72 ºC  – 5 min x 1 












3. CHIKV nsp4-E3 Recombination Control (Go-Taq®) 
 
CHIK nsp4 For (19 bases; 52.6% GC; Tm=51.1 ºC): 
GCTCCAGATCCAACTTCGA  
 
CHIK E3 Rev (19 bases, 52.6% GC; Tm=51.1 ºC): 
CATGACGTTGTCCTCAAGC 
Fragment size     –    1,052 bp 
Denaturation      –    95 ºC  – 2 min x 1 
Denaturation      
Annealing         
Elongation 
–    95 ºC  
–    55 ºC  
–    72 ºC  
– 30 sec 
– 30 sec 
– 1 min 
x 35 
Elongation         –    72 ºC  – 5 min x 1 
4 ºC   ∞ 
 
4. ICRES1 2SG Cloning Control (Go-Taq®) 
 
ICRES1 2SG Control For (22 bases; 54.5% GC; Tm=56.7 ºC): 
GCTGACGAAGTGATCAGATGGC  
 
ICRES1 2SG Control Rev (22 bases, 54.5 % GC; Tm=56.7 ºC): 
CGAGGCTGGTACCTCCTATTGT 
Fragment size 
–    601 bp (miR-142-3P RE) 
–    598 bp (miRNA RE Control) 
Denaturation      –    95 ºC  – 2 min x 1 
Denaturation      
Annealing         
Elongation 
–    95 ºC  
–    55 ºC  
–    72 ºC  
– 30 sec 
– 30 sec 
– 45 sec 
x 35 
Elongation         –    72 ºC  – 5 min x 1 











5. ICRES1 and ChikRepl nsP3 Cloning Control (Go-Taq®) 
 
ICRES1 nsP3 For (22 bases; 54.5% GC; Tm=56.7 ºC): 
CTGCACAGGAGGCGAGTACAAT  
 
ICRES1 nsP3 Rev (22 bases, 54.5 % GC; Tm=56.7 ºC): 
TCACAGTCAGGTTTCTCCCTCG 
Fragment size    
–    399 bp (miR-142-3P RE) 
–    396 bp (miRNA RE Control) 
Denaturation      –    95 ºC  – 2 min x 1 
Denaturation      
Annealing         
Elongation 
–    95 ºC  
–    58 ºC  
–    72 ºC  
– 30 sec 
– 30 sec 
– 30 sec 
x 35 
Elongation         –    72 ºC  – 5 min x 1 
4 ºC   ∞ 
 
6. ChikRepl 3’ UTR Cloning Control (Go-Taq®) 
 
ICRES1 2SG Control For (22 bases; 54.5% GC; Tm=56.7 ºC): 
GCTGACGAAGTGATCAGATGGC  
 
ChikRepl SG Control Rev (22 bases, 54.5 % GC; Tm=56.7 ºC): 
TATTCAGGGGTTGCGTAGCCCT 
Fragment size 
–    503 bp (miR-142-3P RE) 
–    500 bp (miRNA RE Control) 
Denaturation      –    95 ºC  – 2 min x 1 
Denaturation      
Annealing         
Elongation 
–    95 ºC  
–    58 ºC  
–    72 ºC  
– 30 sec 
– 30 sec 
– 30 sec 
x 35 
Elongation         –    72 ºC  – 5 min x 1 











7. SFV4 SbfI Site Cloning Control (Go-Taq®) 
 
SFV4 SbfI Control For (19 bases; 57.9 % GC; Tm=53.2 ºC): 
CATTGAGAATGCCGTCCGG  
 
SFV4 SbfI Control Rev (19 bases; 57.9 % GC; Tm=53.2 ºC): 
GTTTCCGGTTCCACAGGTG 
Fragment size –    367 bp 
Denaturation      –    95 ºC  – 2 min x 1 
Denaturation      
Annealing         
Elongation 
–    95 ºC  
–    51 ºC  
–    72 ºC  
– 30 sec 
– 30 sec 
– 30 sec 
x 35 
Elongation         –    72 ºC  – 5 min x 1 
4 ºC   ∞ 
 
8. SFV4 SacI Site Cloning Control (Go-Taq®) 
 
SFV4 SacI Control For (19 bases; 57.9 % GC; Tm=53.2 ºC): 
GAGTATCACGCAGGTGCAG  
 
SFV4 SacI Control For (19 bases; 57.9 % GC; Tm=53.2 ºC): 
CGGCGTCAGTTCTTTCAGC 
Fragment size –    409 bp 
Denaturation      –    95 ºC  – 2 min x 1 
Denaturation      
Annealing         
Elongation 
–    95 ºC  
–    51 ºC  
–    72 ºC  
– 30 sec 
– 30 sec 
– 30 sec 
x 35 
Elongation         –    72 ºC  – 5 min x 1 












9. SFV4 3’ UTR Cloning Control (Go-Taq®) 
 
SFV4 3’ UTR For (22 bases; 54.5 % GC; Tm=56.7 ºC): 
TGTTTCCAGACATGTCGGGCAC  
 
SFV4 3’ UTR Rev (22 bases; 54.5 % GC; Tm=56.7 ºC): 
AATTGCGCAGGTCTTGTTGCGC 
Fragment size 
–    400 bp (miR-142-3P RE) 
–    397 bp (miR-142-3P Antisense RE) 
–    397 bp (miRNA RE Control) 
–    888 bp (GLuc) 
–    1,043 bp (GLuc-miR-142-3P RE) 
–    1,040 bp (GLuc-miR-142-3P Antisense RE) 
–    1,040 bp (GLuc-miRNA RE Control) 
Denaturation      –    95 ºC  – 2 min x 1 
Denaturation      
Annealing         
Elongation 
–    95 ºC  
–    55 ºC  
–    72 ºC  
– 30 sec 
– 30 sec 
– 60 sec 
x 35 
Elongation         –    72 ºC  – 5 min x 1 




















10. SFV4 nsP3 Cloning Control (Go-Taq®) 
 
SFV4 nsP3 For (22 bases; 59.1 % GC; Tm=58.6 ºC): 
ACGGCTGACGTACACCCTGAAC  
 
SFV4 nsP3 Rev (22 bases; 59.1 % GC; Tm=58.6 ºC): 
AACGCATCGACCTCGTGCTCGT 
Fragment size 
–    401 bp (miR-142-3P RE) 
–    398 bp (miR-142-3P Antisense RE) 
–    398 bp (miRNA RE Control) 
Denaturation      –    95 ºC  – 2 min x 1 
Denaturation      
Annealing         
Elongation 
–    95 ºC  
–    58 ºC  
–    72 ºC  
– 30 sec 
– 30 sec 
– 30 sec 
x 35 
Elongation         –    72 ºC  – 5 min x 1 
4 ºC   ∞ 
  
11. pMK NotI-PmeI Cloning Control (Go-Taq®) 
 
pMK NotI-PmeI Control For (19 bases; 57.9 % GC; Tm=53.2 ºC): 
GACCTGCTCAAGAAGTGGC  
 
pMK NotI-PmeI Control Rev (19 bases; 57.9 % GC; Tm=53.2 ºC): 
GAAAGGAAGGCCCATGAGG 
Fragment size 
–    292 bp (GLuc-miR-142-3P RE) 
–    289 bp (GLuc-miR-142-3P Antisense RE) 
–    289 bp (GLuc-miRNA RE Control) 
Denaturation      –    95 ºC  – 2 min x 1 
Denaturation      
Annealing         
Elongation 
–    95 ºC  
–    51 ºC  
–    72 ºC  
– 30 sec 
– 30 sec 
– 30 sec 
x 35 
Elongation         –    72 ºC  – 5 min x 1 
4 ºC   ∞ 
 
  






12. pcDNATM3.1+ and pcDNATM5/FRT/TO Cloning Control (Go-Taq®) 
 
pcDNA Control For (18 bases; 61.1 % GC; Tm=52.6 ºC): 
AAATGGGCGGTAGGCGTG  
 
pcDNA Control Rev (18 bases; 61.1 % GC; Tm=52.6 ºC): 
AGAAGGCACAGTCGAGGC 
Fragment size 
–    610 bp (miR-142 ‘Core’) 
–    1,105 bp (miR-142 ‘Short’) 
–    1,201 bp (miR-142 ‘Long-3’) 
–    1,249 bp (miR-142 ‘Long-5’) 
–    961 bp (mCherry) 
Denaturation      –    95 ºC  – 2 min x 1 
Denaturation      
Annealing         
Elongation 
–    95 ºC  
–    51 ºC  
–    72 ºC  
– 30 sec 
– 30 sec 
– 1 min 30 sec 
x 35 
Elongation         –    72 ºC  – 5 min x 1 
















13. miRNA RE 5’AvrII and 3’PmeI (Vent® or Go-Taq®) 
 
miRNA RE AvrII For (26 bases; 57.7 % GC; Tm=62.7 ºC): 
ATCCCTAGGTCCGGACCAGGTTCGAA  
 
miRNA RE PmeI Rev (28 bases; 50.0 % GC; Tm=61.4 ºC): 
CGCGTTTAAACCAATTGAGCTCCTGAGG 
Fragment size 
–    161 bp (miR-142-3P RE) 
–    158 bp (miRNA RE Control) 
Denaturation      –    95 ºC  – 2 min x 1 
Denaturation      
Annealing         
Elongation 
–    95 ºC  
–    44 ºC  
–    72 ºC  
– 30 sec 
– 30 sec 
– 30 sec 
x 1 
Denaturation      
Annealing         
Elongation 
–    95 ºC  
–    58 ºC  
–    72 ºC  
– 30 sec 
– 30 sec 
– 30 sec 
x 35 
Elongation         –    72 ºC  – 5 min x 1 


















14. miRNA RE 5’ SpeI and 3’ SpeI (Go-Taq ®) 
 
miRNA RE SpeI For (26 bases; 57.7 % GC; Tm=62.7 ºC): 
CGCACTAGTTCCGGACCAGGTTCGAA  
 
miRNA RE SpeI Rev (26 bases; 53.8 % GC; Tm=61.1 ºC): 
CGCACTAGTCAATTGAGCTCCTGAGG 
Fragment size 
–    159 bp (miR-142-3P RE ) 
–    156 bp (miRNA RE Control) 
Denaturation      –    95 ºC  – 2 min x 1 
Denaturation      
Annealing         
Elongation 
–    95 ºC  
–    44 ºC  
–    72 ºC  
– 30 sec 
– 30 sec 
– 30 sec 
x 1 
Denaturation      
Annealing         
Elongation 
–    95 ºC  
–    58 ºC  
–    72 ºC  
– 30 sec 
– 30 sec 
– 30 sec 
x 35 
Elongation         –    72 ºC  – 5 min x 1 






















15. miRNA RE 5’ ApaI and 3’ BamHI (Pfu or Go-Taq®) 
 
miRNA RE ApaI For (26 bases; 61.5 % GC; Tm=64.3 ºC): 
ATAGGGCCCTCCGGACCAGGTTCGAA  
 
miRNA RE BamHI Rev (26 bases; 57.7 % GC; Tm=62.7 ºC): 
CGTGGATCCCAATTGAGCTCCTGAGG 
Fragment size 
–    159 bp (miR-142-3P RE ) 
–    156 bp (miR-142-3P Antisense RE) 
–    156 bp (miRNA RE Control) 
Denaturation      –    95 ºC  – 2 min x 1 
Denaturation      
Annealing         
Elongation 
–    95 ºC  
–    44 ºC  
–    72 ºC  
– 30 sec 
– 30 sec 
– 30 sec 
x 1 
Denaturation      
Annealing         
Elongation 
–    95 ºC  
–    58 ºC  
–    72 ºC  
– 30 sec 
– 30 sec 
– 30 sec 
x 35 
Elongation         –    72 ºC  – 5 min x 1 




















16. miRNA RE 5’ XhoI and 3’ XhoI (Go-Taq®) 
 
miRNA RE XhoI For (26 bases; 57.7 % GC; Tm=62.7 ºC): 
ATCCTCGAGTCCGGACCAGGTTCGAA  
 
miRNA RE XhoI Rev (26 bases; 57.7 % GC; Tm=62.7 ºC): 
CTCCTCGAGCAATTGAGCTCCTGAGG 
Fragment size 
–    159 bp (miR-142-3P RE ) 
–    156 bp (miR-142-3P Antisense RE) 
–    156 bp (miRNA RE Control) 
Denaturation      –    95 ºC  – 2 min x 1 
Denaturation      
Annealing         
Elongation 
–    95 ºC  
–    44 ºC  
–    72 ºC  
– 30 sec 
– 30 sec 
– 30 sec 
x 1 
Denaturation      
Annealing         
Elongation 
–    95 ºC  
–    58 ºC  
–    72 ºC  
– 30 sec 
– 30 sec 
– 30 sec 
x 35 
Elongation         –    72 ºC  – 5 min x 1 





















17. miRNA RE 5’NotI and 3’ PmeI (Pfu or Go-Taq®) 
 
miRNA RE NotI For (26 bases; 69.2 % GC; Tm=67.4 ºC): 
AGCGGCCGCTCCGGACCAGGTTCGAA  
 
miRNA RE PmeI Rev (28 bases; 50.0 % GC; Tm=61.4 ºC): 
CGCGTTTAAACCAATTGAGCTCCTGAGG 
Fragment size 
–    161 bp (miR-142-3P RE ) 
–    158 bp (miR-142-3P Antisense RE) 
–    158 bp (miRNA RE Control) 
Denaturation      –    95 ºC  – 2 min x 1 
Denaturation      
Annealing         
Elongation 
–    95 ºC  
–    44 ºC  
–    72 ºC  
– 30 sec 
– 30 sec 
– 30 sec 
x 1 
Denaturation      
Annealing         
Elongation 
–    95 ºC  
–    58 ºC  
–    72 ºC  
– 30 sec 
– 30 sec 
– 30 sec 
x 35 
Elongation         –    72 ºC  – 5 min x 1 

















18. miR-142 ‘Core’ 5’ EcorV and 3’ XhoI (Pfu or Go-Taq®) 
 
miR-142 Core EcorV For (28 bases; 57.1 % GC; Tm=64.3 ºC): 
CTCGATATCGGGTTGGGGGGATCTTAGG  
 
miR-142 Core XhoI Rev (28 bases; 57.1 % GC; Tm=64.3 ºC): 
ATACTCGAGTAGGGAGGGGCCGTAAGGT 
Fragment size –    311 bp 
Denaturation      –    95 ºC  – 2 min x 1 
Denaturation      
Annealing         
Elongation 
–    95 ºC  
–    66 ºC (Pfu) / 60 ºC (Go-Taq®) 
–    72 ºC  
– 30 sec 
– 30 sec 
– 60 sec 
x 35 
Elongation         –    72 ºC  – 5 min x 1 
4 ºC   ∞ 
 
19. miR-142 ‘Short’ 5’ EcorV and 3’ XhoI (Pfu or Go-Taq®) 
 
miR-142 Short EcorV For (27 bases; 59.3 % GC; Tm=64.3 ºC): 
CTCGATATCGCCAGCCAGGGGTTCACA  
 
miR-142 XhoI Rev (27 bases; 59.3 % GC; Tm=64.3 ºC): 
ATACTCGAGTCCCCACCCCAGCAACAG 
Fragment size –    806 bp 
Denaturation      –    95 ºC  – 2 min x 1 
Denaturation      
Annealing         
Elongation 
–    95 ºC  
–    66 ºC (Pfu) / 60 ºC (Go-Taq®) 
–    72 ºC  
– 30 sec 
– 30 sec 
– 1 min 30 sec 
x 35 
Elongation         –    72 ºC  – 5 min x 1 











20. miR-142 ‘Long-1’ 5’ EcorV and 3’ XhoI (Pfu or Go-Taq®) 
 
miR-142 Long-1 EcorV For (27 bases; 59.3 % GC; Tm=64.3 ºC): 
CTCGATATCCACGGTTGGGGTGGACTG  
 
miR-142 XhoI Rev (27 bases; 59.3 % GC; Tm=64.3 ºC): 
ATACTCGAGTCCCCACCCCAGCAACAG 
Fragment size –    899 bp 
Denaturation      –    95 ºC  – 2 min x 1 
Denaturation      
Annealing         
Elongation 
–    95 ºC  
–    66 ºC (Pfu) / 60 ºC (Go-Taq®) 
–    72 ºC  
– 30 sec 
– 30 sec 
– 1 min 30 sec 
x 35 
Elongation         –    72 ºC  – 5 min x 1 
4 ºC   ∞ 
 
21. miR-142 ‘Long-2’ 5’ EcorV and 3’ XhoI (Pfu or Go-Taq®) 
 
miR-142 Long-2 EcorV For  (27 bases; 59.3 % GC; Tm=64.3 ºC): 
CTCGATATCCCTCACGGTTGGGGTGGA  
 
miR-142 XhoI Rev (27 bases; 59.3 % GC; Tm=64.3 ºC): 
ATACTCGAGTCCCCACCCCAGCAACAG 
Fragment size –    902 bp 
Denaturation      –    95 ºC  – 2 min x 1 
Denaturation      
Annealing         
Elongation 
–    95 ºC  
–    66 ºC (Pfu) / 60 ºC (Go-Taq®) 
–    72 ºC  
– 30 sec 
– 30 sec 
– 1 min 30 sec 
x 35 
Elongation         –    72 ºC  – 5 min x 1 











22. miR-142 ‘Long-3’ 5’ EcorV and 3’ XhoI (Pfu or Go-Taq®) 
 
miR-142 Long-3 EcorV For  (27 bases; 59.3 % GC; Tm=64.3 ºC): 
CTCGATATCGGTTGGGGTGGACTGGAG  
 
miR-142 XhoI Rev (27 bases; 59.3 % GC; Tm=64.3 ºC): 
ATACTCGAGTCCCCACCCCAGCAACAG 
Fragment size –    902 bp 
Denaturation      –    95 ºC  – 2 min x 1 
Denaturation      
Annealing         
Elongation 
–    95 ºC  
–    66 ºC (Pfu) / 60 ºC (Go-Taq®) 
–    72 ºC  
– 30 sec 
– 30 sec 
– 1 min 30 sec 
x 35 
Elongation         –    72 ºC  – 5 min x 1 
4 ºC   ∞ 
 
23. miR-142 ‘Long-4’ 5’ EcorV and 3’ XhoI (Pfu or Go-Taq®) 
 
miR-142 Long-4 EcorV For  (27 bases; 59.3 % GC; Tm=64.3 ºC): 
CTCGATATCGGACCTCACGGTTGGGGT  
 
miR-142 XhoI Rev (27 bases; 59.3 % GC; Tm=64.3 ºC): 
ATACTCGAGTCCCCACCCCAGCAACAG 
Fragment size –    905 bp 
Denaturation      –    95 ºC  – 2 min x 1 
Denaturation      
Annealing         
Elongation 
–    95 ºC  
–    66 ºC (Pfu) / 60 ºC (Go-Taq®) 
–    72 ºC  
– 30 sec 
– 30 sec 
– 1 min 30 sec 
x 35 
Elongation         –    72 ºC  – 5 min x 1 











24. miR-142 ‘Long-5’ 5’ EcorV and 3’ XhoI (Pfu or Go-Taq®) 
 
miR-142 Long-5 EcorV For  (27 bases; 59.3 % GC; Tm=64.3 ºC): 
CTCGATATCCTGGTGGGGAGGCTGAAG  
 
miR-142 XhoI Rev (27 bases; 59.3 % GC; Tm=64.3 ºC): 
ATACTCGAGTCCCCACCCCAGCAACAG 
Fragment size –    950 bp 
Denaturation      –    95 ºC  – 2 min x 1 
Denaturation      
Annealing         
Elongation 
–    95 ºC  
–    66 ºC (Pfu) / 60 ºC (Go-Taq®) 
–    72 ºC  
– 30 sec 
– 30 sec 
– 1 min 30 sec 
x 35 
Elongation         –    72 ºC  – 5 min x 1 
4 ºC   ∞ 
 
25. mCherry 5’ EcorV and 3’ XhoI (Pfu or Go-Taq®) 
 
mCherry EcorV For (26 bases; 53.8 % GC; Tm=61.1 ºC): 
GACGATATCATGGTGAGCAAGGGCGA  
 
mCherry XhoI Rev (26 bases; 53.8 % GC; Tm=61.1 ºC): 
CGCCTCGAGTTACTTGTACAGCTCGT 
Fragment size –    729 bp 
Denaturation      –    95 ºC  – 2 min x 1 
Denaturation      
Annealing         
Elongation 
–    95 ºC  
–    60 ºC (Pfu) / 58 ºC (Go-Taq®) 
–    72 ºC  
– 30 sec 
– 30 sec 
– 1 min 30 sec 
x 35 
Elongation         –    72 ºC  – 5 min x 1 











26. pcDNATM ORF 5’ MluI and 3’ MluI (Pfu or Go-Taq®) 
 
pcDNA ORF For (26 bases; 53.8 % GC; Tm=61.1 ºC): 
CGGGCCAGATATACGCGTTGACATTG  
 
pcDNA ORF MluI Rev (26 bases; 53.8 % GC; Tm=61.1 ºC): 
ATAACGCGTAAGCCATAGAGCCCACC 
Fragment size 
–    1,325 bp (miR-142 ‘Core’) 
–    1,820 bp (miR-142 ‘Short’) 
Denaturation      –    95 ºC  – 2 min x 1 
Denaturation      
Annealing         
Elongation 
–    95 ºC  
–    60 ºC (Pfu) / 58 ºC (Go-Taq®) 
–    72 ºC  
– 30 sec 
– 30 sec 
– 30 sec 
x 35 
Elongation         –    72 ºC  – 5 min x 1 
































































































































































































































































































































































































































































ANNEX 15: miRNA RE sequences 
 









































ANNEX 16: Hek 293 miR-142 sequences 
 
































































































ANNEX 17: Cloning of SFV4-3H-zsGreen-2SG-miRNA RE 
 
First, all three miRNA REs were amplified by PCR using Pfu DNA polymerase from 
1 µl of annealed and extended oligonucleotides (see 4.3). The protocol described in 
2.11.3 was followed. The cycling parameters and primers used are described in 
Annex 12 (protocol 15). The primers added ApaI and BamHI restriction sites to 5’ 
and 3’ ends of the miRNA REs, respectively. The PCR products were run on a 1% 
agarose gel as described in 2.14 and then purified as described in 2.15.6. SFV4-3H-
zsGreen-2SG-GLuc icDNA and all three amplified miRNA REs were digested with 
ApaI and BamHI as described in 2.16. The digest products were run on a 1% agarose 
gel as described in 2.14 and then were purified as described in 2.15.6. Finally, the 
miRNA REs were ligated to the linearized SFV4-3H-zsGreen icDNA following the 
protocol in 2.18. At the end of the ligation, 5 µl of the reaction mixture was used to 
transform DH5α E. coli as described in 2.19.3. Transformed bacteria were plated on 
a selective LB agar plate with 50 µg/ml kanamycin and incubated overnight at 37 ºC. 
Colonies from each ligation were tested by colony PCR as described in 2.11.5. The 
cycling parameters and primers used are described in Annex 12 (protocol 9). The 
primers had been designed to anneal within the genome of SFV, approximately 100-
150 bases upstream and downstream of the cloning site.  
 
PCR-positive colonies were cultured for 16 hours at 37 ºC in 5 ml of LB broth with 
50 µg/ml kanamycin. Plasmids were purified from bacteria cultures as described in 
2.15.8 (Mini-Prep).  Purified plasmids were sequenced using SFV4 3’ UTR For 
primer (TGTTTCCAGACATGTCGGGCAC) (Annex 10, protocol 9) at GATC 
Biotech. One icDNA with the correct sequence (Supplementary Data, Appendix 8) 
was chosen for each construct. It was subsequently amplified as described in 2.15.9 













ANNEX 18: Generating SFV4-3F-zsGreen-miRNA RE and 
SFV4-3F-zsGreen-2SG-GLuc-miRNA RE constructs 
 
First, pCMV-SFV4-3F-zsGreen-2SG-GLuc icDNA was generated as outlined in 
Annex Figure 1. In brief, pSP6-SFV4-3F-zsGreen and pCMV-SFV4-2SG-GLuc 
were digested with SacI and SbfI as described in 2.16 and run on a 1% agarose gel as 
described in 2.14. The 7,653 bp fragment fromSFV4-3F-zsGreen (icDNA 
nucleotides 1,803 to 9,456) and the 8,699 bp fragment from SFV4-2SG-GLuc 
(icDNA nucleotides 10,181 to 1,802) were purified as described in 2.15.6. The two 
fragments were ligated to each other following 2.18. At the end of the ligation, 5 µl 
of the reaction mixture was used to transform DH5α E. coli as described in 2.19.3. 
Transformed bacteria were plated on a selective LB agar plate with 50 µg/ml 
kanamycin and incubated overnight at 37 ºC. The following day only a single colony 
was present. It was cultured for 16 hours at 37 ºC in 5 ml of LB broth with 50 µg/ml 
kanamycin. Finally, the plasmid was purified from the bacteria culture as described 
in 2.15.8 (Mini-Prep).  
 
The correct ligation was confirmed by PCR. Two protocols were used, each of them 
designed to amplify a region of SFV around one of the two the ligation sites. The 
cycling parameters and primers used are described in Annex 12 (protocols 7 and 8). 
The purified plasmid was sequenced at GATC Biotech using SFV4 SbfI Control Rev 
(GTTTCCGGTTCCACAGGTG) and SFV4 SacI Control Rev 
(CGGCGTCAGTTCTTTCAGC) primers (details in Annex 10, protocols 7 and 8). 
Sequencing data confirmed that the plasmid was correctly ligated (Supplementary 
Data, Appendix 8). Finally, the plasmid was amplified as described in 2.15.9 (Maxi-












Figure 1. SFV4-3F-zsGreen-2SG-GLuc cloning summary. pSP6-SFV4-3F-
zsGreena and pCMV-SFV4-2SG-GLuc plasmids were cut with SbfI and SacI. The 
1,803 to 9,456 fragment from SFV4-3F-zsGreen icDNA and the 10,181 to 1,802 
fragment from SFV4-2SG-GLuc icDNA were ligated to each other. Figure generated 
with SnapGene, GSL Biotech LLC. 
 
 
MiR-142-3P RE and miRNA RE Control, were cloned into pCMV-SFV-3F-zsGreen 
virus following the protocol outlined in 4.4. The resulting constructs were called 
SFV4-3F-zsGreen-miR-142-3P RE and SFV4-3F-zsGreen-miRNA RE Control. 
Altogether, these viruses were named SFV4-3F-zsGreen-miRNA RE. Their 
sequences are provided in Supplementary Data, Appendix 1. 
 
The cloning of the miRNA REs downstream of GLuc in SFV4-3F-zsGreen-2SG-
GLuc was a two-step process. The three REs were first cloned into an intermediate 
vector pMK-SFV4-2SG-GLuc that was kindly donated by Stacey Human, The 
Roslin Institute and the Pirbright Institute. In brief, pMK-SFV4-2SG-GLuc encoded 
a cassette that contained a duplicated SFV subgenomic promoter, a Koazak 
  






sequence, GLuc, and a 140 bp insert between NotI and PmeI restriction sites. This 
entire cassette was inserted into the vector between ApaI and BamHI restriction sites.  
 
First, all three miRNA REs were amplified by PCR using Pfu DNA polymerase from 
SFV4-3H-zsGreen-miRNA RE constructs generated in 4.4. The protocol described in 
2.11.3 was followed. The cycling parameters and primers used are described in 
Annex 12 (protocol 17). The primers added NotI and PmeI restriction sites to 5’ and 
3’ ends of the miRNA REs, respectively. The PCR products were run on a 1% 
agarose gel as described in 2.14 and then purified as described in 2.15.6. Next, pMK-
SFV4-3SG-GLuc vector and all three amplified miRNA REs were digested with 
NotI and PmeI as described in 2.16. The digest products were run on a 1% agarose 
gel as described in 2.14 and then purified as described in 2.15.6. Finally, the miRNA 
REs were ligated to the linearized pMK-SFV4-2SG-GLuc following the protocol in 
2.18. At the end of the ligation, 1 µl of the reaction mixture was used to transform 
DH5α E. coli as described in 2.19.3. Transformed bacteria were plated on a selective 
LB agar plate with 50 µg/ml kanamycin and incubated overnight at 37 ºC. 
 
Colonies from each ligation were tested by colony PCR as described in 2.11.5. The 
cycling parameters and primers used are described in Annex 12 (protocol 11). The 
primers had been designed to anneal approximately 100-150 bases upstream and 
downstream of the cloning site. PCR-positive colonies were cultured for 16 hours at 
37 ºC in 5 ml of LB broth with 50 µg/ml kanamycin. Plasmids were purified from 
bacteria cultures as described in 2.15.8 (Mini-Prep).  Purified plasmids were 
sequenced using pMK NotI-PmeI Control For primer 
(GACCTGCTCAAGAAGTGGC) (Annex 10, protocol 11) at GATC Biotech. One 
icDNA with the correct sequence (Supplementary Data, Appendix 13) was chosen 












Figure 2. pMK-SFV4-2SG-GLuc-miRNA RE cloning summary. Three REs were 
amplified by PCR from the viruses generated in 4.4. The PCR primers added NotI 
and PmeI restriction sites. pMK-SFV4-2SG-GLuc plasmid and the three RE were 
digested with NotI and PmeI, purified, and then ligated together. Figure generated 
with SnapGene, GSL Biotech LLC. 
 
 
Next, pCMV-SFV4-3F-zsGreen-2SG-GLuc and pMK-SFV4-2SG-GLuc-miRNA RE 
plasmids were digested with ApaI and BamHI as described in 2.16. The digested 
products were run on a 1% agarose gel as described in 2.14 and purified as described 
in 2.15.6. The GLuc-miRNA RE cassettes from pMK vectors were ligated to the 
linearized SFV4 vector following 2.18. At the end of the ligation, 1 µl of the reaction 
mixture was used to transform DH5α E. coli as described in 2.19.3. Transformed 
  






bacteria were plated on a selective LB agar plate with 50 µg/ml kanamycin and 
incubated overnight at 37 ºC. The cloning was completed according to the protocol 






Figure 3. pCMV-SFV4-3F-zsGreen-2SG-GLuc-miRNA RE cloning summary 
pCMV-SFV4-3F-zsGreen-2SG-GLuc and pMK-SFV4-2SG-GLuc plasmids were 
digested with ApaI and BamHI, purified, and then ligated together. Figure generated 



















ANNEX 19: Generating Hek 293 miR-142 and Hek 293 
Control cells 
 
First, genomic DNA was extracted from 1 x 10
6
 of Thp-1 cells as described in 2.15.2. 
Next, miR-142 ‘Core’, ‘Short’, ‘Long-3’ and ‘Long-5’ were amplified from 200 ng 
of the extracted DNA using Pfu DNA Polymerase. The protocol described in 2.11.3 
was followed. The primers added EcorV and XhoI restriction sites to 5’ and 3’ ends 
of the PCR products, respectively. The cycling parameters and primers used are 
described in Annex 12 (protocols 18, 19, 22 and 24, respectively). The PCR products 
were run on a 1% agarose gel and then purified as described in 2.15.6. Next, 
pcDNA
TM
5/FRT/TO vector and all four miR-142 constructs were digested with 
EcorV and XhoI as described in 2.16. The digest products were run on a 1% agarose 
gel and then purified as described in 2.15.6. Finally, the miR-142 constructs were 
ligated to the linearized pcDNA
TM
5/FRT/TO vector following 2.18. At the end of the 
ligation, 1 µl of the reaction mixture was used to transform DH5α E. coli as 
described in 2.19.3. Transformed bacteria were plated on a selective LB agar plate 
with 100 µg/ml ampicillin and incubated overnight at 37 ºC. 
 
Colonies from each ligation were tested by colony PCR as described in 2.11.5. The 
cycling parameters and primers used are described in Annex 12 (protocol 12). The 
primers had been designed to anneal approximately 100-200 bases upstream and 
downstream of the cloning site. PCR-positive colonies were cultured for 16 hours at 
37 ºC in 5 ml of LB broth with 100 µg/ml ampicillin. Plasmids were purified from 
bacteria cultures as described in 2.15.8 (Mini-Prep).  Purified plasmids were 
sequenced using pcDNA Control For primer (AAATGGGCGGTAGGCGTG) 
(Annex 10, protocol 12) at GATC Biotech. One icDNA with the correct sequence 
(Supplementary Data, Appendix 12) was chosen for each construct. Sequences of all 
pcDNA5/FRT/TO are provided in Supplementary Data, Appendix 6. 
 
Next, cells were cloned as described in 2.2.11 using pcDNA
TM
5/FRT/TO plasmids 
encoding miR-142 ‘Core’, ‘Short’, ‘Long-3’, ‘Long-5’, and an unmodified 
pcDNA
TM
5/FRT/TO plasmid. The resulting cell lines were called Hek 293 miR-142 
  






‘Core’, Hek 293 miR-142 ‘Short’, Hek 293 miR-142 ‘Long-3’, Hek 293 miR-142 






































ANNEX 20: Generating pcDNA
TM
3.1+ plasmids that co-
express miR-142-3P and mCherry 
 
First, mCherry was cloned into pcDNA3.1+ vector. In brief, mCherry was amplified 
by PCR using Pfu DNA polymerase from 100 ng of pSP6-ICRES1-3F-mCherry.  
The protocol described in 2.11.3 was followed. The cycling parameters and primers 
used are described in Annex 12 (protocol 25). The primers added EcorV and XhoI 
restriction sites to 5’ and 3’ ends of the mCherry, respectively. The cloning was 
completed as described in 4.11. The resulting construct was called pcDNA3.1+ 
mCherry. Its sequence is provided in Supplementary Data, Appendix 5. 
 
Next, the entire expression cassette from pcDNA3.1+ miR-142 ‘Core’ and 
pcDNA3.1+ miR-142 ‘Short’ (from CMV enhancer/promoter to bGH poly(A) site) 
was cloned into the pcDNA3.1+ mCherry (Figure 4). In brief, miR-142 ‘Core’ and 
miR-142 ‘Short’ expression cassettes were amplified by PCR using Pfu DNA 
polymerase from 100 ng of pcDNA3.1+ miR-142 ‘Core’ and pcDNA3.1+ miR-142 
‘Short’. The protocol described in 2.11.3 was followed. The cycling parameters and 
primers used are described in Annex 12 (protocol 26). The primers added MluI 
restriction site to both 5’ and 3’ ends of the product. The PCR products were run on a 
1% agarose gel as described in 2.14 and then purified as described in 2.15.6. Next, 
pcDNA3.1+ mCherry and both PCR products were digested with MluI as described 
in 2.16. The digest products were run on a 1% agarose gel as described in 2.14 and 
then purified as described in 2.15.6. The linearized pcDNA3.1+ mCherry was 
dephosphorylated using TSAP as described in 2.17. Finally, the miR-142 expression 
cassettes were ligated to the linearized pcDNA3.1+ mCherry vector following 2.18. 
At the end of the ligation, 1 µl of the reaction mixture was used to transform DH5α 
E. coli as described in 2.19.3. Transformed bacteria were plated on a selective LB 
agar plate with 100 µg/ml ampicillin and incubated overnight at 37 ºC 
 
Resulting colonies were tested by a control digest using XbaI as described in 2.16. 
This digest gave a distinct band pattern in clones that were ligated in the correct 
orientation (data not shown). Control digest-positive colonies were cultured for 16 
  






hours at 37 ºC in 5 ml of LB broth with 100 µg/ml ampicillin. Plasmids were purified 
from bacteria cultures as described in 2.15.8 (Mini-Prep).  Purified plasmids were 
sequenced at Source Bioscience using the following primers: 
 
1. pcDNA MluI Site Sequencing For (CTGCTTGTGTGTTGGAGGTCG). 
2. pcDNA miR-142 Sequencing  Rev (GCCCACAGTACACTCATCC). 
3. pcDNA miR-142 Sequencing  For (GGAGCAGGAGTCAGGAGG).  
 
One icDNA with the correct sequence (Supplementary Data, Appendix 11) was 
chosen for each construct and subsequently amplified as described in 2.15.9 (Maxi-













Figure 4. pcDNA3.1+ miRNA RE mCherry cloning summary. The miR-142 
expression cassette was amplified by PCR and then ligated into pcDNA3.1+ 















ANNEX 21: Incorporating miRNA REs into chikungunya 
replicon ChikRepl-3F-zsGreen-2SG-mCherry 
 
First, the two miRNA REs were amplified by PCR using Vent® DNA polymerase 
from 1 µl of annealed and extended oligonucleotides (see 4.3). The protocol 
described in 2.11.2 was followed. The cycling parameters and primers used are 
described in Annex 12 (protocol 13). The primers added AvrII and PmeI restriction 
sites to 5’ and 3’ ends of the miRNA REs, respectively. The PCR products were run 
on a 1% agarose gel as described in 2.14 and then purified as described in 2.15.6. 
PSP6-ChikRepl-3F-zsGreen-2SG-mCherry and the two amplified miRNA REs were 
digested with AvrII and PmeI as described in 2.16. The digest products were run on a 
1% agarose gel as described in 2.14 and then were purified as described in 2.15.6. 
Finally, the miRNA REs were ligated to the linearized pSP6-ChikRepl-3F-zsGreen-
2SG-mCherry following the protocol in 2.18. At the end of the ligation, 1 µl of the 
reaction mixture was used to transform SURE2® E. coli as described in 2.19.2. 
Transformed bacteria were plated on a selective LB agar plate with 100 µg/ml 
ampicillin and incubated overnight at 37 ºC. 
 
Colonies from each ligation were tested by colony PCR as described in 2.11.5. The 
cycling parameters and primers used are described in Annex 12 (protocol 6). The 
primers had been designed to anneal approximately 150-200 bases upstream and 
downstream of the cloning site.  
 
PCR-positive colonies were cultured for 16 hours at 37 ºC in 5 ml of LB broth with 
100 µg/ml ampicillin. Plasmids were purified from bacteria cultures as described in 
2.15.8 (Mini-Prep).  Purified plasmids were sequenced using ICRES1 2SG Control 
For primer (GCTGACGAAGTGATCAGATGGC) (Annex 10, protocol 6) at MRC 
PPU DNA Sequencing and Services. One icDNA with the correct sequence 
(Supplementary Data, Appendix 10) was chosen for each construct. It was 
subsequently amplified as described in 2.15.9 (Maxi-Prep). This final icDNA stock 
was re-sequenced as described above.  
 
